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Summary 
Throughout evolution most of the mitochondrial genes have been transferred to the nuclear genome. 
Thus, proteins targeting one of the four mitochondrial compartments have to be translocated after 
their synthesis in the cytosol. This process is essential for mitochondrial biogenesis in all eukaryotes. 
Nevertheless, mitochondrial protein import machineries of parasitic protists differ significantly from 
the established models in opisthokonts (e.g. mammals and yeast), although import signals are 
functionally conserved.  
In yeast and mammals, Mia40/CHCHD4 and the sulfhydryl electron transferase Erv1/ALR are the 
essential components for the import and oxidative folding of sulphur-containing proteins in the 
mitochondrial intermembrane space. Substrates of this pathway carry conserved cysteine motifs that 
are recognised by Mia40 and subsequently oxidized to the formation of intramolecular disulphide 
bonds. In a disulphide relay system, electrons are transported from Mia40 to Erv1 and on to 
cytochrome c, which finally introduces them into the respiratory chain. However, a Mia40 homologue 
could not be identified in the genome of important apicomplexan and kinetoplastid parasites, while 
Erv1 is ubiquitously conserved. Both the Erv homologues from the kinetoplastid parasite Leishmania 
tarentolae (LtErv) and the malaria parasite Plasmodium falciparum (PfErv) were imported into yeast 
mitochondria but failed to replace their yeast counterpart.   
Here I analyse structure-function relationships of LtErv in the endogenous as well as the opisthokont 
model system Saccharomyces cerevisiae. I characterise particularities of the overall structure and the 
cysteine motifs that distinguish the protein from other homologues that actually interact with Mia40. 
The most obvious features comprise an additional C-terminal domain (KISS) restricted to this group of 
parasites and a partially conserved cysteine residue close to the N-terminus (C17). Yeast 
complementation assays suggest that the presence of the KISS domain does not inactivate the protein 
in the yeast system. In contrast, LtErv gained functionality when C17 was removed or the yeast shuttle 
arm was N-terminally fused to the protein. Residue C17 is therefore most likely the reason why LtErv 
does not interact with yeast Mia40 and interrupts the oxidative protein folding machinery in yeast. 
However, the translocation of LtErv itself into yeast mitochondria is not affected. Unlike soluble ScErv1, 
the protist protein is presumably imported due to its membrane association. Whether the 
translocation of LtErv is structurally connected to its dysfunction in yeast and controlled by a conserved 
trans side receptor or by protein-lipid interactions remains to be further investigated. Additionally, the 
data strongly support the existence of a Mia40 replacement in parasitic protists because both LtErv 
and PfErv were unable to initiate substrate import on their own in yeast mitochondria. Potential 
replacement candidates were enriched by trapping mixed disulphide intermediates with a model 
substrate and have to be evaluated in the future. 
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Zusammenfassung 
Im Laufe der Evolution wurden die meisten mitochondrialen Gene in das nukleare Genom überführt. 
So müssen Proteine, die für die Mitochondrien bestimmt sind, nach ihrer Synthese im Cytosol in die 
jeweiligen Kompartimente transloziert werden. Dieser Prozess ist für die Biogenese aller eukaryo-
tischen Mitochondrien unerlässlich. Dennoch unterscheiden sich die parasitären Proteinimport 
Maschinerien deutlich von den etablierten Modellen der Opisthokonta (z.B. Säugetiere und Hefe). Die 
Importsignale der Proteine sind jedoch funktionell erhalten.  
In Hefe und Säugetieren sind Mia40/CHCHD4 und die Sulfhydryl-Elektronentransferase Erv1/ALR die 
wesentlichen Komponenten für den Import und die oxidative Faltung von schwefelhaltigen Proteinen 
im mitochondrialen Intermembranraum. Substrate dieses Importweges tragen konservierte Cystein-
Motive, die von Mia40 erkannt und anschließend zur Ausbildung intramolekularer Disulfidbrücken 
oxidiert werden. In einem „Disulfid Relay System“ werden Elektronen von Mia40 auf Erv1 und weiter 
auf Cytochrom c übertragen, welches diese schließlich in die Atmungskette einführt. Die Genome 
wichtiger parasitärer Eukaryoten (Apicomplexa und Kinetoplastida) kodieren jedoch kein Mia40 
Homolog, während Erv1 durchgehend konserviert ist. Die Erv-Proteine des parasitären Kinetoplastida 
Leishmania tarentolae (LtErv) und des Malariaparasiten Plasmodium falciparum (PfErv) wurden in 
Hefemitochondrien importiert, konnten dort aber das Hefependant nicht ersetzen.  
In dieser Arbeit untersuche ich Struktur-Funktionsbeziehungen von LtErv im endogenen sowie im 
heterologen Modellsystem Saccharomyces cerevisiae. Dabei werden die Besonderheiten der gesamten 
Proteinstruktur und der Cystein-Motive charakterisiert, welche das Protein von jenen Homologen 
unterscheidet, die mit Mia40 interagieren. Die offensichtlichsten Strukturmerkmale von LtErv sind eine 
zusätzliche C-terminale Domäne (KISS), die ausschließlich bei dieser Gruppe von Parasiten vorkommt 
und ein teilweise konservierter Cysteinrest in der Nähe des N-Terminus (C17). Komplementations-
studien deuten darauf hin, dass die KISS-Domäne keinen Einfluss auf die Inaktivität des Proteins im 
Hefesystem hat. Im Gegensatz dazu gewann LtErv an Funktionalität, wenn C17 entfernt oder der 
Hefeshuttlearm N-Terminal mit dem Protein fusioniert wurde. C17 ist daher höchstwahrscheinlich der 
Grund, warum LtErv nicht mit ScMia40 interagiert und die oxidative Proteinfaltungsmaschinerie in 
Hefe stört. Die Translokation von LtErv selbst ist dabei jedoch nicht betroffen. Im Gegensatz zu frei 
löslichem ScErv1 wird LtErv vermutlich aufgrund seiner Membranassoziation importiert. Ob die 
Translokation von LtErv strukturell an die Inaktivität in Hefe gekoppelt ist und über einen konservierten 
transseitigen Rezeptor oder über Protein-Lipid-Interaktionen gesteuert wird, muss noch weiter 
untersucht werden. Darüber hinaus unterstützen die Daten nachdrücklich die Existenz eines Mia40-
Ersatzes in diesen Protisten, da sowohl LtErv als auch PfErv nicht in der Lage waren, eigenständig den 
Substratimport in Hefemitochondrien einzuleiten. Potentielle Kandidaten für ein Ersatzprotein wurden 
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in Form von gemischten Disulfid-Zwischenprodukten über ein Modelsubstrat angereichert, bedürfen 
jedoch noch weiterer Auswertung. 
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TIM  translocase of the inner 
mitochondrial membrane 
Tm melting temperature 
TM  transmembrane domain 
TOB mitochondrial outer membrane 
beta-barrel protein 
TOM  translocase of the outer 
mitochondrial membrane 
Tris  Tris(hydroxymethyl)aminomethane 
tRNA transfer RNA 
U  units 
Ura uracil 
UV ultraviolet 
V  volt 
VL  visceral leishmaniasis 
v/v  volume per volume 
w/v  weight per volume 
WHO World Health Organization 
WR99210  1,6-Dihydro-6,6-dimethyl-1-[3-(2,4,5 
-trichlorophenoxy)propoxy]-1,3,5-
triazine-2,4-diamine 
WT wildtype 
x any  
YP yeast extract peptone 
YPD yeast extract peptone containing 
glucose 
YPG yeast extract peptone containing 
glycerol 
YPGal yeast extract peptone containing 
galactose 
YT yeast extract tryptone 
Zwf1 glucose-6-phosphate 1-
dehydrogenase 
 
 
 
Amino acids were abbreviated using the standard one or three letter code.
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1 Introduction 
1.1 Parasitic protists and their impact on public health 
The paraphyletic group of protozoa comprises more than 200 000 named species of unicellular 
eukaryotes, of which ~10 000 were classified as parasites (Cox, 2002). Since they are not a coherent 
phylogenetic group, protists share biological properties and phylogenetic relationships with other 
eukaryotic lineages, which have distributed them throughout the evolutionary tree (Figure 1.1) 
(Simpson and Roger, 2004; Adl et al., 2005; Ocana and Davila, 2011; Adl et al., 2012). Phyla that contain 
parasitic protists include the Alveolata (apicomplexans, e.g. Plasmodium, Cryptosporidium, Theileria, 
Toxoplasma, Babesia) as a branch of SAR, Discoba (kinetoplastid flagellates, e.g. Trypanosoma, 
Leishmania) and Metamonada (intestinal flagellates, e.g. Giardia, Trichomonas) belonging to the 
supergroup of Excavata, and Archamoebae (Amoebae, e.g. Entamoeba) as a representative of the 
Amoebozoa (Cox, 2002; Adl et al., 2012).  
 
Figure 1.1 | Phylogenetic relationships among eukaryotes. (A) Eukaryotic tree of life indicating the five supergroups and in 
extracts subgroups of free living and parasitic representatives. SAR = Stramenopiles, Alveolata, Rhizaria. Tree was modified 
from Adl et al. (2012). (B, C, D) Phylogenetic relationships within the groups (B) SAR and the subgroup Apicomplexa, (C) 
Excavates and the subgroup Kinetoplastida, and (D) Leishmania. Asterisks indicate parasitic organisms. Figure was modified 
from Chaudhary and Roos (2005) and Bates (2007). 
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Protozoan parasites represent important human pathogens that are responsible for a major part of 
the global health burden and contribute significantly to morbidity and mortality in the developing 
world (Lozano et al., 2012; Andrews et al., 2014). Typically, they cause classical diseases of poverty 
which are hardly considered by the pharmaceutical industry, although many of them are targeted as 
research priorities by the World Health Organization (WHO) (Chaudhary and Roos, 2005; WHO, 2012a).  
Diarrhoeal diseases caused by the enteric protists Entamoeba, Cryptosporidium, and Giardia caused 
the death of 33 900 people in 2010 and rank among the most frequent causes of decease in children 
under the age of five (Liu et al., 2012; Kotloff et al., 2013; Torgerson et al., 2015; Burgess et al., 2017). 
Members of the kinetoplastid parasites are threatening the lives of billions of people in the tropics and 
subtropics causing leishmaniasis, Chagas disease or sleeping sickness (WHO, 2015, 2018). Together 
they were responsible for over 71 000 deaths in 2010 (Lozano et al., 2012). The most severe tropical 
disease caused by a protist remains to be malaria with an estimated 216 million cases annually and 
approximately 445 000 deaths worldwide in the year 2016 (WHO, 2017b).  
 
1.1.1 The apicomplexan parasite P. falciparum – the causative agent of malaria  
Malaria is a vector-borne disease caused by parasitic protists of the genus Plasmodium. It is 
transmitted by female Anopheles mosquitoes in endemic regions of the tropical and subtropical parts 
of Africa, South-East Asia, Oceania, the Indian subcontinent, and Central and South America.  
The disease severely affects the poorest population and the most marginalised communities having 
the least access to prevention, diagnosis, and treatment. Most affected are children under the age of 
five, who account for 78 % of all malaria-related deaths, pregnant women, and immunocompromised 
patients, e.g. co-infected with HIV (WHO, 2012a, 2014). Initial signs of an infection typically occur 
within an incubation period of 7-30 days and herald the disease with periodic fevers and non-specific 
flu-like symptoms, such as headaches, chills, muscle pain, and vomiting. Untreated patients may 
develop severe and potentially fatal illness within 24 hours. Complicated or severe malaria is 
associated with prostration, severe anaemia, and respiratory distress, which can lead to multiorgan 
failure or cerebral malaria (Greenwood et al., 2008; CDC, 2015).      
Within the superphylum Alveolata, Plasmodium species are part of the parasitic group of Apicomplexa 
(Adl et al., 2012). Closely related veterinary pathogens, such as Theileria parva, causing east coast fever 
and theileriosis, Babesia bovis and B. bigemina, the cause of Texas cattle fever, and Toxoplasma gondii 
produce dangerous invasive diseases in livestock and humans (Figure 1.1B) (Esteban-Redondo and 
Innes, 1997; Chaudhary and Roos, 2005; Saadatnia and Golkar, 2012; Yusuf, 2017). Plasmodium further 
belongs to the order of Haemosporoidia and the family of Plasmodiidae (Adl et al., 2012).   
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The parasite’s complex life cycle alternates between the female Anopheles mosquito, for sexual 
reproduction, and a vertebrate host, in which it multiplies asexually. Roughly 200 Plasmodium species 
may cause malaria in vertebrates, such as primates, rodents, birds, or reptiles (Dhangadamajhi et al., 
2010). Six of them are capable of infecting the human host, while Plasmodium falciparum is the most 
virulent, accounting for 99 % of the infections in 2016 (Sutherland et al., 2010; Cowman et al., 2016; 
WHO, 2017b). Outside of the African continent, P. vivax is the predominant pathogen of complicated 
malaria (Naing et al., 2014; WHO, 2017b).  
To complete their life cycle, the parasites undergo several morphological transformations to form 
unique “zoite” forms that allow them to invade different types of cells (Cowman et al., 2016). In short, 
sporozoite-staged parasites are injected into the dermis of a vertebrate host during the blood meal of 
an infected mosquito. The motile parasites travel to the blood stream to reach the liver, in which they 
infect hepatocytes (Yamauchi et al., 2007). During this clinical silent stage, the parasites multiply within 
5-16 days and the newly formed merozoites are released into the blood circulation to invade 
erythrocytes (Prudencio et al., 2006). In the intraerythrocytic cycle, the parasite undergoes schizogony, 
in which it multiplies asexually and develops from the initial ring stage to trophozoites and schizonts. 
The schizonts burst under red cell rupture and release new merozoites for another round of invasion 
and multiplication (Bannister et al., 2000; Bannister and Mitchell, 2003). The cycle closes within one 
day (P. knowlesi), two days (P. falciparum, P. vivax, P. ovale), or three days (P. malariae) leading to the 
periodic fevers each time the host cells burst to unleash a new flood of parasites. During the red blood 
cell cycle, a subset of merozoites are programmed to differentiate into gametocytes that are essential 
for sexual reproduction and can be absorbed by a feeding mosquito (Greenwood et al., 2008; 
Dhangadamajhi et al., 2010; Cowman et al., 2016). 
 
1.1.2 Neglected tropical diseases caused by kinetoplastid parasites 
Chagas disease, sleeping sickness, and leishmaniasis represent three substantially different infectious 
diseases, all induced by kinetoplastid pathogens and geographically limited by the range and 
environment of their insect vectors (Figure 1.1C,D). These devastating yet neglected diseases are hard 
to treat and exert enormous socioeconomic impacts, affecting people and livestock alike (Flohe, 2012).  
The causative agent of Chagas disease, Trypanosoma cruzi, is naturally transmitted by the infective 
faeces of a triatomine bug (“kissing bug”) but may also be received congenital or through infective 
transfusions or contaminated food (Pereira et al., 2010; WHO, 2012b). The disease is endemic in 21 
countries in Latin America with an estimated seven million people infected (WHO, 2012b).  
Sleeping sickness or African trypanosomiasis is caused by either of the species T. brucei gambiense and 
T. brucei rhodesiense in Western and Eastern equatorial Africa, respectively, and affects both humans 
and livestock (Cross, 2005; Ponte-Sucre, 2016). The disease is spread by the bite of the tsetse fly, which 
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threatens the lives of 61 million people in 37 countries on the African continent (WHO, 2012b). 
However, with fewer than 3000 cases reported in 2015, WHO was encouraged to target the human 
disease for elimination by 2020 (Buscher et al., 2017; WHO, 2017a). 
Parasites of the genus Leishmania are another serious public health problem and responsible for a 
variety of clinical manifestations with invasive, disfiguring, or lethal consequences, depending on the 
infectious species and the immune response of the host (Herwaldt, 1999; Torres-Guerrero et al., 2017). 
Worldwide, between 12 and 15 million people are suffering from leishmaniasis and over a billion 
people live exposed to the infectious bites of phlebotomine sand flies in 98 countries in the tropics, 
subtropics, and Southern Europe (Figure 1.2) (WHO, 2012b, 2016; Torres-Guerrero et al., 2017). The 
high burden of disease leads to over 20 000 fatalities annually (WHO, 2012b).        
 
Figure 1.2 | Epidemiology of visceral and cutaneous leishmaniasis in high burden countries.  Source: WHO (2016) 
  
The WHO recognises four major clinical forms of the disease with varying severity resulting from 
parasite replication in macrophages of the mononuclear phagocyte system, the skin, and the naso-
oropharyngeal mucosa (Herwaldt, 1999). Cutaneous leishmaniasis (CL), also known as oriental sore, is 
the most common clinical syndrome and associated with chronic skin ulcer. Causative agents are 
L. tropica, L. braziliensis, and L. major. As a metastatic complication, CL may lead to mucocutaneous 
leishmaniasis (L. braziliensis, L. guyanensis) having a highly defacing, mutilating, and potentially fatal 
outcome. Visceral leishmaniasis (VL) or Kala-Azar (Hindi for black fever) is the most severe clinical form 
and a systematic infection primarily of children in India and East Africa (L. donovani) as well as in 
Southern Europe and the new world (L. infantum). Patients suffer from fever, splenomegaly, weight 
loss, pallor, cough, hepatomegaly, asthenia, anorexia, and eventually die within two years if not 
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treated. Post kala-azar dermal leishmaniasis (L. donovani) is a dermatosis that develops in patients 
following VL treatment and ranges from single papules and nodules to a nodulo-papular rash (WHO, 
2012b, 2015, 2016).  
The treatment of these diseases often involves toxic or inefficient substances, which require extensive 
or prolonged administration. Due to the lack of available drugs for an efficient combination therapy, 
drug resistances are promoted, while vector control is hard to adequately maintain and useless to 
people with lifelong chronic infections. In addition, the parasites’ sophisticated mechanisms of 
immune evasion are clouding the hope for a vaccine (WHO, 2012a). The identification of novel drug 
targets seems as important as ever and is craving for new discoveries on the parasites’ biology on a 
cellular as well as biochemical basis.  
Within the Excavata, protists of the genera Leishmania and Trypanosoma are euglenozoan Discoba 
belonging to the class of Kinetoplastea and the family of Trypanosomatidae (Adl et al., 2012). The 
complex life cycle of Leishmania comprises two developmental stages and involves both the 
invertebrate and the vertebrate host. In the insect vector, the extracellular parasite is flagellated and 
resides in the intestinal tract of the female sand fly (Akhoundi et al., 2016). These promastigotes are 
transmitted into the skin of the vertebrate host and absorbed by macrophages. There they transform 
into intracellular amastigotes that are ovoid and non-motile. Parasites remain in the amastigote stage 
during their entire inhabitation in the vertebrate host (Gossage et al., 2003; Bates and Rogers, 2004).  
About 53 different Leishmania species have been described that are able to infect a variety of 
mammalian, insect, or reptile host species (Akhoundi et al., 2016). Among them, 30 are pathogenic for 
mammals and more than 20 are known human pathogens that can be transmitted by any of the 98 
medically relevant sand fly species (Ashford, 2000; WHO, 2012b). Phylogenetic analyses have further 
subdivided the different Leishmania species (Figure 1.1D) into the three subgenera Vianna, Leishmania 
(consisting of the human infecting species), and Sauroleishmania (the reptile infecting species) 
(Gomez-Eichelmann et al., 1988; Bates, 2007).    
 
1.2 Mitochondria – the organelle and antiparasitic drug target 
Mitochondria are oxygen-consuming “power organelles” that form a dynamic and interconnected 
network found in almost all eukaryotic cell types except for red blood cells (Rich and Marechal, 2010). 
Evolved from the endosymbiotic uptake of an aerobe α-proteobacterium by a primitive, heterotrophic 
eukaryote (Archibald, 2015), the organelle is surrounded by a double membrane generating four 
biochemically distinct compartments: The outer (OM) and the inner mitochondrial membrane (IM) and 
the two aqueous sections, the intermembrane space (IMS) and the matrix (Figure 1.3A). The OM 
separates the organelle from the cytosol but incorporates pore forming proteins for the interchange 
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of small molecules and the passage of cytoplasmically synthesised mitochondrial proteins (Walther 
and Rapaport, 2009; Rich and Marechal, 2010). The IM exhibits a large surface area that is organised 
in the inner boundary membrane as well as numerous invaginations or cristae and may adapt its 
morphology to the necessities of the eukaryotic cell (Heath-Engel and Shore, 2006; Scheibye-Knudsen 
et al., 2015). The increased surface area is required to host the enzyme complexes of the electron 
transport chain (ETC) as well as the adenosine triphosphate (ATP)-synthase for oxidative 
phosphorylation (Sazanov, 2015).  
In the course of evolution, most of the mitochondrial genes have been lost or transferred to the nuclear 
genome. In humans, the mitochondrial genome (mtDNA) consists of a small circular DNA molecule of 
about 16 kilobases (kb) that is inherited through the maternal lineage and located in the matrix (Mishra 
and Chan, 2014; Scheibye-Knudsen et al., 2015). The mtDNA provides the genetic information for 13 
proteins, 22 transfer RNAs (tRNAs), and two ribosomal genes (rRNAs) that are all critical for oxidative 
phosphorylation. The 13 polypeptides are part of the respiratory complexes I, III, IV, and V, which must 
be supplemented by the nuclear encoded subunits to be functional. At the same time, the encoded 
tRNAs and rRNAs are indispensable for the mitochondrial translation machinery that is required for 
the synthesis of the mitochondrial-encoded proteins (Friedman and Nunnari, 2014; Mishra and Chan, 
2014; Scheibye-Knudsen et al., 2015).   
Besides their core function in ATP production, which is part of their prokaryotic heritage, mitochondria 
are involved in a range of cellular processes critical for cell function, health, cellular ageing, and 
apoptosis (Pellegrini and Scorrano, 2007; Larsson, 2010). The dynamic organelles constantly change in 
size and shape through fusion and fission incidences and are capable to move within the cell by 
association with the cytoskeleton (Okamoto and Shaw, 2005; Boldogh and Pon, 2006; Chan et al., 2006; 
Hoppins and Nunnari, 2009; Roy et al., 2015). Also, mitochondria execute important roles in 
biochemical processes, such as calcium homeostasis (De Stefani et al., 2011), steroid metabolism 
(Miller, 2013), fatty acid oxidation (Adeva-Andany et al., 2018), or haem and iron-sulphur cluster 
biosynthesis (Atamna, 2004). They depend on the import of proteins from the cytosol (Chacinska et 
al., 2009) and lipids from the endoplasmic reticulum (ER) for cell survival and membrane formation 
(Flis and Daum, 2013; Scharwey et al., 2013). 
 
1.2.1 Special features of the parasites’ mitochondria 
Unicellular organisms are highly interesting not only from the evolutionary point of view but also 
regarding their cellular biology. They have a collection of special cytoplasmic structures and organelles 
with partially unique metabolic pathways. Among these, the mitochondrion is the most exciting 
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organelle, whose structure and tasks are of vital importance to the cell and in the main focus of both 
scientific fields (Gray et al., 2004; Fidalgo and Gille, 2011).  
Apicomplexan and kinetoplastid parasites usually rely on the proper function of a single, ramified 
mitochondrion, whose structure individually depends on the parasite species, but was generally 
described as peculiar in terms of matrix density as well as number and shape of cristae (Figure 1.3B,C) 
(de Souza et al., 2009).  
 
Figure 1.3 | Particularities of protist mitochondria.  (A) Schematic summary of a mitochondrion. (B) Three-dimensional 
model of Toxoplasma gondii (Apicomplexa) shows the mitochondrion with two lateral branches that are intermediary 
connected (arrowhead). (C) Three-dimensional model of Trypanosoma cruzi (Kinetoplastida). The kinetoplast is marked with 
a star. (D) Electron microscopy picture of a Leishmania mitochondrion with a high metabolic activity showing many cristae. 
(E) Electron microscopy picture of an ultrathin section across the kinetoplast presenting the compact kinetoplast DNA 
network. Figure was modified from de Souza et al. (2009). 
 
The smallest mitochondrial genome of about 6-7 kb was identified for apicomplexans, exhibiting a 
highly reduced gene content that encodes only three proteins of the ETC as well as fragments of rRNA 
(Vaidya et al., 1989; de Souza et al., 2009). All other mitochondrial proteins and tRNAs are nuclear 
encoded and must be imported from the cytosol. In P. falciparum blood stages, energy metabolism is 
primarily based on glycolysis while the ETC is lacking multiple subunits, such as components for proper 
ATP synthesis (Gardner et al., 2002; Mather et al., 2007; Vaidya and Mather, 2009; MacRae et al., 2013; 
Jacot et al., 2016). Yet, the ETC is crucial for parasite survival, accepting electrons that are produced 
during pyrimidine biosynthesis (Painter et al., 2007).  
The mitochondrion of trypanosomatids reacts highly sensitive to nutritional resources, which means it 
may present many cristae and claim up to 13 % (v/v) of the total cell volume under low glucose 
conditions (Figure 1.3D) (de Souza et al., 2009). A special apomorphy of the class Kinetoplastea is the 
kinetoplast (Figure 1.3C), which is positioned in close proximity to the nucleus (Motta, 2008; Adl et al., 
2012; de Souza et al., 2017). The kinetoplast is a dense structure within the mitochondrial matrix that 
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is made of a giant and complex network of circular DNA molecules called kinetoplast DNA (kDNA) 
(Figure 1.3E). The duplex kDNA molecules are arranged in 20-40 kb maxicircles of about 20-50 identical 
copies per network and several thousand minicircles that range in size between 0.5 and 2.5 kb, 
depending on the species (Lukes et al., 2002; de Souza et al., 2009). Maxicircles encode mitochondrial 
gene products, including rRNAs and subunits of the respiratory complexes, while minicircles contain 
the genetic information for guide RNAs that are needed to modify the cryptic maxicircle transcripts by 
insertion or deletion of uridine residues (Lukes et al., 2002; Stuart and Panigrahi, 2002).  
 
1.2.2 Mitochondrial targets and currently used antiparasitic drugs 
Peculiarities of protist mitochondria have attracted much attention for antiparasitic therapies.  
Promising drug targets include the respiratory complexes, lipid metabolism, mtDNA content and 
mitochondrial protein synthesis, protists’ alternative oxidases, or the transport systems importing 
tRNAs and proteins from the cytoplasm into the mitochondria (Kita et al., 2003; Mather et al., 2007; 
Sen and Majumder, 2008; Fidalgo and Gille, 2011; Goodman et al., 2017).  
Several existing drugs are targeting the ETC by inhibiting the respiratory complexes or by excepting 
electrons in competition to the natural acceptors (Olszewska and Szewczyk, 2013), which in turn cause 
the mitochondrial membrane potential to collapse (Srivastava et al., 1997). The antimalarial 
artemisinin was suggested to be a competent inhibitor of the malaria parasite’s alternative complex I 
NADH-quinone oxidoreductase (Li et al., 2005). Since this alternative complex does not encounter a 
match in humans, it appears to be a powerful target whose inhibition has been sought with several 
compounds (Abrahamsen et al., 2004; Biagini et al., 2006; Biagini et al., 2012). The clinically approved 
hydroxynaphthoquinone atovaquone specifically targets the cytochrome b component of complex III 
by acting as a ubiquinone analogue (Fry and Pudney, 1992; Srivastava and Vaidya, 1999; Peters et al., 
2002). The compound was developed as an antimalarial but is also effective in treating trypanosomiasis 
and leishmaniasis (de Souza et al., 2009). A combination therapy of atovaquone and proguanil, 
commercially available under the name MalaroneTM, indirectly arrests the biosynthesis of pyrimidines 
by disrupting the ubiquinone turnover and thereby eliminating the reducing power for the 
dihydroorotate dehydrogenase (Painter et al., 2007). Another drug with multiple modes of action is 
the dicationic pentamidine, which has been used for the past 50 years to treat sleeping sickness or 
antimonial-resistant leishmaniasis (Sands et al., 1985). It has been shown to unbalance the intracellular 
calcium content and block complex II of the ETC (Vercesi and Docampo, 1992). Additionally, it may 
induce apoptotic cell death in L. donovani and promotes linearisation of the kDNA minicircles (Shapiro 
et al., 1989; Mehta and Shaha, 2004). Similar effects are achieved by agents targeting the 
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topoisomerase activity, which is essential for kDNA replication and can be dismissed by competitive 
inhibition or DNA breakage (Motta, 2008). 
 
1.3 Mitochondrial machineries for protein import and assembly  
Human mitochondria are composed of about 1500 different proteins, of which 1 % are synthesised in 
the mitochondrial matrix. The rest derives from nuclear-encoded genes that are translated on 
ribosomes in the cytosol, from which the proteins have to be translocated into the organelle by a 
multicomponent import machinery. Mitochondrial protein import (MPI), folding, and sorting 
machineries are strictly essential for cell viability and encompass at least six different pathways that 
are powered by the membrane potential, ATP metabolism, or redox reactions in the mitochondria 
(Chacinska et al., 2009; Endo and Yamano, 2009; Gross and Bhattacharya, 2009; Dudek et al., 2013; 
Harbauer et al., 2014).  
 
Figure 1.4 | Model of the mitochondrial protein import pathways and machineries in opisthokonts.  (1) Pre-sequence 
pathway of matrix targeting proteins. (2) Stop-transfer pathway into the IM via TIM23. (3) Carrier pathway via TIM22 into the 
IM. (4) OXA pathway into the IM. (5) Oxidative folding pathway or MIA pathway of cysteine-rich proteins into the IMS. (6) 
Beta-barrel pathway into the OM. See text for details. OM = outer mitochondrial membrane, IM = inner mitochondrial 
membrane, IMS = intermembrane space. Figure was modified from Eckers et al. (2012) and Deponte (2013). 
 
Precursor proteins may be scheduled for insertion into the mitochondrial OM or IM or reside soluble 
in the IMS or matrix (Figure 1.4). Independently on the mitochondrial compartment that will be the 
final destination of the proteins, they first have to pass the translocase of the outer mitochondrial 
membrane (TOM complex), whose largest subunit, Tom40, forms a hydrophilic channel through the 
I n t r o d u c t i o n  | 10 
 
 
 
membrane (Hill et al., 1998). Therefore, precursor proteins are either equipped with a cleavable pre-
sequence or one of many internal targeting/sorting signals that bind to receptors of the TOM complex 
(Tom20, Tom22 and Tom70) prior to the translocation process (Brix et al., 1997; van Wilpe et al., 1999; 
Meisinger et al., 2001; Chacinska et al., 2009).  
The classical MPI pathway (route 1) or pre-sequence pathway, guides proteins with a positively 
charged pre-sequence from the IMS to the translocase of the inner mitochondrial membrane (TIM23 
complex). There, the IM potential and the pre-sequence translocase-associated motor (PAM) drive 
their translocation into the matrix (Martin et al., 1991; Chacinska et al., 2005). The two proteins Tim23 
and Tim17 together form the pore of the complex, while Tim50 and Tim21 are receptors facing the 
IMS. The presence of a hydrophobic segment behind the pre-sequence (route 2; bipartite signal), 
causes a lateral release of the protein into the IM by the TIM23 stop-transfer pathway (Glick et al., 
1992; Meier et al., 2005). Alternatively (route 4), proteins intended for the IM are translocated into 
the matrix and are secondarily inserted via the OXA export pathway. Substrates of this pathway usually 
have multiple transmembrane segments and include also mitochondrial-encoded proteins (Harbauer 
et al., 2014). The carrier pathway (route 3) introduces proteins with multiple hydrophobic regions and 
internal targeting signals into the IM by small Tim chaperones and the carrier translocase of the inner 
membrane (TIM22 complex). Chaperones bind to the substrates in the IMS and guide them to the 
multiunit complex, consisting of the Tim22 channel and the associated receptor units Tim54 and Tim18 
(Sirrenberg et al., 1996; Koehler et al., 1998; Sirrenberg et al., 1998). Beta-barrel proteins (route 6) also 
bind to small Tim chaperones that transport them to the sorting and assembly machinery (SAM) or 
mitochondrial outer membrane β-barrel protein (TOB) for sorting into the OM (Wiedemann and 
Pfanner, 2017). Cysteine-rich IMS proteins (route 5) are imported and folded in a disulphide relay 
system via the mitochondrial import assembly (MIA) machinery (Chacinska et al., 2004; Naoe et al., 
2004; Mesecke et al., 2005).  
 
1.3.1 Cysteine-rich proteins of the IMS 
In accordance to their prokaryotic ancestors, mitochondria host fundamental different redox 
processes that have to be separated by kinetic barriers (Rozhkova et al., 2004; Hell, 2008). The IMS is 
supposed to be separated from the reducing cytosol and mitochondrial matrix by two biological 
membranes. However, porins in the OM allow small molecules, such as reduced glutathione (GSH) to 
diffuse from the cytosol and establish a rather reducing environment in the IMS (Kojer et al., 2012; 
Kojer et al., 2015). Nevertheless, in contrast to the cytosol, in which efficient thioredoxin and 
glutathione/ glutaredoxin systems maintain cysteine-containing proteins in their thiol state, the 
narrow IMS catalyses the formation of disulphide bonds (Mesecke et al., 2005; Herrmann and Kohl, 
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2007; Hell, 2008; Deponte and Hell, 2009). The oxidative protein folding pathway in the IMS is 
suggested to be kinetically uncoupled from the otherwise reducing environment (Hu et al., 2008; 
Koehler and Tienson, 2009; Riemer et al., 2009; Stojanovski et al., 2012). Cysteine-rich proteins in the 
are organised in twin, disulphide-bridged Cx3C or Cx9C motifs (Frey and Mannella, 2000; Deponte and 
Hell, 2009). The family of small Tim chaperones is of a low molecular mass (<20 kDa) and has two Cx3C 
segments juxtaposed in antiparallel α-helices that are stabilised by two disulphide bonds (Allen et al., 
2003; Webb et al., 2006).   
Mia40 is an import receptor essential for cell viability and contains six conserved cysteine residues, 
four of which form a twin Cx9C motif. The other two are elements of the redox-active CPC motif 
(Stojanovski et al., 2008; Terziyska et al., 2009). The protein presents two redox-states in the IMS 
(Figure 1.5B). In the fully oxidized form, Mia40 is characterised by the presence of three disulphide 
bonds, one within the CPC motif and two linking the two α-helices of the Cx9C-segment. Oxidized 
Mia40 is further the predominant species, also known as “active” conformation. In this conformation, 
the disulphide bond in the CPC segment is easily accessible to reducing agents. In contrast, partially 
reduced Mia40 has its first two cysteine residues (CPC) in the thiol state (Grumbt et al., 2007). The 
fungal protein possesses a bipartite matrix targeting signal, which drives the import of the pre-
sequence via the classical MPI pathway into the matrix. There, the targeting signal is removed, and the 
protein is laterally sorted into the IM facing the IMS (Naoe et al., 2004; Terziyska et al., 2005). Higher 
eukaryotes have shorter Mia40 homologues, in which the matrix targeting signal as well as the 
hydrophobic membrane anchor is missing and thus Mia40 is soluble inside the IMS (Hofmann et al., 
2005). Depletion of Mia40 is directly related to the abolished import of cysteine-containing proteins 
into the IMS (Chacinska et al., 2004; Naoe et al., 2004; Terziyska et al., 2005). 
 
1.3.2 The Mia40-Erv1 disulphide relay system  
Proteins designated for the IMS of mitochondria reach their destination via one of three pathways 
(Figure 1.5): (I) they have pre-sequences and use the TIM23 complex for sorting, (II) they are rich in 
cysteine residues and trapped by oxidative folding, or (III) they associate with import receptors of the 
mitochondrial membranes (Herrmann and Hell, 2005; Erdogan and Riemer, 2017).  
Class II proteins employ the oxidoreductase Mia40 and the flavoenzyme Erv1 (essential for respiration 
and vegetative growth) or the respective mammalian homologues CHCHD4 and ALR (augmenter of 
liver regeneration). Reduced cysteine-containing proteins in the cytosol possess mitochondrial 
intermembrane space sorting signals (MISS) or intermembrane space targeting signals (ITS) that are 
recognised by the hydrophobic substrate binding cleft of Mia40 (Figure 1.5B) (Sideris et al., 2009; Koch 
and Schmid, 2014b; Peleh et al., 2014; Peleh et al., 2016). The substrate passes the TOM complex and 
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forms a mixed disulphide intermediate with the oxidized CPC motif of Mia40 (Banci et al., 2009). During 
this short-lived disulphide exchange reaction, an electron pair is passed onto Mia40, which introduces 
disulphide bridges in the substrate. The oxidized substrate folds into its functional conformation and 
is released into the IMS (Koch and Schmid, 2014a). It is not yet completely understood how the 
substrate’s second disulphide bond is generated. A second interaction with a Mia40 molecule, 
molecular oxygen, glutathione (GSSG), or even Erv1 are conceivable. At the same time the substrate is 
oxidized, Mia40 is reduced and must be re-oxidized to maintain protein import. Therefore, the partially 
reduced Mia40 interacts with Erv1 in another transient disulphide intermediate. An electron pair is 
transferred to Erv1, leaving Mia40 in the oxidized state (Mesecke et al., 2005; Banci et al., 2011). The 
re-oxidation process is highly efficient, as can be read off the abundant amount of oxidized Mia40 
(Terziyska et al., 2009). The last step connects the disulphide relay system with cellular respiration, 
since Erv1 donates two single electrons to cytochrome c of the respiratory chain, in which molecular 
oxygen is finally reduced to water (Farrell and Thorpe, 2005; Bihlmaier et al., 2007; Dabir et al., 2007).  
 
Figure 1.5 | Protein translocation pathways into the IMS. Proteins of the mitochondrial intermembrane space (IMS) are 
classified into three different groups according to their sorting pathways. (A) Class I proteins have a matrix targeting pre-
sequence followed by a transmembrane segment and use the Tim23 complex for lateral sorting into the IMS. Matrix targeting 
signals are removed from the matrix side while soluble IMS proteins are released by another cleavage in the IMS. (B) Class II 
proteins are small and cysteine-rich and are imported via the Mia40-Erv1 disulphide relay system. See text for details. 
GSH/GSSG = glutathione, Cyt c = cytochrome c, COX = cytochrome c oxidase. (C) Class III proteins associate with binding sites 
at the outer (OM) or inner mitochondrial membrane (IM). Figure was modified from Herrmann and Hell (2005) and Deponte 
and Hell (2009). 
 
1.3.3 Mitochondrial protein import of parasitic protists 
Most of the knowledge concerning the MPI pathways have been collected over decades through 
extensive studies on yeast and other related opisthokonts  (Neupert and Herrmann, 2007; Chacinska 
et al., 2009; Endo and Yamano, 2009; Schmidt et al., 2010; Dimmer and Rapaport, 2012; Dudek et al., 
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2013; Peleh et al., 2016). Data from other eukaryotic lineages just arrived during the last few years and 
illuminated the topic from a broader and evolutionary point of view. Studies, mainly on amoebae, 
apicomplexans and trypanosomes have shown that several components of the opisthokont system are 
altered or even absent (Dolezal et al., 2010; Lithgow and Schneider, 2010; Pusnik et al., 2011; Eckers 
et al., 2012; Pusnik et al., 2012; Singha et al., 2012; Basu et al., 2013).  
The TOM complex as the main entrance gate into the mitochondria is expressed in almost all 
eukaryotes (Figure 1.6). However, in apicomplexans only the pore-forming Tom40 is conserved while 
the pre-sequence receptors are absent or significantly altered (Deponte et al., 2012; Eckers et al., 
2012). Trypanosomes do not even possess a Tom40 homologue but employ an alternative translocase 
called “archaic TOM” (ATOM), which is a member of the Omp85 superfamily (Pusnik et al., 2011). The 
presence of Tim17 and Tim23 homologues as well as several PAM components and chaperones in the 
apicomplexan genome indicate a rather conserved TIM23 complex and associated import pathway 
into the matrix and the IM (Deponte, 2013). In contrast, in silico data indicated the absence of Tim23 
as well as several additional components of the complex in trypanosomes and leishmania (Schneider 
et al., 2008; Singha et al., 2008; Eckers et al., 2012). Despite the compositional changes, the import 
machinery was functionally conserved for matrix-targeting and most likely also for laterally sorted 
proteins by the presence of Tim17 (Eckers et al., 2012). Components of the OXA and β-barrel pathway 
were found in both apicomplexan and kinetoplastid parasites (Deponte et al., 2012; Eckers et al., 
2012), while the multiunit TIM22 complex was roughly conserved in Plasmodium and completely 
absent in kinetoplastids. Nevertheless, substrates of the TIM22 pathway were successfully imported 
into both protist groups (Schneider et al., 2008; Deponte et al., 2012; Eckers et al., 2012).  
 
Figure 1.6 | Oxidative protein folding mechanism in different eukaryotic lineages.  The oxidative protein folding in 
opisthokonts relies on the two proteins Mia40 and Erv1. In contrast, kinetoplastid and apicomplexan parasites only have a 
conserved Erv homologue. Components of the TOM complex are altered or missing (indicated with dashed lines or question 
marks). Figure was modified from Eckers et al. (2012) and contains additional data from Mani et al. (2015). OM = outer 
mitochondrial membrane, IM = inner mitochondrial membrane, IMS = intermembrane space. 
 
MIA40 is expressed in fungi, amoebae, plants and animals. While the protein is essential in yeast but 
dispensable in plants, early branching eukaryotes, such as kinetoplastid and apicomplexan parasites, 
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do not contain a Mia40 homologue at all (Figure 1.6) (Allen et al., 2008; Eckers et al., 2012; Basu et al., 
2013; Eckers et al., 2013). It is therefore controversially discussed whether the oxidative protein folding 
pathway that is now present in yeast and mammals, has gradually evolved from a one-component-
system with only Erv1 (Allen et al., 2008; Haindrich et al., 2017; Peleh et al., 2017) or whether an 
unknown component X replaces Mia40 in these early eukaryotes (Eckers et al., 2013; Liedgens, 2018; 
Specht et al., 2018).  
In summary, the composition of MPI machineries were found to differ significantly between 
eukaryotes. Nevertheless protist proteins were successfully imported into yeast mitochondria and vice 
versa suggesting a functional conservation of the import pathways (Eckers et al., 2012).  
 
1.3.4 The FAD-dependent sulfhydryl electron transferase Erv 
The flavoenzyme Erv1 is an essential protein of the IMS and was first identified in yeast (Lisowsky, 
1992; Lange et al., 2001). Mitochondria were observed to react sensitively on the loss or blockage of 
the protein, which was associated with the loss of the mitochondrial genome, impaired cellular 
respiration, and cell growth as well as defects in the overall mitochondrial morphology and 
distribution. Erv1 was further suggested to contribute to the biogenesis of cytosolic iron sulphur 
clusters, the maturation of haem, and the binding to cytochrome c and cytochrome c peroxidase. In 
general, the loss of Erv1 significantly reduces protein levels in mitochondria. This originates from 
reduced mitochondrial transcripts, impaired import and assembly of small Tim chaperones, and the 
related difficulties in the chaperone-depended import pathways (Lisowsky, 1992, 1994; Becher et al., 
1999; Lange et al., 2001; Allen et al., 2005; Rissler et al., 2005; Dabir et al., 2007). 
In high contrast to Mia40, Erv1 is conserved throughout the eukaryotic phylogenetic tree with 
homologues in fungi, plants, animals, and parasitic protists (Figure 1.7) (Coppock and Thorpe, 2006; 
Allen et al., 2008). Additionally, a distant homologue in the ER of fungi named Erv2 has been detected 
(Stein and Lisowsky, 1998). All homologues belong to the greater family of so-called sulfhydryl oxidases 
and reductases, which are known to connect thiol-disulphide-exchange reactions to the oxidation/ 
reduction of molecular oxygen or cytochrome c, as they fulfil both a reductive and an oxidative half-
reaction. They further act as redox switches in intracellular compartments by accepting an electron 
pair and subsequently transferring two single electrons to the final electron acceptor (Fass, 2008; 
Deponte and Hell, 2009).  
The homologues differ in sequence as well as size and composition (Fass, 2008). Probably the most 
obvious structural difference concerns the additional C-terminal domain of the kinetoplastid Erv that 
comprises almost 200 amino acids (Figure 1.7). The domain is restricted but variable within this 
parasitic group and was called Kinetoplastida-specific second (KISS) domain of Erv (Eckers et al., 2013). 
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In contrast, all members bind a flavin adenine dinucleotide (FAD) in their active site and share several 
conserved cysteine residues (Cabibbo et al., 2000; Lee et al., 2000; Pagani et al., 2000; Gerber et al., 
2001; Lisowsky et al., 2001; Levitan et al., 2004). 
 
Figure 1.7 | Structural features of eukaryotic Erv homologues. Schematic representation of the Erv homologues from 
opisthokonts (ScErv1, ScErv2, ALR), kinetoplastida (LtErv), apicomplexans (PfErv), and plants (AtErv1). The N-terminal FAD-
binding domain is conserved in all homologues while only the kinetoplastida Erv has an additional C-terminal KISS domain. 
The conserved cysteine motifs of the active site (red), the shuttle disulphide (blue), the structural pair (green), and the clamp-
forming residue (brown) are highlighted and the positions are indicated. The electron transport is symbolised with a blue 
arrow. Figure is based on Fass (2008), Deponte and Hell (2009), and Eckers et al. (2013). 
 
The cysteines are arranged in motifs and form up to four disulphide bonds to connect and stabilise the 
homodimer conformation (Gross et al., 2002; Wu et al., 2003; Vitu et al., 2006; Deponte and Hell, 2009; 
Eckers et al., 2013). The “distal” or “shuttle” pair is highly variable in the composition and location of 
the motif, ranging from a four-residues (opisthokonts) and six-residues motif (alveolates) at the N-
terminal arm of the protein to a motif comprising three (Erv2), five (kinetoplastida), or six amino acids 
(plants) at the C-terminal arm. Both of the shuttle cysteines are required to interact with the dithiol 
substrate and relocate the electron pair from the protein surface to the redox centre of the second 
subunit (Gross et al., 2002; Deponte and Hell, 2009; Farver et al., 2009; Eckers et al., 2013; Ang et al., 
2014). The redox active site is composed of a flavin and the “proximal” or “active site” cysteine pair, 
which is highly conserved and essential for the oxidase activity (Ang and Lu, 2009; Daithankar et al., 
2009; Farver et al., 2009; Eckers et al., 2013). Following the formation of an intermediate disulphide 
bond between the shuttle residue and the active site, electrons are transferred via the active site pair 
to the FAD, at the end of which disulphide bonds are restored within the distal cysteine pair (Figure 
1.7). As electrons are used to reduce cytochrome c or, in case of Erv2, molecular oxygen, disulphide 
bonds are reintroduced into the proximal cysteine pair (Deponte and Hell, 2009). Another disulphide 
bond with a conserved Cx16C motif was found in almost all homologues, even in kinetoplastid parasites 
and Erv2, but was absent in apicomplexan parasites (Gross et al., 2002; Wu et al., 2003; Vitu et al., 
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2006; Eckers et al., 2013). This “structural disulphide bond” is located C-terminally within the 
flavodomain and in close proximity of the redox centre. Mutations concerning the participating 
cysteine residues affected protein function in yeast (ScErv1) as well as in Arabidopsis thaliana Erv1 
(AtErv1) (Hofhaus et al., 2003; Farver et al., 2009). Meanwhile, the absence of the structural pair in the 
P. falciparum protein (PfErv) proposes a non-essential effect on proper folding (Eckers et al., 2013). 
The mammalian ALR further holds an intermolecular disulphide bond. The so-called “disulphide camp” 
is generated between a single cysteine residue in a CP motif at the N-terminus of the flavodomain of 
one subunit and another single residue in the C-terminal region of the second subunit. The fully 
devolved clamp seems to be restricted to the mammalian homologue, but conserved N-terminal 
residues were found also in kinetoplastida, ciliates as well as many opisthokonts but not in plants, 
yeast or apicomplexans (Deponte and Hell, 2009; Eckers et al., 2013).  
Despite the long list of conserved patterns, minor structural differences within the homologues 
showed great impact on the protein function. This became clear as both the protist proteins LtErv and 
PfErv were imported into the IMS of yeast mitochondria but did not functionally replace the yeast 
protein (Eckers et al., 2013). The same lack of complementation competence was found for the human 
ALR (Hofhaus et al., 1999) as well as for AtErv1 (Peleh et al., 2017). The incompatibility of the 
kinetoplastid and yeast systems may be due to the fact that LtErv does not interact with the Mia40 
from yeast (ScMia40) and is membrane-associated in the IMS in strict contrast to soluble ScErv1 (Eckers 
et al., 2013). 
 
1.4 Aims of this study 
The main objective of this thesis was to analyse structure-function relationships of the flavoenzyme 
Erv from the non-pathogenic kinetoplastid parasite L. tarentolae. The study was conducted on the basis 
of previous work by Elisabeth Eckers (Eckers et al., 2012; Eckers et al., 2013) and comprises data that 
have been published recently (Specht et al., 2018).  
The first aim was to determine a specific structure of the protist Erv, which causes incompatibility with 
ScMia40 resulting in a disrupted oxidative protein folding pathway in yeast. This pathway is 
functionally preserved in parasitic protists despite the lack of a Mia40 homologue. Nevertheless, 
protist Erv failed to functionally complement for ScErv1 in the yeast IMS and was unable to interact 
with ScMia40 (Eckers et al., 2013). To achieve this goal chimeric constructs, in which LtErv properties 
were exchanged with those of yeast as well as structural mutants of LtErv were tested in ScErv1 
complementation assays to identify a hindering structure. 
The second objective concerned the unusual protein import and the membrane association of LtErv. I 
aimed to characterise the structural requirements as well as a redox-dependence of the membrane 
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association and the protein import process. In addition, it was of interest to determine to which 
mitochondrial membrane LtErv is associated. Since Kinetoplastida do not have a Mia40 homologue it 
is not surprising that LtErv does not cooperate with ScMia40. In addition, it was tested in vivo that LtErv 
is imported into yeast mitochondria independently of Mia40. If the protist Erv is not folding-trapped 
in the IMS by Mia40, how does it accumulate inside the mitochondrial compartment? According to the 
hypothesis to be tested, the tight membrane association of the endogenous and heterologous protein 
(Eckers et al., 2012; Eckers et al., 2013) triggers a class III pathway via a mitochondrial membrane 
binding site (Herrmann and Hell, 2005). Therefore, I performed differential fractionation assays to 
determine the membrane and the potential binding site to which LtErv is associated. Import and 
carbonate fractionation assays with mutant LtErv were conducted to find the property responsible for 
membrane-association and correct localisation inside the IMS of yeast and Leishmania mitochondria.  
The third aim was to analyse the composition of the protist oxidative protein folding pathway. 
Without a Mia40 homologue in parasitic protists, the import pathway of small Tim proteins may 
include a Mia40 replacement or consists exclusively of an Erv performing the functions of both proteins 
in the folding trap mechanism (Haindrich et al., 2017). I tested LtErv in yeast complementation assays 
for its ability to replace ScMia40. In addition, Linda Liedgens (2018) conducted an intensive and 
comprehensive search to find a Mia40 adapter replacement in L. tarentolae. There she tried to stabilise 
mixed disulphide intermediates between LtErv and the adapter replacement and between the 
replacement and a small Tim substrate. Unfortunately, the promising study had to be discontinued 
due to various difficulties with both chosen substrates. Here, I have tried to reactivate the search by 
using precisely selected substrates to overcome the known difficulties.  
The last chapter of this work was intended to test whether Erv is essential in P. falciparum. The absence 
of Mia40 points towards an indispensable Erv protein that is crucial to maintain protein import into 
the IMS as demonstrated for AtErv1 (Carrie et al., 2010; Peleh et al., 2017). On the other hand, the 
potential existence of an import receptor in these parasites might overcome the need for this protein 
as well, and PFERV elimination might not affect parasite survival. Initial knock-out studies with ∆pferv 
were performed to test which of the hypotheses apply.  
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2 Materials and Methods 
2.1 Materials 
2.1.1 Technical equipment 
Table 2.1 | List of equipment 
Device Manufacturer 
Cell culture equipment  
Electroporator for L. tarentolae (Nucleofector 2b) Lonza 
Electroporator for P. falciparum (Gene Pulser) Bio-Rad 
Incubator for L. tarentolae, P. falciparum culture Memmert 
Incubator for yeast, solid culture Heraeus; VWR 
Laminar flow hood for L. tarentolae, P. falciparum (Safe 2020) Thermo Scientific 
Laminar flow hood for yeast Flow Laboratories; Thermo Scientific 
Light microscope for L. tarentolae (AE30) Motic 
Light microscope for P. falciparum (Axio) Zeiss 
Microplate reader (Infinite F200 Pro) Tecan 
Neubauer counting chamber (haemocytometer) Roth 
Rocking platform for L. tarentolae (Rotamax 120) Heidolph 
Shaking incubator for yeast, liquid culture (Innova 4000) Infors AG; New Brunswick 
Water bath for L. tarentolae culture (F12-ED) JULABO 
Water bath for P. falciparum culture (Aqualine AL5) Lauda 
Molecular biology equipment  
DNA electrophoresis apparatus Bio-Rad; Biostep 
Electrophoresis power supply (EPS 601; Mini 300) GE Healthcare; Major Science 
Gel documentation (E.A.S.Y 440K, UVT-28L) Herolab 
Heating block (Thermomixer) Eppendorf 
Incubator for bacteria, solid culture  Heraeus; VWR 
Laminar flow hood for bacteria Flow Laboratories; Thermo Scientific 
Microwave AEG 
PCR cycler (Mastercycler gradient, Nexus gradient) Eppendorf 
Shaking incubator for bacteria, liquid culture (Innova 44, MaxQ4450) New Brunswick, Thermo Scientific 
Spectrophotometer (NanoDrop) Thermo Fisher Scientific 
Protein biochemistry equipment  
Film developer (Curix 60; Lumi-Imager) Agfa; Roche 
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Device Manufacturer 
Heating block (MBT 250) Kleinfeld Labortechnik 
Power supply (PowerPac Basic; EPS 601) Bio-Rad; Amersham Biosciences 
Rocking platform (Duomax 1030) Heidolph 
SDS-PAGE electrophoresis system (Mini-PROTEAN Tetra Cell) Bio-Rad 
Western blot apparatus (PerfectBlue Semi-Dry Electro Blotter) peqlab 
Western blot apparatus (Mini Trans-Blot cell) Bio-Rad 
General equipment  
Autoclave (VX-95) Systec 
Analytical balance Sartorius; Kern 
Centrifuge (J-6B; J2-21M/E, Rotor JA-17, JA-10) Beckman Coulter 
Centrifuge Rotina 380 R Hettich 
Magnetic stirrer Heidolph 
Microcentrifuge (Mikro 220R, Mikro 200) Hettich 
Microcentrifuge SU1550 Sunlab 
Microcentrifuge 5417R Eppendorf 
Multifuge 1 S-R Heraeus 
Multi-function rotator (PTR-30) Grant-bio 
pH meter (Basic Meter PB-11) Sartorius 
pH electrode (Blueline 56 Electrode) SI Analytics 
Pipette (Pipeteman P10-1000) Gielson 
Pipette controller (Accu-jet pro) Brand 
Portable spectrophotometer (Ultrospec 10) Amersham Biosciences 
Vortex-Mixer Heidolph Instruments 
 
2.1.2 Disposables 
Table 2.2 | List of disposables 
Disposable Source 
6 and 96 well plates (cell culture) Greiner bio-one 
Cell culture flasks for L. tarentolae (25 cm2 T-flasks, 125 mL Erlenmeyer) Corning 
Cell culture flasks for P. falciparum Greiner bio-one 
Cryovials Greiner bio-one 
Cuvettes (single-use) Sarstedt 
Electroporation cuvettes for P. falciparum (Gene Pulser, 0.2 cm gap) Bio-Rad 
Microscope slides (SuperFrost) Buddeberg 
Needle (0.4 × 19 mm) BD Mirolance 
Nitrocellulose membrane GE Healthcare 
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Disposable Source 
Parafilm Sigma Aldrich 
PCR reaction tubes Sarstedt 
Petri dishes (cell culture) Greiner bio-one 
Petri dishes  Sarstedt 
Pipette tips Steinbrenner 
PVDF membrane Millipore 
Reaction tubes (1.5 and 2 mL, safe seal) Sarstedt 
Reaction tubes (15 and 50 mL) Greiner bio-one 
Scalpel Braun 
Serological pipettes (1, 5, 10 and 25 mL) Sarstedt 
Sterile syringe filters (0.2 µM) Millipore 
Sterile syringes  BD Plastipak 
Sterile vacuum filter (0.22 µM, Stericup) Millipore 
Whatman paper GE Healthcare 
X-ray films (Super RX-N) Fujifilm 
 
2.1.3 Chemicals 
Table 2.3 | List of chemicals 
Chemical Source 
Acetic acid  Merck 
Acetone Honeywell 
Acrylamide/Bis Solution, 37.5:1 (30 % w/v) Serva 
Adenine sulphate Sigma Aldrich 
Agar Sigma Aldrich 
Agarose Serva 
AlbuMax II  Life Technologies 
Ammonium persulfate (APS) Sigma Aldrich 
Beta-Mercaptoethanol Sigma Aldrich 
Bradford reagent Bio-Rad  
Brain heart infusion (BHI) BD 
Bromophenol blue Waldeck 
BSA (Albumin bovine Fraction V, Fatty acid free) Serva 
Calcium chloride dihydrate Merck 
Complete protease inhibitor cocktail Roche 
Coomassie Brilliant Blue G 250 AppliChem 
Diamide Sigma Aldrich 
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Chemical Source 
Digitonin AppliChem 
Deoxyribonucleoside triphosphate (dNTPs) Thermo Scientific 
Dimethyl sulfoxide (DMSO) Sigma Aldrich 
Dithiothreitol (DTT) Sigma Aldrich 
DNA ladder (100 bp, 1kb) New England Biolabs 
Dnase I Roche 
Ethanol (absolute) VWR 
Ethylenediaminetetraacetic acid (EDTA) Sigma Aldrich 
Foetal calf serum (FCS heat inactivated)  Life Technologies 
Folic acid Sigma Aldrich 
Galactose  Sigma Aldrich 
Gel loading dye, purple 6× New England Biolabs 
Gentamicin Life Technologies 
Giemsa stock solution Carl Roth 
Glass beads 425-600 µm Sigma Aldrich 
Glucose monohydrate (D- Glucose) Merck 
Glycerol AppliChem 
Glycine Merck 
Hemin chloride Calbiochem 
HEPES [4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid] Merck 
Histidine (L-His) Sigma Aldrich 
Hydrochloric acid (HCl) VWR 
Hypoxanthine c.c.pro 
Isopropanol Sigma Aldrich 
Leucine (L-Leu) Sigma Aldrich 
Lithium acetate Sigma Aldrich 
Luria Bertani (LB) agar Carl Roth 
Luria Bertani (LB) medium Carl Roth 
Lysine (L-Lys) Sigma Aldrich 
Manganese (II) chloride  Merck 
Methanol Honeywell 
Methyl-PEG-maleimide (mm(PEG)24) reagent Thermo Scientific 
Midori Green Advance Nippon Genetics 
Milk powder (low-fat) Carl Roth 
MOPS (3-(N-morpholino)propane sulfonic acid) Gerbu Biotechnik 
N-ethylmaleimide (NEM) Sigma Aldrich 
Paraformaldehyde Sigma Aldrich 
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Chemical Source 
Phenylmethylsulphonyl fluoride (PMSF) Serva 
Polyethylene glycol (PEG 3350) Sigma Aldrich 
PonceauS Serva 
Potassium acetate Sigma Aldrich 
Potassium chloride (KCl) AppliChem 
Potassium dihydrogen phosphate Merck 
Potassium monohydrogen phosphate Merck 
Prestained protein ladder Thermo Scientific 
Proteinase K Roche 
RNAse A Sigma Aldrich 
Roti Phenol/Chlorophorm/Isoamylalcohol Carl Roth 
RPMI 1640, HEPES Life Technologies 
Sodium acetate Sigma Aldrich 
Sodium chloride Sigma Aldrich 
Sodium dihydrogen phosphate Merck 
Sodium dodecyl sulphate (SDS) Serva 
Sodium hydroxide  Fischer Scientific 
Sodium monohydrogen phosphate Merck 
Sorbitol (D-sorbitol) Sigma Aldrich 
TCEP (tris(2-carboxyethyl)phosphine) Sigma Aldrich 
Tetramethyl ethylenediamine (TEMED) Serva 
Trichloroacetic acid Merck 
Tris Carl Roth 
Tri-sodium citrate dihydrate Merck 
Triton X-100 Merck 
Tryptone BD 
Tryptophan (L-Trp) Sigma Aldrich 
Tween-20 Sigma Aldrich 
UltraPure Salmon Sperm DNA Solution Invitrogen 
Uracil Sigma Aldrich 
Urea Serva 
Yeast extract BD 
Yeast nitrogen base without amino acids Sigma Aldrich 
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2.1.4 Enzymes 
Table 2.4 | List of enzymes 
Enzyme Operating conditions Source 
Pfu DNA polymerase 72 °C (2 min/kb) Promega 
Phusion DNA polymerase 72 °C (15-30 sec/kb) New England Biolabs 
Proteinase K RT – on ice Roche 
Restriction enzymes 37°C  New England Biolabs 
T4 DNA ligase 16°C – RT  Thermo Scientific 
Taq DNA polymerase 68°C (1 min/kb) New England Biolabs 
 
2.1.5 Antibodies 
All antibodies were diluted in 5 % milk in TBS as indicated. Washing steps were applied at least three 
times for 10 min each in TBS. Antisera as used with α-ScErv1 and α-ScTim23 were washed off once in 
TBS, followed by three times in TBS-TT and once again in TBS to lose the detergent. Membranes that 
were decorated with the commercial antibody α-Flag were first washed once with TBS, then three 
times in TBS-T and finally with TBS. After the incubation of the secondary antibody, these membranes 
(α-Flag) were washed once in TBS, three times in TBS-TT and finally once in TBS. 
TBS    10 mM Tris/HCl, 0.9 % (w/v) NaCl, pH 7.4 
TBS-T    TBS, 0.1 % (v/v) Tween 20 
TBS-TT    TBS, 0.1 % (v/v) Tween 20, 0.2 % (v/v) Triton X-100 
Table 2.5 | List of antibodies used for western blot analysis 
Name Origin Dilution Reference 
Leishmania (primary antibodies) 
α-Cytc Rabbit 1:1000 Cell signalling technology 
α-Ef1-alpha Mouse 1:10000 Merck 
α-Flag Mouse 1:1000 Sigma Aldrich 
α-LtErv Rabbit 1:500 Eckers et al. 2012 
α-LtsTim1 Rabbit 1:500 Eckers et al. 2012 
α-LtTim17 Rabbit 1:500 Eckers et al. 2012 
α-LtTob55 Rabbit 1:250 Eckers et al. 2012 
Yeast (primary antibodies) 
α-ScCmc1 Rabbit 1:250 Johannes Herrmann* 
α-ScErv1 Rabbit 1:2000 Kai Hell** 
α-ScTim23 Rabbit 1:500 Kai Hell** 
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Name Origin Dilution Reference 
α-ScTim44 Rabbit 1:250 Kai Hell** 
α-ScTim50 Rabbit 1:250 Kai Hell** 
α-ScTom70 Rabbit 1:250 Kai Hell** 
α-ScZwf1 Rabbit 1:10 000 Buckau Lab*** 
Secondary antibodies 
α-Mouse IgG (H+L)-HRP conjugate Goat 1:5000 Bio-Rad 
α-Rabbit IgG (H+L)-HRP conjugate Goat 1:10000 Bio-Rad 
*Cell Biology, University of Kaiserslautern, Kaiserslautern, Germany 
**Biomedical Center Munich, Ludwig-Maximilians University, Martinsried, Germany 
***Center for Molecular Biology of Heidelberg University (ZMBH), Heidelberg, Germany 
 
2.1.6 Oligonucleotides (Primers) 
All oligonucleotide primers listed were purchased from Metabion. Restriction sites are underlined, and 
mutations introduced by mutagenesis primers are highlighted in red.  
Table 2.6 | List of primers 
Cloning L. tarentolae expression constructs 
Cloning MIA substrates Sequence 5’ - 3’ 
LtSubstrate1/s ATGGCTCGCTCCCGTGCAGC 
LtSubstrate1/as CTACTGTGGAGGCTGCATCGG 
LtSubstrate2/s ATGATGAAGCCAACGTCCCCTAAC 
LtSubstrate2/as CTAGTACTCCACCTCCTGACCAG 
LtSubstrate3/s ATGGCGAACGGTGTGACGGC 
LtSubstrate3/as TCAGGCCCCCTTCTCCTTCTC 
LtSubstrate4/s ATGCAGGCTCCCAAGACAAGTAC 
LtSubstrate4/as CTACTGCGCCTTCATGCCCTTC 
Mutagenesis primer Sequence 5’ - 3’ 
LtSubstrate2/C105S/s GCGAGCAAAATGATGTCTTTCTACGAAGGTCTTCAG 
LtSubstrate2/C105S/as CTGAAGACCTTCGTAGAAAGACATCATTTTGCTCGC 
LtSubstrate2/C117S/s GTTTCACAAATGGGGCTCCCTTCAGGACGACCTC 
LtSubstrate2/C117S/as GAGGTCGTCCTGAAGGGAGCCCCATTTGTGAAAC 
LtSubstrate4/C122S/s CCACGCCCATCTCGTCTTTTGGGCTGTTC 
LtSubstrate4/C122S/as GAACAGCCCAAAAGACGAGATGGGCGTGG 
LtSubstrate4/C132S/s CATTTTCGCTGCAACATCCATGCAGATGCCGTAC 
LtSubstrate4/C132S/as GTACGGCATCTGCATGGATGTTGCAGCGAAAATG 
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Cloning Flag3 and His8 tags Sequence 5’ - 3’ 
pX-backbone/FLAG/s GATCGGATCCTCTAGAAAGCTTGACTATAAGGACCACGACGGAG 
pX-backbone/FLAG/as GATCGCGGCCGCTTACTTATCGTCATCGTCTTTGTAATC 
pX-backbone/FLAG+His8/as GATCGCGGCCGCTTAGTGATGGTGATGATGGTGATGATGCTTATCGTCA
TCGTCTTTGTAATC 
Subcloning into pX-Flag-(His) Sequence 5’ - 3’ 
LtSubstrat1/BamHI/s GATCGGATCCATGGCTCGCTCCCGTGCAGC 
LtSubstrat1/HindIII/as GATCAAGCTTCTGTGGAGGCTGCATCGGGTG 
LtSubstrat2/BamHI/s GATCGGATCCATGATGAAGCCAACGTCCCC 
LtSubstrat2/HindIII/as GATCAAGCTTGTACTCCACCTCCTGACCAGC 
LtSubstrat3/BamHI/s GATCGGATCCATGGCGAACGGTGTGACGGC 
LtSubstrat3/HindIII/as GATCAAGCTTGGCCCCCTTCTCCTTCTC 
LtSubstrat4/XmaI/s GATCCCCGGGATGCAGGCTCCCAAGACAAGTAC 
LtSubstrat4/HindIII/as GATCAAGCTTCTGCGCCTTCATGCCCTTCG 
pX/SCMIA40/XmaI/s GATCCCCGGGATGCTTCGCAACTTAGTCGTC  
pX/SCMIA40/HindIII*/as GATCAAGCTTAGGTTTGGATTCCTCATTCAATG   
Subcloning into pX-backbone Sequence 5’ - 3’ 
pX/LTERV/BamHI/rN/s GATCGGATCCATGTCGGACGACGACGTAC   
pX/LTERV/XbaI/rC/as GATCTCTAGATTAGAGCTTGAGTTCTTCGTCC   
pX/KISS/BamHI/tN/s GATCGGATCCATGGTGGTGCTGCGTCGG   
pX/LTERV/XbaI/tC/as GATCTCTAGATTATTGTTCCTCGATCGTTGGCG   
Sequencing primer Sequence 5’ - 3’ 
pX-LS-s CACCCTCAACCACCCCTC 
pX-far-as CACCCCAGGCTTTACACTT 
Cloning E. coli expression constructs 
Subcloning into pET28 Sequence 5’ - 3’ 
LtSubstrat1/NcoI/s GATCCCATGGATGGCTCGCTCCCGTGCAGC 
LtSub1/HindIII/*/as GATCAAGCTTCTACTGTGGAGGCTGCATCGG 
LtSubstrat2/NcoI/s GATCCCATGGATGATGAAGCCAACGTCCCC 
LtSub2/HindIII/*/as GATCAAGCTTCTAGTACTCCACCTCCTGAC 
LtSubstrat3/NcoI/s GATCCCATGGATGGCGAACGGTGTGACGGC 
LtSub3/HindIII/*/as GATCAAGCTTTCAGGCCCCCTTCTCCTTCTC 
LtSubstrat4/NcoI/s GATCCCATGGATGCAGGCTCCCAAGACAAGTAC 
LtSub4/HindIII/*/as GATCAAGCTTCTACTGCGCCTTCATGCCCTTC 
M a t e r i a l s  a n d  M e t h o d s  | 26 
 
 
Cloning P. falciparum knock out plasmid pL7 and rescue plasmid 
Mutagenesis primer Sequence 5’ - 3’ 
PFERV/SDM3mis/fw GCTTTTTCAAATTTATATCCTTGCCACATCTGTAAATTAGATTTATTAC 
PFERV/SDM3mis/rw GTAATAAATCTAATTTACAGATGTGGCAAGGATATAAATTTGAAAAAGC 
Cloning primer Sequence 5’ - 3’ 
pL6/gRNA/PFERV/s TAAGTATATAATATTTCTAATTTACAAATATGACAGTTTTAGAGCTAGAA  
pL6/gRNA/PFERV /as TTCTAGCTCTAAAACTGTCATATTTGTAAATTAGAAATATTATATACTTA 
PFERV/5'MCS/SacII/pL6/s  GATCCCGCGGTTATCTATCAAGTTGGAGGTTC  
PFERV/5'MCS XbaI/pL6/as  GATCTCTAGACGTATGCTTTATTTTATCATATTC  
PFERV/3'MCS/EcoRI/pL6/s  GATCGAATTCTTTACATAACATGATCAACCAAG  
PFERV/3'MCS/NcoI/pL6/as  GATCCCATGGTGTATGATTTATATGCTGATTCC  
pL6/gRNA/PFTIM13/s TAAGTATATAATATTTAAAACTGTACACATGTAGAGTTTTAGAGCTAGAA  
pL6/gRNA/PFTIM13/as TTCTAGCTCTAAAACTCTACATGTGTACAGTTTTAAATATTATATACTTA  
PFTIM13/5'MCS/SacII/pL6/s  GATCCCGCGGAACATATTAAGAAGGAACAAGTTC  
PFTIM13/5'MCS/XbaI/pL6/as  GATCTCTAGATACGATGGAATGTATAATATATTC 
PFTIM13/3'MCS/EcoRI/pL6/s  GATCGAATTCGGCGCTTGGAACAGATGAC   
PFTIM13/3'MCS/NcoI/pL6/as  GATCCCATGGCATATGTAACGGTATGTCTCC  
PFERV/pHBIRH/NotI/fw GATCGCGGCCGCATGATATTTATTGAAAAGTGCTATGAAC 
PFERV/pHBIRH/SacI/rw GATCGAGCTCTTAATCAACTGTTTTGTACTTGTC 
Analytical PCR primer Sequence 5’ - 3’ 
PFTIM13-check-PCR/s TTTTCCCATCTTTTCCATTTTGG 
PFTIM13-check-PCR/as CAATGAAGGGTTATGTTAAATATAC 
Sequencing primer Sequence 5’ - 3’ 
gRNA/LanzerLab-fw GTAACCAAAATGCATAATTTTTCC 
gRNA/LanzerLab TAGGAAATAATAAAAAAGCACC 
pL7/MCS1/s TATATCCAATGGCCCCTTTC 
pL7/MCS1/as CAAAATGCTTAAGTCCTCCAC 
pL7/MCS2/as AACATTTGCTTTCTTGAAACGG 
Seq0pBIRTH/Fw TACCTACATACATATACAAACC 
Cloning yeast plasmid shuffling constructs 
Mutagenesis primer Sequence 5’ - 3’ 
LTERV/C17S/s CCCTGGTGAGTCCCCCACCCCGCTG  
LTERV/C17S/as CAGCGGGGTGGGGGACTCACCAGGG  
LTERV/C92S/s TCTCACGCTACGTGTCTGAGATGCACAACAACG  
LTERV/C92S/as CGTTGTTGTGCATCTCAGACACGTAGCGTGAGA  
LTERV/C109S/s CAAAGAACTCTTTGATTCCACCCCTAGCGTGGTGC  
LTERV/C109S/as GCACCACGCTAGGGGTGGAATCAAAGAGTTCTTTG  
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Mutagenesis primer Sequence 5’ - 3’ 
pYX/SCERV1/LtCxC/mut/s GAAGATGGCAAACCTTGTCAAGTGTACTGCAACACCCTACTTGAC 
pYX/SCERV1/LtCxC/mut/as GTCAAGTAGGGTGTTGCAGTACACTTGACAAGGTTTGCCATCTTC 
Cloning primer for chimera Sequence 5’ - 3’ 
pYX232/LTERV/KissEnd/XhoI/as GATCCTCGAGCTAACGCTTGAGACGTTTGAG 
pYX232/LTERV/linker/XhoI/as GATCCTCGAGCTACTCGATCGTTGGCGTATC 
SCERV1Link/XhoI/as GATCCTCGAGTTATTCGTCCCAGCC 
pYX/SCERV1/C-T/EcoRI/s GATCGAATTCATGAAAGCAATAGATAAAATGACG 
overlap pYX/ScCT/LtFAD/s CTCAAGAACATACAGGAAGGTTTGCCCCACCCCGCTGGAG 
overlap pYX/ScCT/LtFAD/as CTCCAGCGGGGTGGGGCAAACCTTCCTGTATGTTCTTGAG 
pYX/LTERV/N-T/XhoI/as GATCCTCGAGCTAGAGCTTGAGTTCTTCGTC 
overlap pXY/ScFAD/LtLinker/s GTAATTTCTGGGAAAAAAGATGGCACCCTGGGTACCCAAACAAG 
overlap pXY/ScFAD/LtLinker/as CTTGTTTGGGTACCCAGGGTGCCATCTTTTTTCCCAGAAATTAC 
Subcloning into pYX232 Sequence 5’ - 3’ 
pYX232/LTERV/EcoRI/rN/s GATCGAATTCATGTCGGACGACGACGTACACG   
pYX232/LTERV/XhoI/rC/as GATCCTCGAGTTAGAGCTTGAGTTCTTCGTCC  
pYX232/KISS/EcoRI/tN/s GATCGAATTCATGGTGGTGCTGCGTCGGTGG   
pYX232/LTERV/XhoI/tC/as GATCCTCGAGTTATTGTTCCTCGATCGTTGGCG  
Cloning Mia40-MTS constructs Sequence 5’ - 3’ 
pYX232/MIA40MTS/EcoRI/s GATCGAATTCATGCTTCGCAACTTAGTCGTC  
pYX232/MIA40MTS/as AGGCTTCCTATTAGGAGCAATA  
pYX232/MIA40MTS/PFERV/overlap/s TATTGCTCCTAATAGGAAGCCTATGATATTTATTGAAAAGTGCTATGAAC  
pYX232/PFERV/XhoI/as GATCCTCGAGTTAATCAACTGTTTTGTACTTGTC  
pYX232/MIA40MTS/LTERV/overlap/s TATTGCTCCTAATAGGAAGCCTATGTCGGACGACGACGTACACG  
pYX232/MIA40MTS/LTERVCterm/overlap/s TATTGCTCCTAATAGGAAGCCTATGGTGGTGCTGCGTCGGTGG  
pYX232/MIA40MTS/SCERVNterm/overlap/s TATTGCTCCTAATAGGAAGCCTATGAAAGCAATAGATAAAATGACGGAT 
Analytical PCR primer Sequence 5’ - 3’ 
SCERVCxxC/s CTTGCCGATCATGTAACACCC    
SCERVLinker/XhoI/as CTCGAGTTATTCGTCCCAGCC  
SCERVLtCxxxC/s GTCAAGTGTACTGCAACACCC  
LTERVLinker/XhoI/as CTCGAGCTACTCGATCGTTGG    
Sequencing primer Sequence 5’ - 3’ 
pYX232-fw GCAGCATAATTTAGGAGTTTA 
pYX232-rev GATGTATCGGTCAGTCATTAATAC 
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2.1.7 Plasmids/constructs 
Table 2.7 | List of plasmids and constructs 
Name Characteristics/Application Reference 
Vectors  
pDRIVE AmpR, KanR, T7 promoter, SP6 promoter; 
Subcloning in E. coli 
Qiagen 
pET28a KanR, T7 promoter, C- and N-terminal His-Tag; 
Expression in E. coli 
Novagen 
pHBIRH AmpR, BlasticidinSR, RLUC; 
Rescue P. falciparum knock out strains 
Kristin Fürle* 
pL6 AmpR, hDHFR, SCFCU1; 
Guide RNA expression and homologous 
recombination in P. falciparum via CRISPR/Cas9 
J.J. Lopez-Rubio** 
pQE30 AmpR, N-terminal MRGSH6GS-Tag, T5 promoter; 
Expression and subcloning in E. coli 
Qiagen 
pX-backbone AmpR, NeoR, N-terminal His8-Tag; 
Expression and pull-down assays in L. tarentolae 
Linda Liedgens* 
pX-Flag AmpR, NeoR, C-terminal Flag-Tag; 
Expression in L. tarentolae 
Mirko Höhn*** 
pX-Flag-His AmpR, NeoR, C-terminal Flag-Tag, C-terminal His8-
Tag; 
Expression and pull-down assays in L. tarentolae 
Mirko Höhn*** 
pYX232 AmpR, 2μ, TRP, TPI promoter; 
Plasmid shuffling in S. cerevisiae 
Eckers et al. 2013 
TOPO-TA AmpR, KanR, T7 promoter; 
Subcloning in E. coli 
Life Technologies 
E. coli cloning and expression plasmids 
pDRIVE/ Sub 1 Putative MIA substrate 1 [LtaP04.0660]  Mirko Höhn*** 
pDRIVE/ Sub 2 Putative MIA substrate 2 [LtaP35.0210] Mirko Höhn*** 
pDRIVE/ Sub 2/ C105S Putative MIA substrate 2, point mutation C105S Mirko Höhn*** 
pDRIVE/ Sub 2/ C117S Putative MIA substrate 2, point mutation C117S Mirko Höhn*** 
pDRIVE/ Sub 3 Putative MIA substrate 3 [LtaP19.1110] Mirko Höhn*** 
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Name Characteristics/Application Reference 
pDRIVE/ Sub 4 Putative MIA substrate 4 [LtaP09.1390] Mirko Höhn*** 
pDRIVE/ Sub 4/ C122S Putative MIA substrate 4, point mutation C122S Mirko Höhn*** 
pET28/ Sub 1 Putative MIA substrate 1 (NcoI /HindIII) Mirko Höhn*** 
pET28/ Sub 2 Putative MIA substrate 2 (NcoI/HindIII) Mirko Höhn*** 
pET28/ Sub 2/ C105S Putative MIA substrate 2 (NcoI/HindIII), point 
mutation C105S 
This work 
pET28/ Sub 2/ C117S Putative MIA substrate 2 (NcoI/HindIII), point 
mutation C117S 
This work 
pET28/ Sub 3 Putative MIA substrate 3 (NcoI/HindIII) Mirko Höhn*** 
pET28/ Sub 4 Putative MIA substrate 4 (NcoI/HindIII) Mirko Höhn*** 
pL6/ gRNA/ PFERV PFERV guide RNA  This work 
pL6/ gRNA/ PFTIM13 PFTIM13 guide RNA This work 
pL7/ gRNA/ 3’/ PFERV PFERV guide RNA and 3’ homologous region 
(EcoRI/NcoI) 
This work 
pL7/ gRNA/ 3’/ PFTIM13 PFTIM13 guide RNA and 3’ homologous region 
(EcoRI/NcoI) 
This work 
pQE30/ #1 LTERV/ C-term LTERV residues 123-314 (BamHI/HindIII) Eckers (2012) 
pQE30/ #2 LTERV/ N-term LTERV residues 1-119 (BamHI/HindIII) Eckers (2012) 
pQE30/ #2 LTERV/ N-term/C17S LTERV residues 1-119 (BamHI/HindIII), point 
mutation C17S 
Specht et al. 2018 
pQE30/ #3 LTERV/ C300S/ 
C304S 
LTERV (BamHI/HindIII), point mutation C300S and 
C304S 
Eckers et al. 2013 
pQE30/ #3 LTERV/ C17S/ 
C300S/ C304S 
LTERV (BamHI/HindIII), point mutation C17S, C300S 
and C304S 
Specht et al., 2018 
pQE30/ #4 LTERV/ C63S LTERV (BamHI/HindIII), point mutation C63S Eckers et al. 2013 
pQE30/ #4 LTERV/ C17S/ C63S LTERV (BamHI/HindIII), point mutation C17S and 
C63S 
Specht et al. 2018 
pQE30/ #5 LTERV/ C300S LTERV (BamHI/HindIII), point mutation C300S Eckers et al. 2013 
pQE30/ #5 LTERV/ C17S/ C300S LTERV (BamHI/HindIII), point mutation C17S and 
C300S 
Specht et al. 2018 
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Name Characteristics/Application Reference 
pQE30/ #6 LTERV/ C17S LTERV (BamHI/HindIII), point mutation C17S  Eckers et al. 2013 
pQE30/ #7 LTERV/ C92S/ C109S LTERV (BamHI/HindIII), point mutation C92S and 
C109S 
Specht et al. 2018 
pQE30/ #7 LTERV/ C17S/ C92S/ 
C109S 
LTERV (BamHI/HindIII), point mutation C17S, C92S 
and C109S 
Specht et al. 2018 
pQE30/ PFERV PFERV (BamHI/HindIII) Eckers et al. 2013 
pQE30/ PFERV/ 3mismatch PFERV (BamHI/HindIII), silent point mutations 
T249C, T252C and T255C  
This work 
TOPO-TA/ PFERV/ 3’ PFERV 3’ homologous region This work 
TOPO-TA/ PFERV/ 5’ PFERV 5’ homologous region This work 
TOPO-TA/ PFTIM13/ 3’ PFTIM13 3’ homologous region This work 
TOPO-TA/ PFTIM13/ 5’ PFTIM13 5’ homologous region This work 
L. tarentolae expression constructs 
pX/ LTERV LTERV (BamHI/HindIII) Linda Liedgens* 
pX/ #1 LTERV/ C-term LTERV residues 123-314 (BamHI/XbaI) This work 
pX/ #2 LTERV/ N-term LTERV residues 1-119  (BamHI/XbaI) This work 
pX/ #3 LTERV/ C300S/ C304S LTERV (BamHI/XbaI), point mutation C300S and 
C304S 
This work 
pX/ #4 LTERV/ C63S LTERV (BamHI/XbaI), point mutation C63S This work 
pX/ #5 LTERV/ C300S LTERV (BamHI/XbaI), point mutation C300S  This work 
pX/ #6 LTERV/ C17S LTERV (BamHI/XbaI), point mutation C17S  This work 
pX/ #7 LTERV/ C92S/ C109S LTERV (BamHI/XbaI), point mutation C92S and C109S This work 
pX-Flag-His/ MIA40s MIA40 residues 1-70 and 284-403 (XmaI/HindIII) This work 
pX-Flag-His/ MIA40s/ SPS MIA40 residues 1-70 and 284-403 (XmaI/HindIII), 
point mutation C85S and C87S 
This work 
pX-Flag-His/ Sub 1 Putative MIA substrate 1 (BamHI/HindIII) This work 
pX-Flag-His/ Sub 2 Putative MIA substrate 2 (BamHI/HindIII) This work 
pX-Flag-His/ Sub 2/ C105S Putative MIA substrate 2 (BamHI/HindIII), point 
mutation C105S 
This work 
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Name Characteristics/Application Reference 
pX-Flag-His/ Sub 2/ C117S Putative MIA substrate 2 (BamHI/HindIII), point 
mutation C117S 
This work 
pX-Flag-His/ Sub 3 Putative MIA substrate 3 (BamHI/HindIII) This work 
pX-Flag-His/ Sub 4 Putative MIA substrate 4 (XmaI/HindIII) This work 
pX-Flag/ MIA40s MIA40 residues 1-70 and 284-403 (XmaI/HindIII) This work 
pX-Flag/ MIA40s/ SPS MIA40 residues 1-70 and 284-403 (XmaI/HindIII), 
point mutation C85S and C87S 
This work 
pX-Flag/ Sub 1 Putative MIA substrate 1 (BamHI/HindIII) This work 
pX-Flag/ Sub 2 Putative MIA substrate 2 (BamHI/HindIII) This work 
pX-Flag/ Sub 2/ C105S Putative MIA substrate 2 (BamHI/HindIII), point 
mutation C105S 
This work 
pX-Flag/ Sub 2/ C117S Putative MIA substrate 2 (BamHI/HindIII), point 
mutation C117S 
This work 
pX-Flag/ Sub 3 Putative MIA substrate 3 (BamHI/HindIII) This work 
pX-Flag/ Sub 4 Putative MIA substrate 4 (XmaI/HindIII) This work 
P. falciparum knock out and rescue constructs 
pL7/ gRNA/ 3’/ 5’/ PFERV PFERV guide RNA, 3’ (EcoRI/NcoI) and 5’ (SacII/XbaI) 
homologous region  
This work 
pL7/ gRNA/ 3’/ 5’/ PFTIM13 PFTIM13 guide RNA, 3’ (EcoRI/NcoI) and 5’ 
(SacII/XbaI) homologous region 
This work 
pHBIRH/ PFERV/ 3mismatch RLUC was replaced with PFERV (NotI/SacI), silent 
point mutations T249C, T252C and T255C 
This work 
Yeast plasmid shuffling constructs 
pRS314/ MIA40s MIA40 residues 1-70 and 284-403  Peleh et al. 2016 
pRS314/ MIA40s/ SPS MIA40 residues 1-70 and 284-403, point mutation 
C85S and C87S  
Peleh et al. 2016 
pYX232/ Chimera 1 SCERV1 residues 1-82 and LTERV residues 17-312 
(EcoRI/XhoI) 
Specht et al. 2018 
Maike Eberhardt* 
pYX232/ Chimera 1/ Mia40MTS SCMIA40 residues 1-70, SCERV1 residues 1-82 and 
LTERV residues 17-312 (EcoRI/XhoI) 
Specht et al. 2018 
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Name Characteristics/Application Reference 
pYX232/ Chimera 2 SCERV1 residues 1-82 and LTERV residues 17-299 
(EcoRI/XhoI) 
Specht et al. 2018 
Maike Eberhardt* 
pYX232/ Chimera 2/ Mia40MTS SCMIA40 residues 1-70, SCERV1 residues 1-82 and 
LTERV residues 17-299 (EcoRI/XhoI) 
Specht et al. 2018 
pYX232/ Chimera 3 SCERV1 residues 1-82 and LTERV residues 17-133 
(EcoRI/XhoI) 
Specht et al. 2018 
Maike Eberhardt* 
pYX232/ Chimera 3/ Mia40MTS SCMIA40 residues 1-70, SCERV1 residues 1-82 and 
LTERV residues 17-133 (EcoRI/XhoI) 
Specht et al. 2018 
pYX232/ Chimera 4 SCERV1 residues 1-181 and LTERV residues 117-312 
(EcoRI/XhoI) 
Specht et al. 2018 
Maike Eberhardt* 
pYX232/ Chimera 4/ Mia40MTS SCMIA40 residues 1-70, SCERV1 residues 1-181 and 
LTERV residues 117-312 (EcoRI/XhoI) 
Specht et al. 2018 
pYX232/ Chimera 5 SCERV1 residues 1-181 and LTERV residues 117-299 
(EcoRI/XhoI) 
Specht et al. 2018 
Maike Eberhardt* 
pYX232/ Chimera 5/ Mia40MTS SCMIA40 residues 1-70, SCERV1 residues 1-181 and 
LTERV residues 117-299 (EcoRI/XhoI) 
Specht et al. 2018 
pYX232/ Chimera 6 SCERV1 residues 1-29, LTERV residues 300-304 and 
SCERV1 residues 34-189 (EcoRI/XhoI) 
Specht et al. 2018 
Maike Eberhardt* 
pYX232/ Chimera 6/ Mia40MTS SCMIA40 residues 1-70, SCERV1 residues 1-29, LTERV 
residues 300-304 and SCERV1 residues 34-189 
(EcoRI/XhoI) 
Specht et al. 2018 
pYX232/ LTERV LTERV (BamHI/XhoI) Eckers et al. 2013 
pYX232/ LTERV/ Mia40MTS SCMIA40 residues 1-70 and LTERV (BamHI/XhoI) Specht et al. 2018 
pYX232/ #1 LTERV/ C-term LTERV residues 123-314  (EcoRI/XhoI) Specht et al. 2018 
pYX232/ #1 LTERV/ C-term/ 
Mia40MTS 
SCMIA40 residues 1-70 and LTERV residues 123-314  
(EcoRI/XhoI) 
Specht et al. 2018 
pYX232/ #2 LTERV/ N-term LTERV residues 1-119 EcoRI/XhoI) Specht et al. 2018 
pYX232/ #2 LTERV/ N-
term/C17S 
LTERV residues 1-119 (EcoRI/XhoI), point mutation 
C17S 
Specht et al. 2018 
pYX232/ #2 LTERV/ N-term/ 
Mia40MTS 
SCMIA40 residues 1-70 and LTERV residues 1-119 
(EcoRI/XhoI) 
Specht et al. 2018 
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Name Characteristics/Application Reference 
pYX232/ #3 LTERV/ C300S/ 
C304S 
LTERV (EcoRI/XhoI, point mutation C300S and C304S Specht et al. 2018 
pYX232/ #3 LTERV/ C17S/ 
C300S/ C304S 
LTERV (EcoRI/XhoI), point mutation C17S, C300S and 
C304S 
Specht et al. 2018 
pYX232/ #4 LTERV/ C63S LTERV (EcoRI/XhoI), point mutation C63S Specht et al. 2018 
pYX232/ #4 LTERV/ C17S/ C63S LTERV (EcoRI/XhoI), point mutation C17S and C63S Specht et al. 2018 
pYX232/ #5 LTERV/ C300S LTERV (EcoRI/XhoI), point mutation C300S Specht et al. 2018 
pYX232/ #5 LTERV/ C17S/ 
C300S 
LTERV (EcoRI/XhoI), point mutation C17S and C300S Specht et al. 2018 
pYX232/ #6 LTERV/ C17S LTERV (EcoRI/XhoI), point mutation C17S Specht et al. 2018 
pYX232/ #6 LTERV/ C17S/ 
Mia40MTS 
SCMIA40 residues 1-70 and LTERV (EcoRI/XhoI), 
point mutation C17S 
Specht et al. 2018 
pYX232/ #7 LTERV/ C92S/ 
C109S 
LTERV (EcoRI/XhoI), point mutation C92S and C109S Specht et al. 2018 
pYX232/ #7 LTERV/ C17S/ C92S/ 
C109S 
LTERV (EcoRI/XhoI), point mutation C17S, C92S and 
C109S 
Specht et al. 2018 
pYX232/ PFERV PFERV (NcoI/XhoI) Eckers et al. 2013 
pYX232/ PFERV/ Mia40MTS SCMIA40 residues 1-70 and PFERV (NcoI/XhoI) Specht et al. 2018 
pYX232/ SCERV1 SCERV1 (EcoRI/XhoI) Eckers et al. 2013 
*Centre for Infectious Diseases, Parasitology, University Hospital Heidelberg  
**Laboratoire de Parasitologie - Mycologie, Montpellier, France 
***Biochemistry, University of Kaiserslautern, Kaiserslautern, Germany 
 
2.1.8 Bacterial strains 
Table 2.8 | List of E. coli strains 
Strain Genotype Application Source 
XL-1 blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 
lac [F´ proAB lacIqZΔM15 Tn10 (Tetr)]. 
Cloning  Qiagen 
NovaBlue SinglesTM 
competent cells 
endA1 hsdR17 (rK12– mK12+) supE44 thi-1 recA1 
gyrA96 relA1 lac F′[proA+B+ lacIqZΔM15::Tn10] 
(TetR) 
Cloning Merck 
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2.1.9 Leishmania strains 
The L. tarentolae WT strain listed below was genetically manipulated by introducing episomal DNA 
using the Leishmania expression vectors pX-backbone, pX-Flag and pX-Flag-His. For a detailed listing 
of constructs transfected into L. tarentolae see Table 2.7. 
Table 2.9 | List of L. tarentolae strains 
Strain Source 
UC André Schneider* 
*Department of Chemistry and Biochemistry, University of Bern, Bern, Switzerland 
 
2.1.10 Plasmodium strains 
The listed P. falciparum strains were used for further genetic manipulations. A complete list of 
constructs that were introduced into these strains can be found in Table 2.7. 
Table 2.10 | List of P. falciparum strains 
Strain Characteristics Source 
3D7 Origin: derived from NF54 Michael Lanzer* 
3D7pUF1-Cas9 Transgene parasite line expressing Cas9 Verena Staudacher* 
*Centre for Infectious Diseases, Parasitology, University Hospital Heidelberg 
 
2.1.11 Yeast strains 
The S. cerevisiae knock out strains listed below were further genetically modified by transfecting 
episomal DNA as part of the yeast expression vectors pRS314 and pYX232. For more detailed 
information see Table 2.7. 
Table 2.11 | List of S. cerevisiae strains 
Strain Genotype                         Application Source 
YPH499Δmia40 ura3-52, lys2-801amber, ade2-101ocre, trp1-63, his3-
200, leu2-1, mia40::His5 [pRS316SCMIA40, URA3] 
Plasmid 
shuffling 
Johannes 
Herrmann* 
YPH501Δerv1 ura3-52, lys2-801amber, ade2-101ocre, trp1-63, his3-
200, leu2-1, erv1::His3 [pRS426MET25SCERV1, 
URA3]  
Plasmid 
shuffling 
Johannes 
Herrmann* 
*Cell Biology, University of Kaiserslautern, Kaiserslautern, Germany 
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2.1.12 Selection drugs 
Antimalarial drugs were prepared in DMSO and further diluted in RPMI1640. All stock solutions were 
stored at -20°C under light protection.  
Table 2.12 | List of selection drugs 
Drug Stock solution Working concentration Supplier 
E. coli    
Ampicillin  100 mg/mL in 50 % ethanol 100 μg/mL AppliChem 
Kanamycin 25 mg/mL in ddH2O 25 μg/mL AppliChem 
L. tarentolae    
G418 disulphate 50 mg/mL in ddH2O 0.1 mg/mL AppliChem 
P. falciparum    
Atovaquone  200 μM in RPMI 1640 100 nM Sigma Aldrich  
Blasticidin S 10 mg/mL in HEPES buffer 2 µg/mL Invivogen 
WR99210  20 μM in RPMI 1640 5 nM Jacobus Pharmaceutical 
 
2.1.13 Kits 
Table 2.13 | List of commercial kits 
Kit Manufacturer 
Amersham ECL Western Blotting Detection Reagents  GE Healthcare 
Basic Parasite Nucleofector™ Kit 2 Lonza 
In Fusion HD Cloning Kit Clontech 
Plasmid Mini/Midi/Maxi Kit  Qiagen 
SuperSignal West Femto  Thermo Scientific 
TOPO TA – Cloning Kit  Invitrogen 
Wizard® SV Gel and PCR Clean-Up System  Promega 
 
2.1.14 Software and databases 
Table 2.14 | List of software and databases 
Software/Database Source 
BioEdit  http://bioedit.software.informer.com/7.2/ 
Clustal Omega Alignment tool https://www.ebi.ac.uk/Tools/msa/clustalo/ 
CorelDraw X7  Corel Corporation 
EndNote X7 Thomson Reuters 
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Software/Database Source 
ExPASy  https://www.expasy.org/ 
JustBio  http://www.justbio.com 
MS Office  Microsoft 
NCBI (Database)  http://www.ncbi.nlm.nih.gov 
NEBcutter  V2.0 http://nc2.neb.com/NEBcutter2/ 
PlasmoDB  http://plasmodb.org/plasmo/ 
Pro-data SX  Applied Photophysics 
Protospacer  http://www.protospacer.com/ 
SigmaPlot 13.0  Systat Software, Inc. 
Saccharomyces Genome Database (SGD) https://www.yeastgenome.org/ 
Spectra manager  JASCO 
TriTrypDB http://tritrypdb.org/tritrypdb/ 
 
2.2 Sterilisation 
All media, buffers and solutions were sterilised by autoclaving at 121 °C for 15 min. Glass materials, 
pipette tips, reaction tubes, other disposals, liquid waste and bags were autoclaved at 121 °C for 
20 min. Heat instable solutions were instead filter sterilised using a pore size of 0.22 µm.  
 
2.3 Molecular biology methods 
2.3.1 Cloning constructs for genetic manipulation of P. falciparum  
The pL7 constructs to knock out PFERV and PFTIM13 were generated over numerous different cloning 
steps. Guide sequences were determined by the protospacer software and generated by annealing the 
complementary primers pL6/gRNA/s and pL6/gRNA/as. Oligonucleotides were therefore boiled at 
94 °C for 2 min and slowly cooled to room temperature (RT). The resulting guide DNA was fused into 
the AvrII/BtgZI restriction sites of plasmid pL6 using the In-Fusion HD Cloning Kit according to the 
manufacturer’s protocol. Three’ and 5’ homologous regions were amplified by polymerase chain 
reaction (PCR) from genomic DNA (gDNA) of strain 3D7 using Taq DNA polymerase and the primer pair 
3'MCS/EcoRI/pL6/s and 3'MCS/NcoI/pL6/as or 5'MCS/SacII/pL6/s and 5'MCS/XbaI/pL6/as, 
respectively. The obtained PCR fragments were subcloned into TOPO-TA according to manufacturer’s 
protocol and introduced into pL6 via the restriction sites EcoRI/NcoI (3’) and SacII/XbaI (5’).  
To generate the pHBIRH/PFERV/3mismatch rescue plasmid, PFERV was first mutated by site-directed 
mutagenesis to protect the episomal ERV copy from Cas9 activity. Silent point mutations were 
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introduced by Gino Turra at the position T249C, T252C and T255C at proximity to the protospacer 
adjacent motif (PAM) to decrease the likelihood of a stable sgRNA/DNA heteroduplex (Cong et al., 
2013; Hsu et al., 2013; Sternberg et al., 2014; Stemmer et al., 2015). The previously cloned 
pQE30/PFERV (Eckers et al., 2013) was used as template. The construct was finally introduced into 
vector pHBIRH via the NotI/SacI restriction sites. 
 
2.3.2 Cloning constructs for genetic manipulation of L. tarentolae 
For protein production in Leishmania and purification purposes, two pX vectors were designed (Linda 
Liedgens and Mirko Höhn) having either a C-terminal FLAG3-tag or a C-terminal FLAG3-His8-tag. Tags 
were amplified from vector pLPC (provided by Gino Turra) using Pfu DNA polymerase and the primers 
pX-backbone/FLAG/s and pX-backbone/FLAG/as or pX-backbone/FLAG+His8/as, respectively. Both 
tags were introduced separately in vector pX-backbone using the restriction sites HindIII/NotI to 
produce the new plasmids pX-Flag and pX-Flag-His (Mirko Höhn).  
The putative substrates 1-4 of the oxidative protein folding pathway were amplified from gDNA by the 
primer pair LtSubstrateX/s and LtSubstrateX/as, and Taq DNA polymerase. Constructs were 
subsequently subcloned into pDRIVE (Mirko Höhn). Cysteine point mutations of the substrates 2 and 
4 were introduced by site-directed mutagenesis using primers listed in Table 2.6 (section “Mutagenesis 
primer”, by Mirko Höhn and myself). All the pDRIVE constructs served as templates in a following PCR 
reaction using Pfu DNA polymerase and the primer pairs LtSubstrateX/BamHI/s and 
LtSubstrateX/HindIII/as or LtSubstrate4/XmaI/s and LtSubstrate4/HindIII/as, respectively. Substrates 
were introduced into the BamHI/HindIII or in case of substrate 4 into the XmaI/HindIII restriction sites 
of the Leishmania expression vectors pX-Flag and pX-Flag-His. For recombinant expression in E. coli, 
the substrates were amplified from pDRIVE by the primer pair LtSubstrateX/NcoI/s and 
LtSubX/HindIII/*/as and cloned into pET28 using the NcoI/HindIII restriction sites (Mirko Höhn).  
MIA40s and MIA40s-SPS were obtained from PCR using the primers pX/SCMIA40/XmaI/s and 
pX/SCMIA40/HindIII*/as, the plasmids pRS314/MIA40s or pRS314/MIA40s/SPS as templates, and Pfu 
DNA polymerase. Both constructs were subsequently cloned into the vectors pX-Flag and pX-Flag-His 
as exemplified above.  
LTERV truncations and cysteine mutants were previously cloned in plasmids pQE30 and pYX232 by 
Elisabeth Eckers and Maike Eberhardt (Eckers et al., 2013; Specht et al., 2018) and were Taq-amplified 
with the primers pairs pX/KISS/BamHI/tN/s and pX/LTERV/XbaI/rC/as (LTERVC-term), and 
pX/LTERV/BamHI/rN/s and pX/LTERV/XbaI/tC/as (LTERVN-term), or pX/LTERV/BamHI/rN/s and 
pX/LTERV/XbaI/rC/as (LTERVC300S/C304S, LTERVC63S, LTERVC300S, LTERV C17S, LTERV C92S/C17S). All PCR products 
were finally cloned into the BamHI/XbaI restriction sites of vector pX-backbone. 
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2.3.3 Polymerase chain reaction (PCR) 
PCR was used to amplify DNA fragments or to introduce mutations by site-directed mutagenesis. 
Reactions were performed in a total volume of 50 µL with gDNA or plasmid DNA as templates and 
primers listed in Table 2.1. Pfu DNA polymerase was favoured over Taq for fragments larger than 
500 bp. Overlap extension PCR was performed with Phusion DNA polymerase. A standard cloning PCR 
reaction was pipetted on ice as described in Table 2.15. 
Table 2.15 | Pipetting scheme of a standard cloning PCR reaction 
Volume Component 
5 µL 
2 µL 
0.5 µL 
1 µL 
1 µL 
0.5 µL 
ad 50 µL 
10× Taq buffer 
dNTPs 
DNA template 
sense primer (100 µM) 
antisense primer (100 µM) 
Taq DNA polymerase 
ddH2O 
 
PCR cycling conditions (Table 2.16) were chosen according to fragment size, operating polymerase (see 
Table 2.4) and melting temperature of the primers. The latter was calculated using the formula: 
Tm = 4 × N (G + C) + 2 × M (A + T) – 5 °C 
Table 2.16 | Standard PCR program using Taq DNA polymerase 
Step  Cycles Temperature Time  
Initial denaturation  
Denaturation 
Annealing 
Elongation 
Final elongation 
 
1 
30 
30 
30 
1 
hold 
94 °C 
94 °C 
52 °C 
68 °C 
68 °C 
4 °C 
120 sec 
45 sec 
45 sec 
60 sec 
120 sec 
 
 
2.3.4 Site-directed mutagenesis 
Point mutations were generated by site-directed mutagenesis. Mutated oligonucleotides were 
between 25 and 45 bases in length, which should result in a melting temperature of Tm > 78 °C. They 
were further designed to terminate at either the bases G or C and the mismatch was ideally introduced 
in the middle of the primer. Mutagenesis PCR was carried out in four different batches (A-D) in a total 
reaction volume of 50 µL each, adopting Pfu polymerase (Table 2.17). 
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Table 2.17 | Pipetting scheme for a standard mutagenesis PCR 
A B C D Component 
- 
5 µL 
4 µL 
1 µL 
1 µL [100 µM] 
1 µL [100 µM] 
1 µL 
ad 50 µL 
- 
5 µL 
4 µL 
1 µL 
1 µL [1 µM] 
1 µL [1 µM] 
1 µL 
ad 50 µL 
2 µL 
5 µL 
4 µL 
1 µL 
1 µL [100 µM] 
1 µL [100 µM] 
1 µL 
ad 50 µL 
2 µL 
5 µL 
4 µL 
1 µL 
1 µL [1 µM] 
1 µL [1 µM] 
1 µL 
ad 50 µL 
DMSO 
Pfu buffer with MgSO4 
dNTPs 
DNA template  
sense primer  
antisense primer  
Pfu DNA polymerase 
ddH2O  
 
Typically, a mismatch reaction was cycled as follows in Table 2.18. 
Table 2.18 | Standard PCR program for mutagenesis PCR  
Step  Cycles Temperature Time  
Initial denaturation  
Denaturation 
Annealing 
Elongation 
Final elongation 
 
1 
18 
18 
18 
1 
hold 
94 °C 
94 °C 
65 °C 
72 °C 
72 °C 
4 °C 
60 sec 
30 sec 
60 sec 
9 min 
9 min 
 
  
Following PCR reaction, the pooled 200 µL of methylated template DNA was digested by adding 22.5 µL 
buffer CutSmart (NEB) and 2 µL DpnI. The mixture was incubated overnight at 37 °C.  
 
2.3.5 Purification of DNA 
DNA fragments obtained from PCR or preparative restriction digestion were purified directly or after 
agarose gel electrophoresis and extraction from the gel by using the Wizard® SV Gel and PCR Clean-Up 
System. Thereby primers, salts, enzymes and agarose were removed. Clean-up was performed 
according to the manufacturer’s protocol and DNA was finally eluted in 30 µL of the supplied water.   
 
2.3.6 Restriction digest of DNA 
DNA fragments obtained from PCR or plasmid DNA were subsequently cleaved with restriction 
endonucleases for subcloning or analytical purposes, respectively. Restriction enzymes were handled 
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according to manufacturer’s recommendations. For subcloning, 30 µL of the purified PCR product or 
5 µL of a plasmid preparation were digested in a total volume of 50 µL, containing 5 µL of the 
appropriate 10× buffer (NEB) and 0.5 µL of each restriction enzyme. The mixture was typically 
incubated at 37 °C for 3 h or overnight. Analytical digestions were set in a total volume of 20 µL. 
Therefore 5 µL plasmid DNA were incubated with 2 µL 10× buffer and 0.1 µL of each restriction enzyme 
at 37 °C for at least 1 h. Restriction digestions were subsequently evaluated by agarose gel 
electrophoresis.  
 
2.3.7 Agarose gel electrophoresis  
DNA fragments and plasmids were examined for their size, quantity and purity by agarose gel 
electrophoresis. Samples were supplemented with 6× loading dye purple (NEB) and loaded to a 1-2 % 
agarose gel in 1× TAE buffer. For detection, 1 μL/mL Midori Green was added to the loading dye as 
well as the DNA ladder. Gels were run at 100-150 V for 15-40 min, visualised by an UV transilluminator 
and documented with a camera.  
1× TAE buffer   40 mM Tris/HAc, 1 mM EDTA, pH 7.6 
 
2.3.8 Ligation of DNA fragments 
Recombinant plasmids were generated by joining DNA fragments into the vector using cohesive ends. 
Typically inserts were mixed in a ratio of 5:1 with the digested vector reaching a total volume of 20 µL. 
Additionally 2 µL buffer and 1 µL T4 ligase were added before incubating the mixture at 16 °C overnight.  
 
2.3.9 Transformation of chemically competent E. coli cells 
Chemically competent E. coli XL1-blue cells (stored at -80°C, 50 µL) were thawed on ice, homogenised 
and complemented with 0.5-10 µL of plasmid DNA or ligation mixture. Cells were hold on ice for at 
least 20 min, heat shocked at 42 °C for 90 sec and rested on ice for another 5 min. Afterwards 500 µL 
of pre-warmed SOC or LB medium was added, and the cells were incubated in a thermomixer at 
500 rpm and 37 °C for 1 h. Finally, 20-200 µL of the cell mixture were plated on agar plates containing 
100 μg/ml ampicillin or kanamycin, depending on the resistance cassette of the vector. For delicate 
ligations, cells were centrifuged at 3000× g for 30 sec and all cells were spread in a total volume of 
200 µL. Plates were incubated at 37 °C overnight, sealed by parafilm, and stored at 4 °C for up to three 
weeks.   
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NovaBlue Singles™ Competent Cells were handled and transformed according to manufacturer´s 
protocol.   
SOC-medium  2 % (w/v) tryptone, 0.5 % (w/v) yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM 
MgCl2, 20 mM glucose 
 
2.3.10 Analytical PCR 
E. coli colonies obtained from transformation were screened for the desired insert by analytical PCR. 
A single E. coli colony was picked from the transformation plate and transferred to a new agar plate, 
which was sectioned and labelled clone by clone, as well as into a PCR reaction tube containing 5 µL 
ddH2O. The plate was incubated at 37 °C overnight and the cell-water-mixture was used as template 
for the following PCR reaction. Ideally, primer pairs were chosen to bind to the vector on one side and 
to the insert on the other side. Colony PCR reactions were performed according to the conditions 
stated in Table 2.16 after blending the components mentioned below. 
Table 2.19 | Pipetting scheme for a colony PCR 
Volume Component 
5 µL  
1 µL 
0.4 µL 
0.2 µL 
0.2 µL 
0.1 µL 
Ad 10 µL 
DNA template (colony resuspended in water) 
10× Taq buffer  
dNTPs 
sense primer (100 µM) 
antisense primer (100 µM) 
Taq DNA polymerase 
ddH2O  
 
2.3.11 Culture of E. coli 
E. coli cells were cultured in LB, SOC or YT medium supplemented either with ampicillin or kanamycin, 
depending on the resistance cassette of the vector. 
For plasmid DNA Mini, Midi and Maxi preparations, a single E. coli colony was picked from a LB agar 
plate and cultured in a total volume of 3 mL, 200 mL or 500 mL of liquid LB medium at 37 °C and 
160 rpm overnight. Midi and Maxi cultures were inoculated with a pre-culture of 3 mL that was grown 
for at least 4 h.  
Small-scale cultures of E. coli were grown in 10 mL YT medium overnight under standard conditions to 
produce recombinant DNA sufficient for a single L. tarentolae transfection.  
LB-medium   25 g LB- medium (Roth), ad 1 L ddH2O, autoclaved 
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LB-agar   40 g LB-agar (Roth), ad 1 L ddH2O, autoclaved 
SOC-medium  2 % (w/v) tryptone, 0.5 % (w/v) yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM 
MgCl2, 20 mM glucose, sterile filtered 
2× YT-medium  2.5 % (w/v) tryptone, 2 % (w/v) yeast extract, 0.5 % (w/v) NaCl, pH 7, 
autoclaved 
 
2.3.12 Isolation of plasmid DNA from E. coli cells 
Plasmid DNA was isolated from E. coli cells following the alkaline lysis protocol from Birnboim and Doly 
(1979). In a small-scale isolation, 2 mL of an overnight culture were centrifuged (>13000× g, 1 min, 
4 °C) and the harvested cells were subsequently resuspended in 100 µL ice-cold buffer P1. Cell lysis 
was initiated upon addition of 200 µL buffer P2, maintained for up to 5 min on RT and finally terminated 
by 150 µL buffer P3. Cell waste and gDNA was pelleted (>13000× g, 10 min, 4 °C) and the supernatant 
was precipitated with 600 µL isopropanol. The isolated plasmid DNA was washed in 600 µL ice-cold 
70 % ethanol (>13000× g, 5 min, 4 °C), dried under red light for 15-30 min and dissolved in 30 µL ddH2O. 
Alternatively, 2-8 mL of E. coli cultures were harvested, and plasmid DNA was isolated using the 
QIAprep™ Spin Miniprep Kit according to manufacturer´s protocol. DNA was eluted in 30-60 µL ddH2O.  
Plasmid DNA Midi and Maxi preparations were performed employing the respective Qiagen kit 
according to the manufacturer´s protocol. Midi preparations were eluted in 200 µL ddH2O whereas 
Maxiprep’s were dissolved in 800 µL TE buffer. 
Buffer P1   50 mM Tris, 10 mM EDTA, pH 8, 0.1 mg/mL RNase A, stored at 4 °C  
Buffer P2   0.2 M NaOH, 1 % (w/v) SDS, stored RT 
Buffer P3   1.8 M KAc/HAc, pH 5.2, stored at 4 °C 
TE buffer   10 mM Tris/HCl, 1 mM EDTA, pH 7.5 
 
2.3.13 Sequencing 
DNA sequences were verified by Sanger sequencing executed by GATC Biotech (Konstanz, Germany) 
or Seq-it (Kaiserslautern, Germany). Primers were provided by the companies or are described in Table 
2.6. To meet the requirements of the companies, DNA obtained from Mini plasmid preparations were 
diluted 1:5 or 1:10 and primers were sent in a concentration of 10 pmol/µL. The results were analysed 
with the program BioEdit and the online tools JustBio, ClustalOmega and ExPASy.  
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2.3.14 Determination of DNA concentration 
For L. tarentolae and P. falciparum transfections, it was necessary to determine the concentration and 
purity of the prepared plasmid DNA. Therefore, the absorption at 280 and 260 nm was measured with 
a NanoDrop™ spectrophotometer and the concentration was calculated from that. Purity was checked 
by evaluation of the quotient A260nm/A280nm. Pure DNA showed values between 1.8 and 2.0 while 
lower or higher values were indicating contaminations with proteins or RNA.   
 
2.3.15 Precipitation of plasmid DNA 
Plasmid DNA was disinfected prior to transfection of P. falciparum and L. tarentolae parasites. 
Therefore, aliquoted DNA was acidulated with 20 µL 3 M sodium acetate at pH 5 in a total volume of 
200 µL and precipitated by adding 500 µL ice-cold 100 % ethanol. The mixture was vortexed shortly 
and incubated at -20 °C for at least 30 min. Afterwards, the DNA was pelleted at 20800× g and 4 °C for 
30 min and washed with 500 µL ice-cold 70 % ethanol. Finally, the DNA pellet was air-dried under 
sterile conditions and resuspended in 10-30 µL sterile ddH2O or TE buffer. Sterile DNA aliquots were 
stored at -20 °C. 
TE buffer   10 mM Tris/HCl, 1 mM EDTA, pH 7.5 
 
 
2.4 Biochemical methods 
2.4.1 Bradford-Assay for determination of protein concentration 
Protein concentrations were determined based on the protocol of Bradford (1976). For this purpose, 
a calibration curve was generated with 0-14 µg/mL BSA, which was prepared freshly for each 
measurement. Single-use cuvettes were filled with 800 µL ddH2O less the volume of the protein 
solution, which was previously determined as an appropriate dilution. All samples were assembled in 
triplicates and for at least two different protein dilutions. The reaction was initiated by adding 200 µL 
Bradford reagent to each sample in an interval of exactly 20 sec and mixed thoroughly. Samples were 
incubated for 15 min at RT and subsequently the absorbance at 595 nm was measured using the 
software spectra manager. The calibration curve was fitted to a hyperbolic function using Sigma Plot 
and the desired protein concentration was computed using the formula:   
y = a * x / (b + x)     (with y=absorbance and x= concentration) 
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2.4.2 Precipitation of proteins 
Proteins were precipitated from a solution by the addition of five to six volumes (for one volume 
solution) of ice-cold 100 % acetone (Fic et al., 2010). The mixture was vortexed shortly and incubated 
at -20 °C overnight. After centrifugation (15 000× g, 15 min, 4 °C), the protein pellet was air-dried for 
15 min at RT and dissolved in the appropriate amount of 2-5× Laemmli buffer (+15 % β-
mercaptoethanol [β-ME]). This was vortexed at least twice for 30 sec or until the pellet had completely 
dissolved and boiled at 95 °C for 5 min unless otherwise stated.  
2× Laemmli buffer 125 mM Tris/HCl pH 6.8, 20 % glycerol, 4 % (w/v) SDS, 0.04 % bromophenol 
blue 
5× Laemmli buffer 50 mM Tris/HCl pH 6.8, 25 % glycerol, 10 % (w/v) SDS, 0.1 % bromophenol blue 
 
2.4.3 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
Recombinant and native proteins were separated by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) according to their molecular mass. Correspondingly, the pore size of the 
gel was matched using 10-18 % acrylamide in the separating gel.  
Small polyacrylamide gels were cast with the Mini-PROTEAN system (BioRad), while large gels (approx. 
16 × 14 cm) were prepared using a lab own technique. In any case, ethanol-cleaned glass plates were 
separated by a spacer and placed in the supplied casting stand (BioRad) or in a liquid agar-sealed stand. 
Separating and stacking gels were prepared as indicated below. The cast separating gel (approx. 5 mL 
for a small and approx. 15 mL for a large gel) was covered with 100 % isopropanol until complete 
polymerisation. Thereafter, isopropanol was discarded and the stacking gel (approx. 2 mL for a small 
and approx. 5 mL for a large gel) was poured and completed with a comb (10-15 wells for a small and 
14-21 wells for a large gel). 
Proteins were resolved under denaturing conditions (95 °C for 5-10 min) or after heating (37 °C for 
30 min) using a discontinuous buffer system (Laemmli, 1970). The samples were boiled or heated in 
2-5× Laemmli buffer under non-reducing or reducing (with 15-30 % β-ME) conditions. Polyacrylamide 
gels were set in an electrophoresis tank filled with SDS running buffer, loaded with 5-20 µL sample 
along with 5 µL protein marker and run at 25 mA per small or 70 mA per large gel for at least 1 h. After 
electrophoresis had ended, the gel was either stained in Coomassie Brilliant Blue or processed via 
western blot analysis.  
Separating gel buffer   1.5 M Tris/HCl, pH 8.8 
Stacking gel buffer   1 M Tris/HCl, pH 6.8 
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Table 2.20 | Pipetting scheme for separating and stacking gels sufficient for four small or two large 
polyacrylamide gels  
Separating gel 12 % 15 % 18 % Stacking gel  
30 % acrylamide mix 
 buffer 
10 % SDS 
10 % APS 
TEMED 
ddH2O 
12 mL 
7.5 mL 
0.3 mL 
0.3 mL 
0.012 mL 
ad 30 mL 
15 mL 
7.5 mL 
0.3 mL 
0.3 mL 
0.012 mL 
ad 30 mL 
18 mL 
7.5 mL 
0.3 mL 
0.3 mL 
0.012 mL 
ad 30 mL 
1.7 mL 
1.25 mL 
0.1 mL 
0.1 mL 
0.01 mL 
ad 10 mL 
 
 
 
Sealing agar  1 % agar (w/v) in SDS running buffer 
SDS running buffer 25 mM Tris, 250 mM glycine, 0.1 % (w/v) SDS, pH 8.3 
2× Laemmli buffer 125 mM Tris/HCl pH 6.8, 20 % glycerol, 4 % (w/v) SDS, 0.04 % bromophenol 
blue 
5× Laemmli buffer 50 mM Tris/HCl pH 6.8, 25 % glycerol, 10 % (w/v) SDS, 0.1 % bromophenol blue  
 
2.4.4 Coomassie Brilliant Blue staining 
Protein samples separated by SDS-PAGE were stained in Coomassie Brilliant Blue to visualise all 
present proteins. Separating and stacking gels were therefore disassembled and only the separating 
gel was carefully transferred to the staining solution, which was incubated at RT for at least 1 h or 
overnight on a rocking platform. Subsequently, the staining solution was replaced with destainer and 
washed several times. For complete clearance of background staining, the gel was additionally 
incubated in ddH2O overnight without shaking.    
Staining solution  25 % (v/v) isopropanol, 10 % (v/v) acetic acid, 0.05 % (w/v) Coomassie Blue 
G250 
Destaining solution  25 % (v/v) isopropanol, 10 % (v/v) acetic acid 
 
2.4.5 Western blot analysis 
SDS-PAGE-separated proteins that were not stained with Coomassie Blue were transferred by semi-
dry or wet electro transfer systems to nitrocellulose or PVDF membranes for immunodetection. All 
membranes, acrylamide gels, Whatman papers and sponges were pre-incubated in transfer buffer 
before usage.  
For wet blotting, the gel was placed onto a nitrocellulose membrane or alternatively onto a PVDF 
membrane, that was previously activated in methanol. Membrane and gel were sandwiched between 
M a t e r i a l s  a n d  M e t h o d s  | 46 
 
 
 
three Whatman papers and a sponge on each side. The blotting sandwich was assembled to the Mini-
PROTEAN blotting module (BioRad) according to manufacturer’s instructions. Transfer buffer and a 
cooling unit were filled into the blotting chamber before protein transfer was initiated at 100 V for 1 h.  
In a semi-dry transfer procedure, the membrane was placed onto five Whatman papers and 
was covered with the gel. The blotting pile was completed by another five sheets of Whatman paper 
and arranged at the anode of the PerfectBlue Semi-Dry Electro Blotter. One small gel was blotted at 
100 mA and a large gel at 250 mA for 1 h.  
Transfer buffer  20 mM Tris, 150 mM glycine, 20 % (v/v) methanol, 0.02% (w/v) SDS 
 
2.4.6 Membrane staining with Ponceau S 
Loading controls for immunoblotting were obtained by reversible visualisation using PonceauS. Above 
that, the transfer efficiency could be monitored, and the membrane could be cut more precisely. PVDF 
membranes were rinsed in methanol for 30 sec before they were transferred to the PonceauS solution 
whereas nitrocellulose membranes were directly incubated in the dye. Membranes were rotated on a 
rocking platform for up to 10 min and rinsed with ddH2O until the background became clear. Protein 
staining was documented before the membrane was completely destained in TBS.  
Ponceau S solution  3 % (w/v) Ponceau S, 3 % (w/v) trichloroacetic acid 
TBS    10 mM Tris/HCl, 0.9 % (w/v) NaCl, pH 7.4 
 
2.4.7 Immunodetection of proteins 
Individual proteins on the blotted membrane were identified by immunodecoration employing a 
variety of self-made or commercial antibodies (Table 2.5).  
Following PonceauS staining, the completely destained membrane was treated with blocking buffer to 
prevent nonspecific binding of antibodies. The blocking step was carried out at RT for 1 h on a rocking 
platform. Afterwards the membrane was incubated shaking with the primary antibody at 4 °C 
overnight. The next day, the primary antibody was removed, and the membrane was washed at least 
three times for 10 min each in TBS. To meet the requirements of a specific antibody, this washing step 
might be expanded and/or enhanced to TBS-T or TBS-TT buffer. A horseradish peroxidase-conjugated 
secondary antibody was supplied for 1-2 h with shaking at RT. The membrane was subsequently 
washed for at least three times à 10 min in TBS, TBS-T or TBS-TT.  
For protein detection, freshly mixed detection reagent (Amersham ECL Western Blotting Detection 
Reagents or SuperSignal West Femto) was applied equally onto the membrane and incubated shortly. 
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Chemiluminescence was exposed to a radiographic film or alternatively captured by a Lumi-Imager 
(Roche).   
TBS    10 mM Tris/HCl, 0.9 % (w/v) NaCl, pH 7.4 
TBS-T    TBS, 0.1 % (v/v) Tween 20 
TBS-TT    TBS, 0.1 % (v/v) Tween 20, 0.2 % (v/v) Triton X-100 
Blocking buffer  5 % (w/v) low-fat milk powder in TBS 
Antibody solutions  antibodies were diluted in blocking buffer as indicated in Table 2.5  
 
2.4.8 Membrane stripping 
Membranes may be used several times to detect various proteins of a similar molecular weight. To 
avoid a confused signal due to a previously applied primary antibody, this procedure should only be 
used for primary antibodies that respond to unequal secondary antibodies (rabbit vs. mouse).  
After one protein of interest was detected via chemiluminescence activity, the remaining 
detection reagent was removed by washing the membrane in TBS for 10 min. The previously applied 
antibodies were detached from the membrane while shaking in stripping buffer. The stripping buffer 
was replaced three times every 10 min. Finally, the membrane was washed twice in TBS for 10 min 
each and twice in TBS-T for 5 min each. After this, the standard protocol for immunodecoration was 
followed starting with the blocking step.  
Stripping buffer  15 g glycine, 1 g SDS, 10 mL Tween 20, ad 1 l ddH2O pH 2.2 
 
 
2.5 Cell biological procedures and genetic manipulation of L. tarentolae 
L. tarentolae UC wildtype parasites were cultivated and genetically manipulated in a sterile 
environment by using a laminar flow hood. Therefore, all buffers, solutions and disposals were 
autoclaved or sterile filtrated (section 2.2) and additionally disinfected with 70 % ethanol before being 
transferred to the sterile bench.    
 
2.5.1 Cryoconservation of L. tarentolae 
For long-term storage, Leishmania strains were cryopreserved in liquid nitrogen. Healthy moving 
parasites in the mid-logarithmic phase (5-9× 107cells/mL) were diluted 1:2 in 700 µL freshly prepared 
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brain heart infusion (BHI) freezing solution and translocated to a cryovial. This was wrapped in paper 
tissue and incubated at -80 °C for at least 24 h before the vial was frozen in liquid nitrogen.   
BHI freezing solution 370 mg BHI, 30 % (v/v) glycerol, 10 μg/mL hemin solution, ad 10 mL 
 
2.5.2 Thawing of L. tarentolae cryocultures 
Cryotubes of frozen L. tarentolae cells were removed from the liquid nitrogen and thawed quickly in a 
27 °C water bath. Thawed parasites were inoculated in 10 mL pre-warmed BHI medium and carefully 
stirred before the remaining glycerol was removed by centrifugation (1500x g, 10 min, RT). The 
parasite pellet was dissolved in 1 mL of fresh BHI medium and incubated for the first 24 h at 27 °C 
without shaking or antibiotics, before cells were finally transferred to continuous culture.  
 
2.5.3 Continuous culture of L. tarentolae 
L. tarentolae promastigotes were cultivated in BHI liquid medium at 27 °C and 50 rpm. Under standard 
conditions, parasites were grown in a 25 cm2 culture flasks (standing upright) in a total culture volume 
of 10 mL. In case larger numbers of parasites were needed, culture volume was increased up to 1 L, 
with the culture claiming max. 33 % of the Erlenmeyer flask. The culture was maintained in the mid-
log phase (approx. 5× 107 cells/mL) by splitting the cells 1:10 or according to their condition every day 
or at every other day. To select for transgenic parasite lines, G418 was added to the medium at a 
concentration of 0.1 mg/mL.  
BHI medium   37 g BHI powder, ad 1 L ddH2O, 10 μg/mL hemin solution 
Hemin solution  2 mg/mL hemin chloride in 0.05 M NaOH 
G418    50 mg/mL G418 sulphate in ddH2O 
 
2.5.4 Determination of cell density  
To determine the specific number of cells in a culture, 100 µL of the suspended cells were mixed with 
1× SSC fixation solution and incubated at RT for 5 min. The suspension was injected into a Neubauer 
counting chamber and analysed under a microscope by counting at least four of the 16 squares. The 
overall cell density was calculated by multiplying the average number of the cells counted by the 
dilution factor (in 1× SSC) and dividing this by the volume of the square (4 nL). The calculated number 
corresponded to × 106 cells/mL of cell culture. 
20× SSC    3 M NaCl, 0.3 M Na3citrate, pH 7.4  
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1× SSC fixation solution  10 % (w/v) paraformaldehyde in 1× SSC 
 
2.5.5 Transfection of L. tarentolae 
L. tarentolae parasites in the mid-log phase, were stable transfected (Beverley and Clayton, 1993) using 
the Basic Parasite Nucleofector Kit 2 (Lonza) based on the manufacturer’s protocol.  
For each trial, 5× 107 cells were harvested by centrifugation (1500× g, 3 min, RT), washed in 1 mL 
transfection buffer and finally dissolved in 100 µL Nucleofector solution. The suspension was 
supplemented with 7-20 µg sterile plasmid DNA and transferred into the provided electroporation 
cuvette. Cells were electroporated using the program U-033 and afterwards immediately inoculated 
in 9.5 mL pre-warmed BHI by rinsing the cuvette with 500 µL medium. For recreation, the 
electroporated cells were first incubated in liquid medium overnight without shaking or antibiotics 
before the culture was centrifuged (1500× g, 10 min, RT) and reduced to 1 mL, which was spread onto 
a selection BHI agar plate. The plate was sealed with two layers of parafilm and incubated at 27 °C with 
the agar at the bottom. First colonies of transgenic parasites were expected ten days post transfection.   
For each transfected parasite line, up to four single clones were picked from the agar plate and 
inoculated in 30 µL BHI medium, which was cultivated without shaking. The motion and density of the 
young cells were checked daily by examining a drop of culture on a glass slide under the microscope. 
Healthy cultures were gradually up-scaled to standard culture volumes. 
BHI agar  3.7 % BHI, 0.08 % (w/v) folic acid, 0.8 % (w/v) agar, 10 % (v/v) heat-inactivated 
FCS, 20 μg/mL hemin, 40 μg/mL G418 
Transfection buffer  21 mM HEPES, 137 mM NaCl, 5 mM KCl, 0.7 mM NaH2PO4, 6 mM Glucose in 
ddH2O, pH 7.4 
 
2.5.6 Analysis of growth characteristics of L. tarentolae cells 
The impact of genetic modifications on the Leishmania organism was analysed by observing parasite 
growth. Wildtype and transgenic parasite lines from a continuous culture were counted (section 2.5.4) 
and 5× 106 cells/mL were transferred into a new culture flask comprising 10 mL of culture volume. Cell 
growth was studied under standard conditions including shaking and selection pressure. Every 24 h 
and for a period of six days, the cells were counted and the optical density (OD) was measured at 
600 nm (cells were previously diluted to OD600 < 1). The SigmaPlot software graphically evaluated the 
collected data set and was used to fit a regression line.  
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2.5.7 Preparation of L. tarentolae cell lysates 
Whole cell lysates of L. tarentolae were prepared for western blot analysis and contained 5× 107 
parasites for a single sample. The cells were collected by centrifugation (1500× g, 10 min, RT) and 
directly lysed in the presence of 5× Laemmli buffer. For reducing conditions, the buffer was 
supplemented with 15-30 % β-ME. Parasites were resuspended, and gDNA was disrupted by shearing 
the samples eight times over a reaction tube rack. Before storage or application onto an SDS-PAGE gel, 
the samples were heated at 37 °C for 30 min or boiled at 95 °C for 10 min.  
5× Laemmli buffer 50 mM Tris/HCl pH 6.8, 25 % glycerol, 10 % (w/v) SDS, 0.1 % bromophenol blue 
 
2.5.8 Preparation of L. tarentolae cell lysates treated with NEM 
Parasites were previously treated with NEM to alkylate free thiols and thereby enrich a potentially 
mixed disulphide intermediate. Parasites were harvested, dissolved in 2 mL PBS and separated into 
two 1 mL samples of 5× 107 cells each. A freshly prepared NEM solution was added to both samples to 
a final concentration of 100 mM and was incubated for 5 min in the dark. After the NEM was removed 
(10 000× g, 3 min), one sample was lysed under reducing and the other under non-reducing conditions 
in a 5× Laemmli buffer containing 10 mM NEM as described earlier (section 2.5.7). 
PBS  1.84 mM KH2PO4, 10 mM Na2HPO4, 137 mM NaCl, 2.7 mM KCl, pH 7.4 
NEM  200 mM N-ethylmaleimide in PBS 
 
2.5.9 Preparation of L. tarentolae cell lysates treated with diamide and DTT 
To stabilise potential intermolecular disulphide bonds, parasites were pre-treated with the oxidizing 
agent diamide or the reducing agent DTT. For each treatment 108 cells were harvested and 
resuspended in 2 mL PBS. The suspension was subsequently complemented with the same volume of 
a 10 mM diamide or 4 mM DTT solution and was incubated at RT for 5 min. After centrifugation 
(1500× g, 10 min, RT), the parasites were treated with NEM and lysed as described above.  
Diamide 10 mM diamide in PBS 
DTT  4 mM dithiothreitol in PBS 
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2.5.10 Redox mobility shift assay 
Proteins were examined for their redox state by adding the alkylating substance mm(PEG)24 to 
L. tarentolae cell lysates in Laemmli buffer to alter the migration behaviour of reduced proteins in SDS-
PAGE. 
For each sample 5× 107 cells were collected and resuspended in 20 µL 5× Laemmli buffer (without β-
ME) as mentioned above (section 2.5.7). The lysates for reducing controls were supplemented with a 
freshly prepared 3.75 mM TCEP solution and incubated at 27 °C for 30 min (mild reduction) or at 95 °C 
for 10 min (strong reduction). Afterwards, all samples were supplemented with 15 mM mm(PEG)24 or 
DMSO as control and incubated in the dark for 1 h. Samples were finally boiled at 95 °C for 10 min. 
TCEP   50 mM Tris(2-carboxyethyl)phosphine in ddH2O, pH 7.4 
mm(PEG)24  250 mM methyl-PEG-maleimide in DMSO 
 
2.5.11 Differential fractionation of L. tarentolae  
The membrane association of mitochondrial proteins was studied with a combination of hypotonic cell 
swelling followed by mild and selective lysis by digitonin (Vercesi et al., 1991; Castro et al., 2008; Hide 
et al., 2008; Peleh et al., 2014).  
Cells were harvested in the mid-log phase by spinning 109 cells at 1500× g and 4 °C for 10 min and 
resuspended in 10 mL ice-cold PBS, of which 1 mL was removed as untreated control (sample A). After 
another centrifugation step, the sample A pellet was dissolved in 300 µL SH buffer and stored on ice. 
The remaining PBS suspension (9 mL) was centrifuged, resuspended in 245 µL of ice-cold swelling 
buffer per 108 cells (2205 mL), and incubated on ice for 20 min. Sucrose stock solution was added to a 
final concentration of 7.5 % (w/v) to stop cell lysis and the mixture was aliquoted into eight 280 µL 
samples. Each of the eight samples containing 108 cells were supplemented with 20 µL SH buffer 
containing varying amounts of digitonin (0, 1.25 mg/mL, 2.5 mg/mL, 5 mg/mL, 10 mg/mL, 25 mg/mL, 
50 mg/mL) or 2 % (v/v) Triton X-100. The solubilisation was performed for 30 min on ice while 
occasionally vortexing. Finally, all samples, including sample A, were centrifuged (20 000× g, 30 min, 
4 °C) to separate the mitoplast pellet from the soluble protein content in the supernatant. The 
supernatant was precipitated (2.4.2) before both fractions were resuspended in 50 µL 5× Laemmli 
(+ 6 M Urea + 15 % β-ME) as explained earlier (2.5.7) and heated at 37 °C for 30 min.   
PBS   1.84 mM KH2PO4, 10 mM Na2HPO4, 137 mM NaCl, 2.7 mM KCl, pH 7.4 
SH buffer  0.6 M sorbitol, 20 mM HEPES, pH 7.4, 1× protease inhibitor was added freshly 
Swelling buffer  20 mM HEPES, pH 7.2, 1× protease inhibitor was added freshly 
Sucrose stock  60 % (w/v) sucrose in ddH2O 
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2.6 Cell biological procedures and genetic manipulation of P. falciparum 
P. falciparum parasites were cultivated and treated sterile using a laminar flow hood. All media, 
solutions and disposals were sterilised as described in section 2.2 and stored at 4 °C or -20 °C. Materials 
were further disinfected with 70 % ethanol before entering the laminar flow hood.  
 
2.6.1 Cryoconservation of P. falciparum parasites 
P. falciparum infected red blood cells (iRBCs) were stored for long-term in liquid nitrogen. Therefore, 
a 3-5 % ring stage parasite culture was centrifuged (300× g, 5 min) and the pellet was resuspended 
dropwise in the same amount of pre-warmed freezing solution. The mixture was transferred to a 
cryovial and frozen immediately.  
Freezing solution  28 % (v/v) glycerol, 0.65 % (w/v) NaCl, 3 % (w/v) sorbitol 
 
2.6.2 Thawing of P. falciparum cryocultures 
Cryovials containing frozen iRBCs were removed from the liquid nitrogen and thawed quickly at 37 °C 
in a water bath. The cells were transferred to a 15 mL tube and taken up dropwise in 0.2 volumes of 
thawing solution I, which was incubated for 2 min. Afterwards, ten volumes of thawing solution II were 
added stepwise before the cell suspension was centrifuged at 300× g for 5 min. The cell pellet was 
resuspended slowly in ten volumes thawing solution III and centrifuged again. Cells were finally washed 
in 10 mL pre-warmed complete medium, supplemented with an equal amount of fresh human 
erythrocytes and continuously cultured.  
Thawing solution I  12 % (w/v) NaCl 
Thawing solution II  1.6 % (w/v) NaCl 
Thawing solution III  0.9 % (w/v) NaCl, 0.2 % (w/v) glucose 
Complete medium  RPMI 1640 (25 mM HEPES, L-Glutamine), 4.5 % AlbuMax II, 200 μM 
hypoxanthine, 2.7 μg/mL gentamicin 
 
2.6.3 Continuous culture of P. falciparum blood stage parasites 
Blood stage parasites of the P. falciparum 3D7 strain were cultured based on standard procedures 
(Trager and Jensen, 1976) in an atmosphere of 5 % CO2, 5 % O2 and 90 % N2 at 37 °C and a humidity of 
90 %. The parasites were grown with 3.6 % human A+ erythrocytes in cell culture flasks or petri dishes 
reaching a total volume of 14 mL. Depending on the parasitaemia or the condition of the cells, the 
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culture medium was renewed daily, every other day or three times a week, with a parasitaemia ranging 
between 0.5 and 10 %. A >9 % ring stage or >5 % trophozoite/schizont stage culture was split to 
maintain optimal growth conditions. For genetic manipulations, the medium was supplemented with 
100 nM Atovaquone to maintain the pUF1-Cas9 transfected cell line, with 5 nM WR99210 for pL7 or 
with 2 µg/mL Blasticidin for positive selection of pHBIRH. 
Complete medium  RPMI 1640 (25 mM HEPES, L-Glutamine), 4.5 % AlbuMax II, 200 μM 
hypoxanthine, 2.7 μg/mL gentamicin 
 
2.6.4 Giemsa staining 
Giemsa-stained blood smears were evaluated to estimate the parasitaemia and parasite stages as well 
as the viability and morphology of a parasite culture. A blood sample was taken from the bottom of 
the cell culture and spread onto a glass slide, which was air-dried, fixed in 100 % methanol for 30 sec 
and subsequently stained in a freshly prepared 10 % (v/v) Giemsa solution for at least 20 min. The 
stained slides were rinsed with deionised water to remove the surplus Giemsa solution and analysed 
under a light microscope at 100× magnification. To calculate the parasitaemia of a culture, a serious 
number of RBCs were counted and parasitaemia was expressed as the percentage of iRBCs relative to 
the total number of RBCs.  
 
2.6.5 Synchronisation of a P. falciparum culture 
In order to obtain a tightly synchronised parasite culture, trophozoite and schizont stage parasites 
were eliminated by osmotic lysis sparing only parasites in the early ring stage (Lambros and 
Vanderberg, 1979). This procedure was applied in preparation for parasite transfection. 
Cells were harvested by centrifugation (300× g, 5 min) and resuspended in ten volumes of a pre-
warmed 5 % sorbitol solution, which was incubated for 5 min at RT. The remaining ring stage parasites 
were washed in 10 mL of medium and transferred to a new culture dish for cultivation. 
Sorbitol solution  5 % (w/v) sorbitol in ddH2O 
 
2.6.6 Transfection of P. falciparum schizont stage parasites 
P. falciparum parasites were genetically manipulated by the spontaneous uptake of DNA from pre-
loaded non-infected RBCs (Deitsch et al., 2001).  
A tightly synchronised parasite culture (36 h after the synchronisation) was diluted to a parasitaemia 
of 1 % schizonts and prepared in a culture dish with 100 µL iRBCs and 8 mL medium. The loading of 
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RBCs was initiated by washing 2 mL of freshly donated erythrocytes twice in 6 mL ice-cold incomplete 
cytomix (centrifugation at 800× g for 2 min). The washed cells (400 µL) were mixed with 400 µL cytomix 
and 100 µg plasmid DNA and transferred into two chilled electroporation cuvettes in which the mixture 
was incubated on ice for 5 min. Electroporation was carried out at 0.3 kV voltage and 950 µF 
capacitance with a time constant ranging between 12 ms and 18 ms using Gene Pulser (BioRad). 
Alternatively, blood cells were prepared as described above and electroporated using Nucleofector 2b 
(Lonza) with one of the programs X-001 or U-033. Thereafter, the cuvettes were incubated on ice for 
another 5 min and rinsed twice with 2 mL medium to relocate all loaded RBCs into a 15 mL tube. Lysed 
cells were discarded with the supernatant after centrifugation (800× g, 2 min) and the loaded RBC 
pellet was taken up in 5 mL medium and added to the previous prepared schizont culture. 
The culture was inspected after 24 h with an expected parasitaemia of 1-2 % rings and the medium 
was exchanged. To increase parasite’s chances of invading a loaded RBC, the procedure was repeated 
48 h after the first transfection. The appropriate selection marker (Table 2.12) was first added to the 
medium, the day after the second transfection (day 3). The culture was fed with fresh medium at each 
day of the first week after transfection, and three times a week afterwards. Fresh erythrocytes were 
added once a week in a volume of 50-100 µL. A first appearance of transfectants was expected three 
weeks post transfection and a culture was discontinued after 60 days without visible parasites.  
The plasmids pL7/PFERV and pL7/PFTIM13 were transfected into the transgenic parasite line 
3D7pUF1-Cas9 (Table 2.10). 
Cytomix (incomplete)  120 mM KCl, 0.15 mM CaCl2, 2 mM EGTA, 5 mM MgCl2, 10 mM 
K2HPO4, 10 mM KH2PO4, 25 mM HEPES, pH 7.6 
 
2.6.7 Limiting dilution assay 
Clonal lines of transfected parasites were produced by limiting dilution. The transgene culture was 
synchronised 24 h in advance and parasitaemia was determined shortly before the procedure. 
Furthermore, the concentration of RBCs was estimated by a haemocytometer and used to calculate 
the concentration of parasites per millilitre of resuspended culture. The starting culture was set to 
2 parasites/mL, 2 % haematocrit plus the appropriate selection marker and distributed to the first two 
rows of a 48-well-plate by adding 500 µL per well. Cells were further diluted 1:10 and 1:100 in the next 
two rows to increase the chances of a clonal line. The medium was replaced three times a week and 
10 µL fresh erythrocytes were added once a week to each well. Clonal lines were expected after two 
weeks and were then transferred into continuous culture.  
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2.7 Cell biological procedures and genetic manipulation of S. cerevisiae 
S. cerevisiae was cultivated and genetically modified under sterile conditions. Cells were handled under 
a laminar flow hood and all media, solutions and disposals were autoclaved (chapter 2.2) or sterile 
filtrated using a pore size of 0.2 µm. Sterile media and solutions were stored at 4 °C or -20 °C.  
 
2.7.1 Continuous culture and storage of S. cerevisiae  
S. cerevisiae cells were grown at 30 °C in synthetic minimal medium (S) or in YP medium in liquid and 
on agar plates. Liquid cultures were shaken at 130-160 rpm. Culture medium was supplemented with 
either of the carbon sources glucose (D), galactose (Gal), or glycerol (G) and auxotrophic mutant strains 
were additionally supplied with the amino acids tryptophan, lysine, leucine, and histidine as well as 
the bases adenine and uracil depending on their genetic background.  
For long-term storage, 800 µL of a liquid culture were mixed 1:2 with freezing solution and 
cryopreserved at -80 °C. Cells were thawed by scraping off tiny amounts of the glycerol culture and 
streaking the material onto an agar plate. Plates were incubated at 30 °C for three days before cells 
could be transferred into liquid culture. Agar plates were sealed with parafilm and stored at 4 °C for 
up to a month. 
YP medium 10 g Bacto yeast extract, 20 g peptone, 2 % glucose (YPD) or 2 % galactose 
(YPGal) or 3 % Glycerol (YPG), ad 1 L ddH2O 
YP agar 10 g Bacto yeast extract, 20 g peptone, 20 g agar, 2 % glucose (YPD) or 2 % 
galactose (YPGal) or 3 % Glycerol (YPG), ad 1 L ddH2O  
S medium 6.7 g Difco YNB w/o AS, 2 % glucose (SD) or 2 % galactose (SGal) or 3 % Glycerol 
(SG), if required: 20 mg adenine sulphate, 20 mg uracil, 20 mg tryptophan, 20 
mg histidine, 30 mg leucine, 30 mg lysine, ad 1 L ddH2O 
S agar 6.7 g Difco YNB w/o AS, 20 g agar, 2 % glucose (SD) or 2 % galactose (SGal) or 
3 % Glycerol (SG), if required: 20 mg adenine sulphate, 20 mg uracil, 20 mg 
tryptophan, 20 mg histidine, 30 mg leucine, 30 mg lysine, ad 1 L ddH2O  
Freezing solution 30 % (v/v) glycerol in ddH2O, sterile filtrate 
 
2.7.2 Transformation of S. cerevisiae 
Yeast strains were genetically manipulated based on standard protocols (Gietz and Schiestl, 2007a;b). 
Therefore, a single colony of the host strain was cultured in 10 mL SD medium (including auxotrophic 
nutrients) until mid-logarithmic (mid-log) phase. The approximate number of cells in the culture was 
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determined by measuring the optical density (OD) at 600 nm, with cultures diluted to a reading of 
OD600 <1. Within that range, a value of 0.1 was considered to be roughly proportional to a cell density 
of 3× 106 cells/mL (Bergman, 2001). For a single transformation, 5× 108 cells were harvested by 
centrifugation (1750× g, 5 min, 4 °C), washed once in 10 mL ddH2O and resuspended in 50 µL ddH2O.  
Salmon sperm carrier DNA was denatured at 95 °C for 10 min and chilled immediately on ice. 
The transformation buffer was composed of 50 µL resuspended cell pellet, 240 µL PEG solution, 36 µL 
LiOAc solution, 10 µL denatured carrier DNA, 21 µL ddH2O and 3 µL plasmid DNA. The mixture was 
vortexed at high speed for 1 min and incubated at 42 °C and 500 rpm for 50 min in a thermomixer. 
Afterwards the cells were centrifuged at 13 000× g for 30 sec and the cell pellet was resuspended in 
500 µL ddH2O of which 200 µL were spread onto selection agar plates without tryptophan. These were 
incubated at 30 °C for up to four days before single colonies were picked and cultured independently. 
LiOAc solution  1 M lithium acetate dihydrate in ddH2O, sterile filtrate 
PEG solution  50 % (w/v) PEG 3350 in ddH2O 
Carrier DNA  10 µg/µL salmon sperm DNA solution 
SD agar (-Trp) 6.7 g Difco YNB w/o AS, 20 g agar, 2 % glucose, 20 mg adenine sulphate, 30 mg 
leucine, 30 mg lysine, if required: 20 mg histidine, ad 1 L ddH2O  
 
2.7.3 Plasmid shuffling/ complementation assays 
Proteins were tested for their ability to functionally replace essential yeast proteins by plasmid 
shuffling assays (Eckers et al., 2013; Specht et al., 2018). The constructs to test were introduced (on 
pYX232) into a knock out cell line, in which the essential yeast gene was deleted from the chromosome 
(Δerv1, Δmia40) but which possessed an episomal copy on the URA3-expressing plasmid pRS426 
(SCERV1) or pRS316 (SCMIA40). Up to six single clones of the transfected cell line were grown in highly 
uracil-containing medium SD+2.5xUra (without tryptophan to preserve the pYX232 plasmid) at 30 °C 
and 130 rpm overnight. 
The cultures of individual clones were diluted 1:50 in ddH2O and spotted in 10 µL drops onto SD agar 
and FOA plates for control and selection, respectively. Plates were sealed with parafilm and incubated 
for three to four days at 30 °C, 37 °C or RT. 
For drop dilution assays, a single clone was cultured as described above and first diluted to OD600 = 0.1. 
This was passed through a serial dilution to obtain a blend of 1:10, 1:100 and 1:1000. Drops of the 
undiluted culture and of each dilution were spotted on SD agar plates and on FOA plates, sealed and 
incubated for up to four days at 30 °C, 37 °C or RT. For documentation purposes, the plates were 
photographed on each day.  
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Cell material obtained from FOA plates was examined for the presence of viable cells by cultivating 
single colonies or, in absence of such, smears of background material in liquid FOA medium under 
standard conditions. If cell accumulation was detected within three days, cultures were subsequently 
diluted and spotted onto FOA and SD agar plates (-Ura) as described above. Colonies, expressing 
proteins that could complement for the essential yeast protein, were expected to only grow on FOA 
but not on the control plates (-Ura), since they lack the URA3-plasmid. 
SD+2.5×Ura 6.7 g Difco YNB w/o AS, 2 % glucose, 50 mg uracil, 20 mg adenine 
sulphate, 30 mg leucine, 30 mg lysine, if required: 20 mg histidine, ad 1 L 
ddH2O 
SD agar (-Trp-Ura) 6.7 g Difco YNB w/o AS, 20 g agar, 2 % glucose, 20 mg adenine sulphate, 
30 mg leucine, 30 mg lysine, if required: 20 mg histidine, ad 1 L ddH2O  
SD agar (-Trp+Ura+FOA) 6.7 g Difco YNB w/o AS, 20 g agar, 2 % glucose, 50 mg uracil, 20 mg 
adenine sulphate, 30 mg leucine, 30 mg lysine, 1 g FOA, if required: 20 mg 
histidine, ad 1 L ddH2O  
SD (-Trp+Ura+FOA) 6.7 g Difco YNB w/o AS, 2 % glucose, 50 mg uracil, 20 mg adenine 
sulphate, 30 mg leucine, 30 mg lysine, 1 g FOA, if required: 20 mg 
histidine, ad 1 L ddH2O  
 
2.7.4 Cell fractionation/quick mitochondria isolation  
Clones which were studied after FOA selection and found to only grow in the presence of uracil were 
subsequently fractionated into mitochondria-containing pellet and cytosol-containing supernatant 
and examined for their protein content by western blot analysis. Alternatively, mitochondria were 
roughly isolated from yeast cells to use in other experiments as mentioned below.  
Each of the clonal cell lines were cultured in 50 mL SD+Ura medium under standard conditions in the 
late-log phase (OD600 = 0.8-1.8). Cell amounts equivalent to ten OD volumes were harvested (1750× g, 
10 min, 4 °C) and taken up in 300 µL ice-cold SMK80 buffer. For cell disruption, 200 µL glass beads were 
added and the suspension was vortexed six times for 30 sec each (stored on ice in between) before 
cell debris were removed together with the glass beads by centrifugation (1000× g, 3 min, 4 °C). The 
supernatant was transferred to a fresh reaction tube and mitochondria were pelleted at 20 000× g for 
15 min at 4 °C. The pellet was directly boiled at 95 °C for 5 min in 20 µL 2× Laemmli buffer (+15 % β-
ME). The supernatant was precipitated (section 2.4.2) and dissolved as described for the pellet.  
To isolate mitochondria, yeast strains were grown in complete YP medium complemented with 
either glucose or glycerol as carbon sources and cultured until the late exponential phase (OD600 = 2-
4). Ten OD volumes of culture were used to gain approximately 25 µg mitochondria. Cells 
M a t e r i a l s  a n d  M e t h o d s  | 58 
 
 
 
corresponding to 10 OD volumes were harvested (1750× g, 10 min, 4 °C) and dissolved in 150 µL ice-
cold SMK80 buffer. Afterwards 200 µL glass beads were added to vortex the cells for 2 min at highest 
speed. After glass beads and cell debris were pelleted (1000× g, 3 min, 4 °C), mitochondria were 
collected by centrifugation (20 000× g, 30 min, 4 °C) and resuspended in 20 µL SH buffer. Of the 
supernatant, 75 µL were precipitated as defined earlier (section 2.4.2). 
SD (-Trp+Ura) 6.7 g Difco YNB w/o AS, 2 % glucose, 20 mg uracil, 20 mg adenine sulphate, 30 
mg leucine, 30 mg lysine, if required: 20 mg histidine, ad 1 L ddH2O  
SMK80 buffer 0.6 M sorbitol, 20 mM MOPS, 80 mM KCL, pH 7.4, 1 mM PMSF was added 
freshly 
PMSF   100 mM phenylmethylsulphonyl fluoride in 100 % ethanol  
2× Laemmli buffer 125 mM Tris/HCl pH 6.8, 20 % glycerol, 4 % (w/v) SDS, 0.04 % bromophenol 
blue 
 
2.7.5 DNA extraction from S. cerevisiae 
To verify the genotype of a yeast strain, genetic material was extracted from the cells (Looke et al., 
2011) and subjected to analytical PCR (2.3.2). 
The yeast cells of a liquid culture (100-200 µL) measuring an OD600 of 0.4 were centrifuged (1750× g, 
5 min, 4 °C) and incubated in 100 µL extraction buffer at 70 °C for 5 min. Subsequently, 300 µL of 100 % 
ice-cold ethanol were added and the mixture was vortexed briefly. The DNA was obtained by 
centrifugation (15 000× g, 3 min) and rinsed with 300 µL of ice-cold 70 % ethanol before being 
dissolved in 100 µL ddH2O. The DNA solution was spun at 15 000× g for 15 sec to pellet cell debris 
before 1 µL was used in PCR. 
Extraction buffer 200 mM lithium acetate dihydrate, 1 % (w/v) SDS in ddH2O 
 
2.7.6 Analysis of growth characteristics of S. cerevisiae 
In order to study the influence of genetic modifications on the organism, particular strains were 
monitored in liquid medium and on agar plates while metabolising a variety of carbon sources. For 
growth assays on agar plates, cells were cultured in SD medium in the logarithmic growth phase under 
standard conditions. Cultures were diluted to an absorbance of 0.1 in sterile ddH2O and drop dilution 
assays were performed as described in section 2.7.3. Cells in each dilution were applied in 10 µL drops 
onto SD, SGal and SG agar plates without tryptophan and incubated at 30 °C for up to 12 days. Pictures 
were taken for documentation at day three, five, eight and twelve.  
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Growth assays in liquid medium were carried out in a Tecan plate reader, which recorded the OD at 
600 nm every hour after shaking the cultures for 550 sec at 183 rpm. Cells were previously cultured in 
liquid SD, SG or SGal medium for at least 5 days before the growth curve started. The cultures were 
diluted to OD600 = 0.1 in the corresponding medium and 200 µL were transferred in triplicates to a flat 
transparent 96-well-plate (Greiner). The growth was monitored over a period of 48 h at 30 °C. 
S medium (-Trp) 6.7 g Difco YNB w/o AS, 2 % glucose (SD) or 2 % galactose (SGal) or 3 % Glycerol 
(SG), 20 mg adenine sulphate, 20 mg uracil, 30 mg leucine, 30 mg lysine, if 
required: 20 mg histidine, ad 1 L ddH2O 
S agar (-Trp) 6.7 g Difco YNB w/o AS, 20 g agar, 2 % glucose (SD) or 2 % galactose (SGal) or 
3 % Glycerol (SG), 20 mg adenine sulphate, 20 mg uracil, 30 mg leucine, 30 mg 
lysine, if required: 20 mg histidine, ad 1 L ddH2O 
 
2.7.7 Proteolytic susceptibility assay 
The localisation of proteins within mitochondria was approached in more detail by solubilising isolated 
mitochondria in steps and assaying the protein accessibility for proteinase K. Please keep in mind that 
the protocol below did not reach satisfaction with mitochondria isolated by quick preparation. 
Forty OD volumes of yeast culture were prepared according to standard protocol (section 2.7.4) and 
finally dissolved in 80 µL SH buffer (containing ~100 µg mitochondria). To gradually open the 
mitochondria, the suspension was aliquoted into four 20 µL samples and replenished with either 
180 µL SH, swelling, or lysis buffer to reach a final concentration of 100 µg/mL. All buffers were 
incubated on ice for 20 min before proteinase K (or water as control) was added at a concentration of 
0.1 mg/ml. Proteolysis was carried out on ice for 30 min and was terminated by the addition of 4 mM 
PMSF which was incubated on ice for 10 min. The suspension was finally centrifuged (20 000× g, 
30 min, 4 °C) and boiled for 5 min in 80 µL 2× Laemmli buffer (+ 15 % β-ME). 
SH buffer  0.6 M sorbitol, 20 mM HEPES, pH 7.4 
Swelling buffer  20 mM HEPES, pH 7.2 
Lysis buffer   20 mM HEPES, 1 % (v/v) Triton X-100, pH 7.4 
Proteinase K  10 mg/mL in ddH2O 
PMSF   100 mM phenylmethylsulphonyl fluoride in 100 % ethanol 
2× Laemmli buffer 125 mM Tris/HCl pH 6.8, 20 % glycerol, 4 % (w/v) SDS, 0.04 % bromophenol 
blue 
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2.7.8 Carbonate extraction assay 
Membrane association of mitochondrial proteins was studied, among others, by carbonate extraction 
assays that were modified from a previously described protocol (Eckers et al., 2013). Please note that 
the following approach has not yet matured to full satisfaction when using mitochondria isolated by 
quick preparations.  
Yeast strains were cultured in complete YPG medium in the late-log phase (OD600 = 2-4) before 10 OD 
volumes (~25 µg mitochondria) were harvested twice and disrupted (chapter 2.7.4). One of the 
mitochondrial pellets was directly boiled in 25 µL 2× Laemmli buffer (+ 15 % β-ME). The other pellet 
was resuspended in 100 µL swelling buffer supplemented with freshly prepared 100 µL Na2CO3, mixed 
for 15 sec and incubated on ice for 1 h. The suspension was ultracentrifuged (125 000× g, 1 h, 4 °C) and 
the pellet was dissolved in 25 µL Laemmli buffer (+ 15 % β-ME) while the supernatant was precipitated 
first (chapter 2.4.2).  
Swelling buffer  20 mM TRIS, pH 7.2 
Na2CO4   200 mM sodium dihydrogen carbonate, pH 11 
 
2.7.9 Differential fractionation of yeast mitochondria by digitonin  
Another method to investigate the membrane association of proteins in yeast mitochondria comprised 
a stepwise solubilisation process using hypotonic swelling and a digitonin concentration gradient 
(Cordeiro and Freire, 1995). 
Yeast cells were cultured in complete YPD medium under standard conditions until 40 OD volumes 
were collected (2500× g, 5 min, 4 °C) in the late-log phase (OD600 = 2-5). Cells were generally treated 
as shown for Leishmania (section 2.5.11) with minor modifications. Briefly, hypotonic swelling was 
carried out in 2205 µL ice-cold swelling buffer that was incubated for 30 min on ice and terminated 
upon the addition of 315 µL sucrose stock solution. The cells were aliquoted into eight 280 µL samples 
and replenished with different dosages of digitonin (0, 0.2 mg/mL, 1 mg/mL, 2 mg/mL, 4 mg/mL, 
10 mg/mL, 20 mg/mL) or 2 % (v/v) Triton X-100 in 20 µL SH buffer. The digitonin was incubated for 
30 min at 30 °C before it was removed by centrifugation (20 000× g, 20 min, 4 °C) and replaced by 45 µL 
2× Laemmli buffer (+ 15 % β-ME; 95 °C for 5 min).   
SH buffer  0.6 M sorbitol, 20 mM HEPES, pH 7.4, 1× protease inhibitor was added freshly 
Swelling buffer  20 mM HEPES, pH 7.2, 1× protease inhibitor was added freshly 
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3 Results 
3.1 Yeast SCERV1 complementation assays  
LtErv appears to operate in Leishmania without a Mia40 homologue, resulting in the inability to 
interact with ScMia40 and to replace ScErv1 (Eckers et al., 2013). Clearly, the leishmania oxidative 
protein folding system has evolved structural features that make it incompatible with the yeast system. 
To define structure-function-relationships that might be relevant to the lack of communication 
between both systems, a set of chimeras as well as mutant LtErv variants were generated (by Maike 
Eberhardt, Elisabeth Eckers, and myself) and analysed in a yeast ∆erv1 background (Specht et al., 
2018). 
 
3.1.1 Chimeric LtErv can functionally replace ScErv1 
The two most prominent structural variations between the Erv homologues of Leishmania and yeast 
are (I) the C-terminal addition of a KISS-domain to LtErv and (II) the position and composition of the 
redox-active “shuttle” cysteine pair (Figure 3.1A). The relevance of the latter was approached as the 
first 16 amino acids of the LtErv N-terminus were replaced by the yeast shuttle arm (chimera 1-3) or 
as the complete ScErv1 N-terminus and flavodomain were fused to the C-terminal part of LtErv 
(chimera 4 and 5). Concurrently, the C-terminal arm and the KISS-domain were systematically removed 
from the constructs (chimera 1-3 and 4-5) to demonstrate the influence of these protist structures. In 
chimera 6, the yeast shuttle arm’s CRSC-motif was exchanged with the Leishmania CQVYC-motif to 
address the activity of the protist shuttle cysteine pair independently of its position in the protein 
(Figure 3.1A).  
Chimeric constructs were introduced into a haploid yeast ∆erv1 strain that additionally expressed 
wildtype SCERV1 on a URA3 plasmid (Figure 3.1B). For negative selection and plasmid shuffling, 
transfected cells were grown on 5-fluoroorotic acid (FOA), which is converted to toxic 5-fluorouracil in 
the presence of URA3. Since the only available full-length copy of the essential SCERV1 must be 
dismissed in the presence of FOA, yeast cell survival depends on a functional chimeric Erv as illustrated 
in Figure 3.2. 
In contrast to the negative control that expressed LtErv, viable cells could be isolated from FOA agar 
plates for all the chimera (Figure 3.1B, Supplementary figure 1A). To ensure complete plasmid 
shuffling, the absence of ScErv1 and presence of the chimeric protein in yeast mitochondria were 
confirmed for at least three different clones of each strain by subcellular fractionation and western 
blot analysis (Figure 3.1C, Supplementary figure 2A). For chimera 3 and 6, I additionally confirmed the 
genotype by analytic PCR (Supplementary figure 2B). 
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Figure 3.1 | Yeast SCERV1 complementation assays with chimeric and mutant LTERV.  (A) Schematic summary of the 
constructs encoding ScErv1 (red), LtErv (blue) and the indicated chimera 1-6. The peptide antibody binding site for α-LtErv is 
marked with an asterisk. (B, E) ∆erv1 cells containing SCERV1 on a URA3 plasmid and the indicated chimera or mutant (or WT 
yeast or WT parasite Erv) on plasmid pYX232 were subjected to plasmid shuffling using 5-fluoroorotic acid (FOA). Shown are 
representative drop dilution assays on agar plates with and without FOA for one of four independent biological replicates. All 
chimera, mutant LtErvC17S and WT ScErv1 rescued the loss of endogenous yeast Erv1. Strains expressing any of the other 
mutant or truncated LtErv variants as well as the negative control (WT LtErv) died in the presence of FOA. (C, F) Western blot 
analysis of subfractionated yeast cells expressing the indicated constructs. Chimera and LtErvC17S were imported into 
mitochondria (pellet fraction) while WT ScErv1 was lost in all strains. Cytosolic glucose-6-phosphate dehydrogenase (ScZwf1) 
and mitochondrial ScTim50 were used as controls. (D) Schematic summary of truncated and mutant LtErv variants. Cysteine 
point mutations are highlighted in separate colours for the “distal” or “shuttle” cysteine pair (blue), the clamp forming residue 
(brown), the “proximal” or active site pair (red), and the structural disulphide bond (green). For additional information see 
Supplementary figure 1-3. Adapted from Specht et al. (2018). 
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Figure 3.2 | Schematic representation of plasmid shuffling assays. A ∆erv1 strain with an episomal SCERV1 copy on the URA3 
plasmid pRS426 was transfected with plasmid pYX232 expressing either of the chimeras (left). Strains were negatively 
selected in the presence of 5-fluoroorotic acid (FOA) to exclude the URA3 plasmid, which would otherwise turn FOA into a 
toxic substance. Once the only source of yeast Erv1 has been eliminated, the cell depends on a functional chimeric Erv to 
complement the loss (right). Modified from Specht et al. (2018). 
 
3.1.2 Mutant LtErvC17S can functionally complement the loss of ScErv1 
Complementation assays with chimeric LtErv suggested that this protist Erv homologue can, at least in 
principle, adopt the function of ScErv1. To further investigate the structural requirements for a 
successful ScErv1 complementation, I analysed additional LtErv variants, that were either N- or C-
terminally truncated (LtErvC-term and LtErvN-term) versions of the full-length protein or in which the distal, 
proximal, structural, and clamp cysteine residues were replaced (Figure 3.1D). 
Although the different LtErv mutants grew normally in the absence of FOA, neither LtErvC-term nor 
LtErvN-term were able to rescue the loss of ScErv1 (Figure 3.1E, Supplementary figure 1A). However, the 
systematic replacement approach yielded the functional mutant LtErvC17S, in which the clamp residue 
was replaced. Single clones of the LtErvC17S strain were subcellular fractionated and the replacement 
of ScErv1 by the mutant Leishmania protein was verified by western blot analysis (Figure 3.1F). Cells 
from the other mutant strains that were isolated from FOA agar plates, were either dead or still 
contained ScErv1 (Supplementary figure 3).   
It might be worth mentioning that the mutation in LtErvC17S had an additional effect on the localisation, 
since the protein was found to a certain degree in the cytosolic fraction. In contrast, mutations of the 
distal cysteine residues in LtErvC300S/C304S or of one of the proximal cysteines in LtErvC63S did not interfere 
with the mitochondrial localisation of the protein (Supplementary figure 3). 
 
3.1.3 Cys17 does not interfere with the complementation ability of other mutants  
Mutations of the distal, proximal, and structural cysteines did not alter the ability of LtErv to rescue a 
scerv1 knock out strain but only the replacement of the clamp residue C17 resulted in successful 
complementation. This result indicates a dominant negative effect of this cysteine residue that may 
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have overshadowed the actual complementation ability of the remaining cysteine mutants. To exclude 
this possibility, I exchanged the clamp residue Cys17 by a serine in all the cysteine mutants and 
repeated the complementation experiments (Figure 3.3A). Nevertheless, none of the new constructs 
showed any gain of ScErv1 function (Figure 3.3B). 
 
Figure 3.3 | Yeast SCERV1 complementation assays with mutant LtErvC17S constructs.  (A) Schematic representation of 
LtErvC17S constructs. (B) Drop dilution assay on agar plates as described in Figure 3.1. Shown are representative drop dilutions 
for one of three independent biological replicates. Adapted from Specht et al. (2018). 
 
3.1.4 LtErvC17S and chimera 1, 2 and 6 have specific growth phenotypes 
Yeast strains that were previously able to complemented for ScErv1 were further characterised in 
liquid medium and on agar plates by their growth in minimal medium with glucose (SD), galactose 
(SGal), or glycerol (SG) as the provided carbon source (Figure 3.4, Supplementary figure 4). Chimera 1 
displayed a prominent phenotype in metabolising each of the three carbon sources, which could be 
observed in liquid as well as on agar medium. Chimera 2 grew normally in glucose and galactose 
medium, but the growth in glycerol liquid medium was impaired. This phenotype was not present on 
SG agar plates. Chimera 3 showed no abnormalities in growth compared to WT ScErv1. In contrast, 
chimeras 4 and 5 exceeded the growth of the control strain on SGal and SG agar plates but not in liquid 
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medium. The growth of chimera 6 was affected on glycerol agar plates and marginally in liquid SD 
medium. Cells expressing LtErvC17S revealed no deviation from the control when grown on agar plates 
and in liquid glucose medium. However, the growth of these cells in liquid SGal and SG was increased 
in the initial 12 h but was saturated earlier at a lower overall final cell density.  
 
Figure 3.4 | Growth assays of complemented ∆erv1 strains.  Yeast strains expressing chimera 1-6 or LtErvC17S were analysed 
in liquid and on agar minimal medium containing (A) 2 % glucose (SD) or (B) 3 % galactose (SGal) or (C) 3 % glycerol (SG) as 
carbon source. Individual values of growth curves in liquid medium represent the mean ± standard deviation of three to five 
independent biological replicates. Values were normalised to the growth of the ∆erv1 strain complemented with WT SCERV1 
(black diamonds). Representative drop dilution assays for one of three to four independent biological replicates were pictured 
at day 3 (SD), day 5 (SGal) or day 8 (SG). For more detailed information see Supplementary figure 4. Adapted from Specht et 
al. (2018).   
 
3.2 Yeast SCMIA40 complementation assays  
The absence of a Mia40 homologue in parasitic protists may be due to the fact that LtErv is a single 
player who fulfils both the functions of Erv1 and Mia40 (Haindrich et al., 2017). Since the above results 
suggest that the KISS domain, which is by name specific for kinetoplastid protists, does not inhibit LtErv 
in yeast and no obvious function for this domain is known so far, there is plenty of room to hypothesise. 
In one of these, the KISS domain acts as a receptor that binds the hydrophobic patch of imported 
proteins before they interact with the shuttle disulphide (Sideris and Tokatlidis, 2007; Banci et al., 
2009; Kawano et al., 2009; Sideris et al., 2009; Koch and Schmid, 2014b; Peleh et al., 2016). In short, 
the hitherto unknown function of the KISS domain, in combination with the shuttle arm, might be the 
replacement of the missing Mia40. Another potential replacement candidate is residue C17, which is 
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absent in yeast Erv1 and might also exert a receptor function (Deponte and Hell, 2009; Guo et al., 2012; 
Eckers et al., 2013). 
In order to test the hypothesis, weather protist Erv and in particular the mentioned structures actually 
possess Mia40 functions in yeast, I followed another plasmid-shuffling approach in ∆mia40 yeast cells.  
 
3.2.1 Protist Erv homologues cannot complement the loss of ScMia40 
Expression plasmids with full-length PFERV, LTERV and the mutants LTERVC-term, LTERVN-term, and 
LTERVC17 were transfected into a haploid ∆mia40 yeast strain and tested for their ability to functionally 
replace a wildtype SCMIA40-expressing URA3 plasmid upon negative selection with FOA (Figure 3.5B, 
C; Supplementary figure 1B). The absence of viable cells on selection plates indicated that none of the 
protist Erv variants could complement the loss of ScMia40. Endogenous Mia40 could only be replaced 
by the truncated functional version ScMia40s. The results were reproduced in drop dilution assays 
using alternative temperatures (Figure 3.5D).  
To exclude the possibility that the tested Erv constructs were not complementary due to 
mislocalisation within the yeast mitochondria, I adapted them to yeast standards. Fusing the 
N-terminal mitochondrial targeting signal and transmembrane segment of ScMia40 (Mia40N) to the 
constructs, should target them to the same location in the IM as the endogenous protein (Figure 3.5E). 
Yet, all the constructs failed to complement the loss of yeast Mia40 (Figure 3.5F, G).  
 
3.2.2 Chimeric Erv cannot perform Mia40 operations 
Chimeric Erv was previously shown to complement the loss of ScErv1 (Figure 3.1). Furthermore, some 
of the chimeras showed defects in oxidizing ScMia40, suggesting that these chimeras might have a 
Mia40-like activity that would obviate oxidation of the yeast protein (Specht et al., 2018). I tested this 
hypothesis for chimera 1-6 as well as for their Mia40N-fusion constructs in SCMIA40 complementation 
assays (Figure 3.6). Again, none of these constructs were able to rescue the ∆mia40 strain. 
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Figure 3.5 | Yeast SCMIA40 complementation assays with full-length, truncated and mutant protist Erv.  (A) Schematic 
representation of wildtype ScMia40 (left) and its N-terminally truncated version (right). N-terminal mitochondrial targeting 
signal and transmembrane segment (Mia40N) are highlighted. (B) Schematic summary of constructs encoding wildtype PfErv, 
LtErv and its truncated and mutated variants. Disulphides are highlighted in colours. (C) A ∆mia40 strain harbouring an 
episomal copy of SCMIA40 on a URA3 plasmid was transfected with the indicated constructs on plasmid pYX232 and subjected 
to plasmid shuffling. SCMIA40short on plasmid pRS314 served as positive control. (D) Drop dilution assays were performed in 
parallel and incubated at the indicated temperatures. Shown are representative experiments for one of three independent 
biological replicates. (E) Schematic summary of Mia40N-fusion-constructs (F) and (G) Plasmid shuffling approaches with 
Mia40N-fusion-constructs. RT= room temperature. Adapted from Specht et al. (2018). 
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Figure 3.6 | Yeast SCMIA40 complementation assays with chimeric LTERV constructs.  (A) Schematic summary of full length 
ScMia40 and truncated ScMia40short. N-terminal mitochondrial targeting signal and transmembrane domain (Mia40N) are 
highlighted. (B) and (E) Schematic representation of chimeric LtErv 1-6 with and without Mia40N. (C) and (F) 
Complementation assays with indicated constructs as described earlier. (D) and (G) Plasmid shuffling experiments were 
repeated as drop dilution assays at the indicated temperatures. RT= room temperature. Adapted from Specht et al. (2018). 
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3.3 Membrane association studies with LtErv 
In contrast to soluble ScErv1, LtErv receives a tight membrane association in the IMS of both 
Leishmania and yeast (Eckers et al., 2012; Eckers et al., 2013). This property might also include the 
mechanism used to import LtErv into mitochondria in a Mia40-independent manner. Nevertheless, 
one of the main goals of this study was to identify the membrane that LtErv is associated with by 
establishing a differential fractionation protocol to solubilise the intact cells down to the IMS (Figure 
3.7).    
 
 
Figure 3.7 | Schematic summary of the differential fractionation protocol for L. tarentolae.  (1) Intact parasites were 
harvested and subjected to a solubilisation procedure consisting of (2) hypotonic swelling and (3-6) a digitonin concentration 
gradient to progressively lyse the membranes of the parasite and its mitochondrion. Samples were taken from each step, 
separated into pellet and supernatant fraction and analysed by immunoblotting. The solubilisation process was followed by 
decoration with specific marker antibodies against the mitochondrial compartments and the cytosol.  
 
3.3.1 Establishing a protocol for differential fractionation in L. tarentolae 
In order to establish a reliable procedure for differential fractionation of Leishmania parasites, I tested 
and combined many protocols provided for yeast (Cordeiro and Freire, 1995) and Kinetoplastida 
(Vercesi et al., 1991; Castro et al., 2008; Hide et al., 2008; Basu et al., 2013; Peleh et al., 2014; Mani et 
al., 2017) to optimise each step along the experiment. Major attention was paid to buffer composition 
and final volume, incubation temperature and duration, proper amount of physical and chemical 
stress, supernatant precipitation, and western blot conditions. Samples were taken after each step, 
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centrifuged and analysed by western blotting using specific marker antibodies against each 
mitochondrial compartment and the cytosol.  
In a first set of experiments, parasites were directly subjected to a digitonin concentration gradient to 
make sure, mitochondria are intact, and the lysis effects are due to a defined amount of digitonin 
(Figure 3.8A). As a result, Erv became soluble from the pellet at the addition of 200 µg of digitonin per 
108 cells (indicated by red arrow) while the marker proteins for the OM (Tob55) and IM (Tim17) were 
still attached to the mitochondria. This indicates a porous OM, unable to preserve the IMS content 
(similar to scenario 3 in Figure 3.7). Although, acetone precipitation significantly improved the yield of 
the supernatant proteins as compared to trichloroacetic acid (TCA), bands were still faint und unsteady 
in appearance.   
To overcome these problems, I applied an additional shear stress to the lysed cells to proper detach 
the OM from the mitochondria (see scenario 4 in Figure 3.7). I tested the influence of increasing shear 
stress on parasites under two different digitonin pressures (Figure 3.8B). At 100 µg digitonin/108 cells, 
the OM was usually destroyed to such an extent that Erv protein levels reached 50 % in the pellet and 
supernatant. In contrast, at 250 µg digitonin/108 cells, all of the IMS protein was soluble in the 
supernatant. Shear stress had no effect on Tob55 protein levels in the pellet. Acetone precipitation 
was prolonged to an overnight incubation at -20 °C and resulted in reliable strong protein bands. The 
shear stress procedure was finally extended by a hypotonic swelling step in advance of the physical 
pressure (Figure 3.8C). Consequently, Tob55 gradually accumulated in the supernatant fraction, while 
the IMS content became soluble exclusively upon lysis with Triton X-100. This approach was promising 
but never reproducible which is why strategies were changed. 
Another barrier on the way to an evaluable outcome involved the α-LtTim17 antibody activity. To 
define western blot conditions suitable for both, the intermembrane proteins LtTob55 and LtTim17, 
as well as membrane-associated LtErv, I screened several SDS-PAGE and western blot alterations. This 
included Laemmli buffers supplemented with different amounts of urea (0, 4 M, 6 M) and incubation 
temperatures (5-10 min at 95 °C, 10-20 min at 65 °C, 10 min at 70°C, 30 min at 37 °C) as well as blotting 
membranes (nitrocellulose vs. PVDF), techniques (semidry vs. wet) and buffers (incl. 20 % [v/v] 
methanol, w/o SDS). The most important conditions are summarised in Figure 3.8D. Best results were 
obtained with samples incubated for 30 min at 37 °C in a 6 M urea-5× Laemmli buffer prior to 
separation by SDS-PAGE and subsequently wet-blotted on PVDF membrane (Figure 3.8E). 
Since shear stress did not provide the intended effect, I tried to weaken the attachment of the OM 
with a gentle hypotonic buffer system that would allow to restrain mitochondrial leakage until the 
intended digitonin lysis (see scenario 2 in Figure 3.7). I first analysed the effect of the standard DT or  
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Figure 3.8 | Preliminary experiments for a differential fractionation protocol.  L. tarentolae WT cells (5× 107 per lane) were    
harvested and treated as indicated before fractionation into pellet and supernatant. Samples were analysed by 
immunoblotting using marker antibodies against the outer (α-LtTob55, OM) and the inner mitochondrial membrane (α-
LtTim17, IM), and the intermembrane space (α-LtErv, IMS) (A) Preliminary treatment with an increasing digitonin 
concentration gradient (0, 50, 100, 150, 200, 250 µg digitonin/108 cells). Erv was lost in the pellet upon 200 µg digitonin while 
Tob55 and Tim17 were unaffected (red arrow). Supernatant was precipitated in acetone at -20 °C for 1 h (and overnight in 
the following approaches) and all samples were boiled at 95 °C in 5× Laemmli buffer (+ 15 % β-ME) and blotted semidry on 
nitrocellulose membrane. (B) Influence of increasing shear stress (0, 2, 4, 6, 8×) onto parasites after digitonin treatment. Erv 
was equally distributed in pellet and supernatant at 100 µg digitonin/108 cells and almost completely soluble upon 250 µg 
digitonin. Shearing had no effect. (C) Influence of increasing shear stress after parasite swelling in hypotonic buffer (1 mM 
Tris). Tob55 was gradually accumulating in the supernatant. Tim17 detection failed. Samples were dissolved in Laemmli as 
described in A. (D) and (E) Troubleshooting for western blot conditions. Cells were harvested, and the pellet resuspended in 
5× Laemmli with or without urea and incubated as indicated. Samples were blotted wet or semidry on nitrocellulose or PVDF 
membrane. (E) Best signals were obtained by blotting wet on PVDF with samples in 6 M urea buffer and incubation at 37 °C 
for 30 min. These conditions were used for the following experiments. (F) Troubleshooting for hypotonic swelling conditions. 
Cells were resuspended in the indicated buffers following different protocols. Tested were [A] 1 mM EDTA, 1mM Tris, pH 7.9 
for 10 min at RT, [B] 5 mM KxHxPO4, pH 7.9, 5 mM EDTA, 1 mM PMSF for 25 min on ice, [C] 1 mM MOPS-KOH pH 7.2, 0.25 mM 
EDTA, 25 mM sucrose for 30 min on ice, and [D] 20 mM HEPES-KOH pH 7.2 for 20 min on ice. Buffer D induced the intended 
gentle detachment of the OM (seen in supernatant). (G) Different volumes of HEPES buffer were tested to resuspend the cell 
pellet. Most promising results were obtained with 234 µL buffer without shear stress. (H) Parasites were resuspended in PBS 
supplemented with either 100 µg (↓) or 250 µg (↑) digitonin/108 cells and incubated on ice as indicated. Major differences 
between both concentrations were captured in the pellet at 30 min and in the supernatant at 5 min incubation. Both were 
tested further. 
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DTE buffer at various concentrations (1-20 mM) and incubation procedures (5-10 min at RT or 5-20 min 
on ice). None of the conditions achieved the desired result (data not shown). Therefore, I compared 
four different buffer systems with and without the application of additional shear stress. The outcome 
was quite diverse, ranging from no (buffer C) and reverse-intended (buffer A) effects to the actual 
intended effect of slowly dissolving the OM without damaging the IMS (see supernatant fraction, 
Figure 3.8F). This effect was still weak in buffer B but striking in buffer D, consisting of 20 mM HEPES. 
The gentleness of this treatment became clear as neither the pellet fraction showed any differences 
compared to the negative control nor the IM was affected in any way. Again, shear stress did not 
influence the outcome. In follow-up approaches, I determined a final volume of 234 µL 20 mM HEPES 
buffer to resuspend the cell pellet and incubation for 20 min on ice (data not shown) for optimal 
swelling conditions (Figure 3.8G). 
Finally, the incubation time of the digitonin concentration gradient was reviewed on ice for 5 min, 
30 min and 60 min. Despite auspicious preliminary results with the 5 min-approach (Figure 3.8H), 
incubation at 30 min was later found to provide more conclusive and reproducible data. That is 
because after 5 min, sufficient to accumulate proteins in the supernatant, the majority of 
mitochondrial proteins remained in the pellet fraction and this protein overload affected the running 
behaviour of the samples and thus the reproducibility of the experiment (data not shown). 
In summary, an extensive evaluation of different conditions was carried out to establish a protocol for 
the differential fractionation of leishmania mitochondria. The complete final protocol provided 
reproducible results and is explained in detail in section 2.5.11.   
 
3.3.2 LtErv is associated to either the inner or outer mitochondrial membrane 
The strategy to identify the mitochondrial membrane in question involved a stepwise solubilisation 
procedure of the entire parasite by hypotonic cell swelling in combination with a mild detergent to 
lyse the parasite and the OM (Figure 3.9). 
The OM was attacked and became slightly permeable upon parasite swelling in hypotonic 20 mM 
HEPES buffer, as suggested by the LtTob55 signal in the supernatant (line 11). LtErv remained inside 
mitochondria until the addition of 50 µg digitonin/108 cells (lines 10-13) that released significant 
amounts of the IMS protein into the soluble fraction (line 14). At 100-200 µg digitonin/108 cells, the 
OM was completely detached from the mitochondria, as indicated by the loss of LtTob55 signal in the 
pellet (lines 6-7), and major proportions of LtErv accumulated in the supernatant (lines 15-16). In 
contrast, the signals for the IM proteins LtTim17 and Cytc were present in the pellet fraction up to a 
concentration of >500 μg digitonin/108 cells (lines 1-8). Both of these signals appeared in the 
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supernatant fraction in the presence of 2 % Triton X-100 (line 18) while only the LtTim17 was lost in 
the pellet (line 9).  
 
Figure 3.9 | Western blot analysis of differential fractionation of L. tarentolae wildtype cells.  Cells (5× 107 per lane) were 
harvested, washed in PBS and treated as indicated before fractionation by centrifugation. Pellet samples were dissolved in 
5× Laemmli + 6 M Urea and heated at 37 °C for 30 min. The supernatant was first precipitated in acetone overnight at -20 °C. 
Western blot was carried out in a wet blot process using PVDF membrane. Specific antibodies were used to label the outer 
mitochondrial membrane (LtTob55), the inner membrane space (LtErv), and the inner mitochondrial membrane using both 
the integral protein LtTim17 and the associated Cytc. Digitonin concentration gradient: 0, 10, 25, 50, 100, 200, 500 µg/108 
cells. Figure represents preliminary results in a representative western blot analysis of at least two biological replicates.  
 
3.3.3 Characteristics of the Mia40-independent protein import of LtErv  
Erv is a central component of the redox-relay system importing cysteine-rich proteins into the IMS but 
also substrate to this machinery (Terziyska et al., 2007). Although, LtErv does not cooperate with 
ScMia40 it was shown to accumulate inside the IMS when imported into yeast mitochondria (Eckers et 
al., 2013). Taking LtErv mutant constructs (Figure 3.1D) I intended to investigate the underlying 
property for its import and correct localisation in yeast mitochondria.  
Preliminary experiments with a ∆scerv1 strain expressing LtErv on plasmid pYX232 and ScErv1 on 
pRS426 were performed to re-establish a protocol for submitochondrial localisation (Figure 3.10). 
Mitochondria were isolated in a quick procedure and subjected to proteolysis. The cytosolic fraction 
could be successfully separated from the mitochondria-containing pellet fractions (SN vs. P1). The 
largest part of the IMS marker proteins were protected from proteolytic degradation as long as the 
OM was intact (P2). Under hypoosmotic conditions, the OM was expected to rupture surrendering IMS 
proteins to protease activity. Unexpectedly, LtErv was still not affected from protease activity, such as 
the matrix marker Tim44, while the IMS marker proteins ScErv1 and Tim50 were degraded. However, 
the slight degradation of the IMS content in P2 suggest that the mitochondria are already slightly 
damaged before hypotonic treatment. 
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Figure 3.10 | Submitochondrial localisation studies in yeast. Yeast mitochondria were obtained by quick mitochondria 
preparation and incubated with or without proteinase K at isosmotic or hypoosmotic conditions. Immunodecoration was 
carried out using marker antibodies against the cytosol, outer mitochondrial membrane (OM), intermembrane space (IMS) 
and matrix. The figure shows a representative western blot of at least two independent biological replicates. 
 
3.4 Knock out studies of PFERV and PFTIM13 
While Erv1 was discovered decades ago as an essential protein in yeast (Lisowsky, 1992) and more 
recently in T. brucei (Basu et al., 2013) and L. infantum (Specht et al., 2018), PfErv was still unexplored. 
I generated a CRISPR/Cas9 strategy to knock out PFERV and the small PFTIM13 by double crossover 
(Figure 3.11). Viable clonal lines were obtained for a potential ∆pftim13 strain by limiting dilution and  
are yet to be analysed. In contrast, the attempt to knock out PFERV was unsuccessful, suggesting 
another essential Erv homologue. However, only one guide RNA was tested in a single experiment. 
 
Figure 3.11 | Generation of P. falciparum 3D7 ∆pferv and ∆pftim13 knockout strains. Schematic summary of the (A) ∆pferv 
and (B) ∆pftim13 knockout strategy by double crossover with the plasmids pL7-PfErv or pL7-PfTim13, respectively. Annealing 
sites of primers for ∆pftim13 and the size of the expected PCR products are indicated.  
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3.5 Examination of the oxidative folding machinery in L. tarentolae  
In a previous study, we aimed to identify a potential Mia40-replacement candidate by using 
overexpressed LtErv and LtsTim1 as bait proteins in pull-down experiments. Since both proteins proved 
to be inappropriate for that purpose, due to technical reasons (Liedgens, 2018), we switched to newly 
discovered substrates of the oxidative protein folding pathway (Peikert et al., 2017). Four candidates 
were cloned into a Leishmania expression vector (Mirko Höhn) encoding either a C-terminal Flag- or 
Flag-His-tag and analysed in a wildtype background. Simultaneously, I introduced ScMia40s into 
L. tarentolae to study the behaviour of the parasites in presence of this otherwise missing redox 
enzyme. 
 
3.5.1 Trapping of mixed disulphide intermediates with putative MIA substrates 
Peikert et al. (2017) have recently published a list of putative substrates of the oxidative folding 
pathway obtained from knockdown studies in T. brucei. Out of 25 proteins, four were chosen according 
to several characteristics, including molecular mass, sequence coverage, existence of cysteine motifs 
and total number of cysteines, and finally phylogenetic conservation in Kinetoplastida, Apicomplexa 
and Opisthokonts (Liedgens, 2018). Homologues were cloned from L. tarentolae gDNA (Mirko Höhn) 
and were consequently overexpressed in a wildtype strain.  
The substrates have two to four cysteines. Substrate 1 (Tb927.9.7980/LtaP04.0660) and substrate 3 
(Tb927.10.15790/LtaP19.1110) contain classical twin Cx9C motifs (Figure 3.12A). All substrates were 
24 kDa or smaller in size to separate them from LtErv in western blot analysis and either soluble in the 
IMS or equipped with one or two putative transmembrane domains. Cysteine point mutations were 
introduced in substrate 2 (Tb927.10.4280/LtaP35.0210) and substrate 4 (Tb927.11.13510/ 
LtaP09.1390) to further stabilise mixed disulphide intermediates (Mirko Höhn).  
Substrates 1-4, including two cysteine mutants of substrate 2 (C105S or C117S), were successfully 
expressed in L. tarentolae and one of four clones for each line was selected for the following 
experiments (data not shown). In order to chemically trap a mixed disulphide intermediate, formed 
between a potential Mia40 adapter replacement and the substrate, free cysteines were blocked with 
N-ethylmaleimide (NEM). If such a short-lived intermediate was formed, the NEM should stabilise this 
structure since an intramolecular disulphide bond cannot be restored with an alkylated cysteine. 
Additionally, the living cells were previously treated with the oxidizing agent diamide or the reducing 
component DTT to alter the redox state and potentially generate a more fortunate redox equilibrium. 
In the end, the cells were boiled in Laemmli buffer under non-reducing and reducing (+ β-ME) 
conditions and analysed by immunoblotting.   
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Figure 3.12 | Chemically trapping of a Mia40 adapter replacement.  (A) Schematic summary of the selected new substrates 
of the oxidative protein folding pathway of the IMS that were selected by Linda Liedgens based on the identified homologues 
in T. brucei by Peikert et al. (2017). Boxes symbolise putative transmembrane elements and the position of cysteine residues 
are highlighted with black numbers. Flag- and His-tags are displayed disproportionally. Substrate size with and without tags 
are indicated below. (B) Parasites expressing Flag-His-tagged substrate 2 or the cysteine point mutants C105S or C117S were 
harvested and treated as indicated. Free thiols were modified by NEM and subsequently analysed by western blotting under 
non-reducing and reducing (+β-ME) conditions. Immunodecoration with α-Flag showed higher molecular bands at ~30 kDa 
(green arrow), ~34 kDa (purple arrow), ~50 kDa (orange arrow), ~60 kDa (red arrow). Exposure times are highlighted. (C) 
Comparison of western blot membranes decorated with α-Flag or α-LtErv. Higher molecular bands are highlighted with 
arrows as described above. Figure represents preliminary data of up to two biological replicates with 5× 107 cells per lane.  
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A representative blot for this procedure using parasite strains that express Flag-His-tagged substrate 2 
or the cysteine mutants C105S or C117S is shown in Figure 3.12B. The Flag antibody visualised the 
substrate under reducing conditions with a double band at around 26 kDa. Under non-reducing 
conditions, the conspicuous double band was lost, and the size shifted to a molecular mass of about 
30 kDa in the presence of NEM (green arrow). A sample without NEM was loaded as a control and 
displayed a band corresponding to the calculated molecular substrate mass of 28 kDa as well as several 
unspecific higher molecular bands and one lower molecular band at ~20 kDa. Only the cysteine point 
mutant C105S revealed potential interaction candidates at a mass of ~60 kDa (red arrow), ~50 kDa 
(orange arrow), and ~34 kDa (purple arrow).  
In another approach, both cysteine mutants were treated as described above and the western blot 
membrane was probed with either α-Flag or α-LtErv to check whether they disclose a common higher 
molecular weight band (Figure 3.12C). This would suggest LtErv interacting directly with the substrates. 
Decoration with α-Flag presented again a band in the higher molecular range at about ~60 kDa for 
substrate 2 C105S-Flag-His (red arrow). After diamide treatment, α-LtErv exposed an additional protein 
of about ~50 kDa (orange arrow) for both the Flag-His-tagged C105S and C117S mutant substrates. 
In summary, preliminary results with the cysteine point mutants of substrate 2, propose 
potential mixed disulphide intermediates of a molecular mass of ~60 kDa (red arrow), ~50 kDa (orange 
arrow), or ~34 kDa (purple arrow). The ~50 kDa band might reflect a direct interaction of LtErv with 
the substrate.   
 
3.5.2 Redox inactive ScMia40SPS triggers a hyperactive phenotype in L. tarentolae  
Mia40 is an essential redox enzyme in yeast and other Opisthokonts importing cysteine-rich proteins 
into the IMS of mitochondria. L. tarentolae as a member of the parasitic protists is missing this 
homologue and, so far, no replacement was discovered. We were therefore curious to know how 
parasites would handle the sudden presence of Mia40 and expressed a redox-active (Mia40sFlag) and 
inactive (Mia40s-SPSFlag) version of the protein in a Leishmania wildtype background (Figure 3.13). 
Mia40-SPSsFlag grew slightly faster than the wildtype strain (no plasmid) during the initial two 
days and reached earlier the stationary phase with a lower overall cell density (Figure 3.13A). In 
contrast, wildtype cells grew hardly better than the strain expressing Mia40sFlag. The most prominent 
feature concerned the increased motility of Mia40s-SPSFlag cells. While all the three strains showed 
classic cell morphology (Figure 3.13B), parasites harbouring Mia40s-SPSFlag appeared to move 
hyperactively when observed on a glass slide (data not shown). This phenotype has not yet been 
further investigated but seemed to be absent in cells expressing redox-active Mia40sFlag. Finally, 
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western blot analysis with a α-Flag antibody verified the presence of the Mia40 variants in the 
indicated lines while LtErv and LtTob55 served as loading controls (Figure 3.13C).  
 
Figure 3.13 | Heterologous expression and characterisation of ScMia40 in L. tarentolae. (A) Growth curve analysis of 
wildtype (WT) parasites or cells expressing Flag-tagged ScMia40short or ScMia40s-SPS. Cell density was determined by counting 
every 24 h over a period of six days. Values represent the mean ± standard deviation of three independent biological 
replicates. Transgenic parasite lines grew under G418 selection pressure. (B) Light microscopy images of L. tarentolae 
promastigotes harbouring the indicated constructs. (C) Western blot analysis with 5× 107 cells per line. Immunodecoration 
was performed with α-Flag to visualise the substrates and α-LtErv and α-LtTob55 as loading controls.  
 
3.5.3 Redox state of ScMia40 in L. tarentolae 
After heterologous expression and characterisation of ScMia40 in L. tarentolae, I was interested in the 
redox-state that this protein has in the host organism. In yeast, ScMia40 contains six cysteine residues. 
Four of which form intramolecular structural disulphide bonds in a Cx9C motif and two are present in 
the redox active CPC motif (Figure 3.14A). At steady-state level, the CPC motif was shown to be 70-
80 % oxidized to maintain oxidative protein folding (Kojer et al., 2012). If ScMia40 is functional in 
L. tarentolae, one would expect a similar redox-state as shown for yeast, with a stable, hardly 
reduceable disulphide bond in the Cx9C motif and a simple-to-reduce CPC motif.  
In a redox mobility shift assay, free cysteines were modified with the alkylating compound methyl-
PEG-24-maleimide (mmPEG24), which slowed migration of the affected protein on SDS-PAGE by 
1.2 kDa per accessible thiol (Figure 3.14B). Without the thiol modifying compound, the mildly reduced 
ScMia40 showed a band at the calculated molecular mass of about 24 kDa (line 1). A similar band was 
produced for the untreated and unmodified sample, which reflects the physiological redox state (line 
2). The addition of mmPEG24 led to a migration change of about 2 kDa (line 3+10) compared to the 
unmodified protein (line 2+9), indicating the presence of two accessible cysteine residues. In addition, 
cells were treated with the reductant tris(2-carboxyethyl)phosphine (TCEP) at 27 °C or 95 °C for mild 
or harsh reduction, respectively and were subsequently modified with mmPEG24. Reduction at 27 °C 
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shifted the molecular mass of ScMia40 to about 26 kDa, which likely corresponds to modification of 
the reduced CPC motif (line 4). In contrast, ScMia40 gained an additional mass of ~7 kDa under harsh 
reducing conditions, signalling modification of all cysteines in the protein (line 5). Both the diamide 
and DTT control presented very faint bands at a molecular mass of 26 kDa, indicating a partially 
reduced redox state (line 6+7).    
In conclusion, preliminary results suggest a partially reduced redox state of ScMia40 in L. tarentolae, 
indicating that the yeast protein is not functional in the protist host.  
 
 
Figure 3.14 | Redox state of ScMia40 in L. tarentolae.  (A) Schematic representation of ScMia40 in its oxidized, partially 
reduced and fully reduced redox state. C= cysteine, P= proline, x= any amino acid, S= sulphide, SH= thiol (B) Redox mobility 
shift assay. Parasites expressing Flag-tagged ScMia40s were treated with diamide, DTT, or PBS as control and lysed in Laemmli 
buffer with or without the reductant TCEP at 27 °C or 95 °C. Free thiols were subsequently modified with mmPEG24 resulting 
in a mass shift of 1.2 kDa per accessible cysteine residue. Samples containing 1.25× 107 cells per lane were analysed by 
western blotting using α-Flag. Shown is one blot at two different exposure times. Redox. = redox agent.  
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4 Discussion 
The mitochondrial protein import is a central component of life and has been in the focus of research 
for decades, studying model organisms mainly belonging to the group of opisthokonts (Neupert and 
Herrmann, 2007; Chacinska et al., 2009; Endo and Yamano, 2009; Schmidt et al., 2010; Dimmer and 
Rapaport, 2012; Dudek et al., 2013; Peleh et al., 2016). Although this group contains many important 
representatives, such as mammals and yeast, it only speaks for one of five major eukaryotic lineages 
(Adl et al., 2012) and therefore cannot reflect a general picture. In the present study, protocols and 
procedures for the standard model organism S. cerevisiae were used and combined with organisms 
from two other eukaryotic branches, P. falciparum from the group of SAR and L. tarentolae as a 
member of the Excavates (Figure 1.1). With these comparative studies it should be possible to better 
understand the evolution of eukaryotes.  
 
4.1 Structure-function analyses of LtErv 
The main objective of this thesis was to unravel structure-function relationships of the protist protein 
LtErv and its unusual C-terminal KISS domain. LtErv accumulates inside the IMS of yeast mitochondria 
but is unable to adopt the function of its yeast homologue ScErv1 (Eckers et al., 2012). The underlying 
hypothesis claimed a structure within the parasite protein to prevent LtErv to be functional with 
ScMia40 in the redox-relay system of yeast. A set of chimeric constructs were generated, in which 
certain Leishmania properties were exchanged by critical yeast protein structures to narrow a potential 
inhibiting or incompatible arrangement (Figure 3.1). Fusing the N-terminal “shuttle” arm of ScErv1 to 
the truncated Leishmania amino terminus allowed the protist protein to properly function in a ∆scerv1 
knock-out strain (chimera 1-3). This behaviour was slightly negatively influenced by truncation of the 
parasite’s C-terminal “shuttle” arm (chimera 2) and even more by removal of the entire carboxyl 
terminus including the KISS domain (chimera 3). Nevertheless, cells harbouring chimera 3 were viable 
and showed a normal growth behaviour in the following experiments (Figure 3.4). This proposes that 
the Erv domain is in principle functional in yeast when extended by the yeast shuttle arm to 
communicate between ScMia40 and the LtErv domain.  
The Erv shuttle arm is required for the oxidase activity of the protein and consists of an conserved 
cysteine pair in a highly variable motif (Figure 1.7) and is either located at the N-terminus, as in yeast, 
mammals and apicomplexans, or at the C-terminus (Hofhaus et al., 2003; Levitan et al., 2004; Vitu et 
al., 2006; Ang and Lu, 2009; Bien et al., 2010; Banci et al., 2011; Basu et al., 2013; Eckers et al., 2013; 
Ang et al., 2014). Similar to LtErv, AtErv1 was not functional in yeast having a CEQKSC motif in the C-
terminal shuttle arm (Levitan et al., 2004). On the other hand, the N-terminal shuttle cysteine motif of 
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apicomplexan parasites (Cx4C) or mammals (Cx2C) also failed to complement for ScErv1 (Lange et al., 
2001; Eckers et al., 2013). Yet, Leishmania’s CQVYC motif replaced the yeast CRSC motif in the yeast 
shuttle arm (chimera 6), proposing that not exclusively the composition of the motif is crucial for the 
interaction with ScMia40. Modifications of the shuttle cysteine pair (C300S/C304S, C300S), the active 
site (C63S), or the structural bond (C92S/C109S) in LtErv did not change the proteins dysfunction 
(Figure 3.1). Yet, upon mutation of the clamp residue (C17S), the parasite Erv was able to functionally 
replace its yeast homologue. The N-terminal clamp residue is therefore most likely the reason why 
LtErv is incompatible with ScMia40 in the oxidative folding system in yeast mitochondria.  
Residue C17 is partially conserved and forms a clamp disulphide bond in the mammalian ALR to 
stabilise the homodimer conformation but is absent in many other eukaryotes, including yeast and 
apicomplexan parasites (Wu et al., 2003; Farrell and Thorpe, 2005; Deponte and Hell, 2009; Banci et 
al., 2011; Eckers et al., 2013). In accordance with the present results, it was reported that heterologous 
human ALR remains in the cytosol and does not complement for ScErv1 when imported synthetically 
into yeast mitochondria. However, when the amino terminus of ALR was extended by a bipartite pre-
sequence or replaced by the first 92 amino acids of the yeast protein, it was imported and functional 
in yeast mitochondria (Lange et al., 2001; Sztolsztener et al., 2013). How C17 exactly causes 
incompatibility of LtErv in yeast and which may be its physiological relevance in Leishmania remains to 
be investigated. Likewise, the effectiveness of the interaction between LtErvC17S and ScMia40 needs to 
be explored in more detail, since yeast cells expressing the mutant Erv grew fine on glucose but were 
facing trouble on non-fermentable carbon sources (Figure 3.4). This behaviour reflects an impaired 
mitochondrial respiration potentially caused by a defective protein import machinery. A similar 
phenotype was observed for the chimera 1, 2, and 6, which grew normally on FOA media, but revealed 
certain growth defects on non-fermentable carbon sources (Figure 3.4). The same chimeras interacted 
with but only ineffectively oxidized ScMia40, which in turn had a negative impact on the import of 
cysteine-rich proteins into the IMS (Specht et al., 2018). In contrast, yeast cells containing the chimeras 
4 or 5 were free of any growth defect and the interplay between the yeast shuttle arm and the yeast 
flavodomain coordinated an optimal oxidation of Mia40 regardless of the KISS domain (Specht et al., 
2018). Previously, a ScErv1-defective strain was reported with reduced vegetative growth on glucose 
and the immediate deprivation of respiratory functions on non-fermentable carbon sources that was 
associated with the loss of the mitochondrial genome (Lisowsky, 1994). However, viability and 
consistent growth of yeast also on non-fermentable carbon sources confirmed that mitochondria 
containing LtErvC17S or the chimeras 1, 2, and 6 were able to respire. The respective mutant/chimera 
must therefore be at least partially functional in yeast.  
Truncation constructs showed that neither the Erv nor the KISS domain alone are sufficient to 
complement for ScErv1. In addition, no negative effect of the KISS domain was observed; instead, its 
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presence even improved survival of chimeras 1 and 2 compared to chimera 3 (Figure 3.1) and did not 
affect normal growth by extending the ScErv1 domain (chimera 4 and 5; Figure 3.4). Apart from the 
redox-active cysteine pairs (shuttle and active site pair), the partially conserved structural disulphide 
bond also proved to be essential after the removal of the interfering C17 (Figure 3.3).  
In summary, the protist LtErv in its wildtype form is insufficient to cooperate with Mia40 in yeast but 
functional when the clamp residue is exchanged by a serine or when the yeast shuttle arm is attached 
to the N-terminus of the protein. Nevertheless, due to phylogenetic distances, the opisthokont and 
kinetoplastid flavodomains are not interchangeable without complications. It is not surprising that in 
the course of evolution the interaction between electron donor (e.g. ScMia40) and shuttle arm as well 
as shuttle arm and flavodomain have been optimised. Yet, it is interesting that certain variations are 
still accepted.   
 
4.2 The unusual protein import and membrane association of LtErv 
There are three common sorting pathways that import proteins from their site of synthesis in the 
cytosol to their site of action in the IMS (Figure 1.5). Erv is a major key player of one of them, trapping 
small and cysteine-rich proteins via the MIA pathway (Herrmann and Hell, 2005). Likewise, ScErv1 uses 
this very same pathway for its own translocation and accumulation inside the IMS (Gabriel et al., 2007; 
Terziyska et al., 2007). The C-terminal part of the flavodomain (residues 134-176) is sufficient to drive 
import of the yeast protein, with the structural cysteine pair binding to ScMia40 for an electron 
exchange reaction (Kallergi et al., 2012). In the present study, I aimed to identify a special structure or 
redox property that drives the translocation of LtErv into Leishmania and yeast mitochondria. In a first 
set of experiments, I systematically replaced all the disulphide bond forming cysteine pairs of LtErv and 
in combination with a mutation of the clamp residue, I tried to rescue a yeast ∆scerv1 strain with them 
(Figure 3.3). In contrast to the wildtype protein, the clamp mutant LtErvC17S was able to adopt ScErv1 
function. Meaning, it likely interacted with ScMia40 to oxidize the partner protein and potentially also 
to initiate its own import. Further disruption of the redox-sensitive cysteine pairs at the shuttle arm or 
the active site interrupted the oxidoreductase activity of the protein, which unavoidable led to cell 
death. In addition, also the structural disulphide bond (C92 and C109) claimed its right to exist. 
Mutation of this cysteine pair may have disturbed the protein’s import in a Mia40-dependent manner, 
as described previously by Kallergi et al. (2012) in experiments with ScErv1. As a result, the expressing 
strain was not viable. Also, subcellular fractionation of yeast cells expressing LtErvC17S revealed a dual 
localisation of the mutant protein in the cytosol and yeast mitochondria (Supplementary figure 3). This 
suggests an important role for residue C17 as a signal for mitochondrial localisation. Nonetheless, 
specific import assays with the mutants have to test this first lead. A rather simple procedure might 
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include an extension of the submitochondrial localisation studies that have been performed by Eckers 
et al. (2013) and have shown that LtErv accumulates in the IMS of yeast mitochondria. Similar studies 
may be carried out with yeast strains expressing either of the mutant LtErv variants listed in Figure 
3.1D to confirm the structure that abolishes protein import. Therefore, first experiments have been 
done in the framework of this thesis (Figure 3.10). Even though a quick procedure effectively separated 
the cytosolic fraction from the protein content of the mitochondria, the overload of protist Erv and the 
rather small proportions of endogenous IMS proteins (e.g. ScTim50) made it difficult to evaluate. For 
future attempts, it might be worth switching to a gentler procedure, which isolates mitochondria to a 
purer extent and makes sure they are intact upon treatment. 
The absence of a Mia40 homologue in certain protist mitochondria, however, proposes an alternative, 
Mia40-independent explanation for the Erv import in these eukaryotes. Class I proteins, such as 
cytochrome b2, Mgm1, cytochrome c peroxidase or even ScMia40 possess mitochondrial pre-
sequences followed by hydrophobic sorting domains that direct them to the TIM23 complex and via 
the stop-transfer model into the inner membrane (Figure 1.5A). Afterwards, matrix targeting pre-
sequences are removed from the matrix side and soluble IMS proteins can be released after a second 
cleavage inside the IMS (Herrmann and Hell, 2005). Sztolsztener et al. (2013) demonstrated that the 
human ALR is imported into yeast mitochondria when supplemented by the bipartite pre-sequence of 
cytochrome b2, suggesting that this import route is possible but probably not exploited in vivo. 
Additionally, LtErv did not present “striking hydrophobic patches” in the analyses by Eckers and co-
workers (2012; 2013), which likely excludes the TIM23 pathway. On the other hand, the same studies 
also uncovered a tight membrane association of endogenous and heterologous LtErv (Eckers et al., 
2012; Eckers et al., 2013). This characteristic might out LtErv as a classical class III protein that are 
permanently associated to binding sites at the mitochondrial membranes (Herrmann and Hell, 2005). 
Class III proteins are imported independently of membrane potentials and ATP levels and fold rapidly 
after translocation through the TOM complex (Steiner et al., 1995). To substantiate this suspicion, I 
established a differential fractionation protocol for Leishmania parasites to separate the OM from the 
IM and define to which membrane endogenous LtErv is associated. If the binding site contains a trans 
side receptor, it will be of advantage to know its localisation for identification and characterisation 
purposes. Considering the role that Erv is playing in the IMS and its final interaction with cytochrome 
c of the respiratory chain, the IM seemed to be more likely. However, preliminary results were 
inconclusive but rather suggested LtErv to reside close the OM. In at least two biological replicates the 
protist protein became free from the IMS shortly after the OM started to rupture while the marker 
proteins for the IM remained inside the mitochondria (Figure 3.9). This result was rather surprising and 
has to be substantiated by further experiments. Nevertheless, an association to the OM may be 
explained by the presence of the unusual ATOM complex of trypanosomatids, which takes the place 
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of the common OM pore Tom40 (Pusnik et al., 2011). Our understanding of this noncanonical complex 
is still limited and novel components of the complex and the entire protist OM are constantly being 
discovered (Pusnik et al., 2012; Niemann et al., 2013; Mani et al., 2015; Mani et al., 2017). Therefore, 
it may be not unlikely that the wanted binding site for LtErv coincides with the ATOM complex, 
importing and trapping the protein inside the IMS. If not linked to ATOM, a potential import receptor 
may represent at least one of the 82 proteins that make up the proteome of the OM in 
trypanosomatids (Niemann et al., 2013). Being located close to the OM would also have the advantage 
for LtErv to be in close proximity to substrates after their translocation, which have to be folded to 
remain in the IMS.  
Additionally, one have to keep in mind that the IMS is a tiny compartment measuring only a few 
nanometres (Frey and Mannella, 2000) that makes harsh procedures like hypotonic swelling and 
detergent lysis vulnerable to errors. Further experiments have to be done to support or correct these 
findings. Peleh et al. (2014) have applied a similar approach to isolated yeast mitochondria to 
determine the sublocalisation of the proteins Dre2 and imsDre2 but combined the swelling and the 
digitonin concentration gradient with an additional proteolytic lysis. This may be an intervention to 
define the separation between the OM and the IM more clearly. If this strategy is not sufficient, a 
density gradient flotation centrifugation could be tested as used previously to identify proteins of the 
mitochondrial contact sites or the OM (Harner et al., 2011; Niemann et al., 2013). Thereby, the protein 
content of the different compartments can be obtained from different gradients and analysed more 
precisely by western blot analysis. The use of additional marker antibodies, especially for the IMS and 
the two membranes is highly recommended to assign the localisation clear and without ambiguity. 
Since LtErv is membrane associated not only in Leishmania but also in yeast mitochondria (Eckers et 
al., 2013), there is the opportunity to study the same subject in two evolutionary distant organisms 
and in the best case, to obtain two independent but explicit results. In other words, if none of the 
proposed procedures succeed satisfaction, one still has the chance to study the import of LtErv at a 
simpler model. 
Understanding where LtErv is associated is an important first step to unravel the nature of the import 
machinery of this protein and to identify potentially involved components. Next, it is of interest to 
describe the property, which causes this membrane association in the trypanosomatid protein but not 
in the yeast homologue. The mutant LtErv constructs have to be introduced into a ∆lterv strain or 
tagged in order to differentiate the mutants from the endogenous protein by western blot analysis. So 
far, we have intended to avoid the tagging of proteins to bypass potential localisation artefacts, which 
is why Gino Turra is currently establishing a CRISPR/Cas9 strategy for L. tarentolae to realise a ∆lterv 
strain in our lab. Once this is done, carbonate extraction assays and differential fractionation can be 
applied to comprehend which structure is mandatory for membrane association and for specific 
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localisation. So far, preliminary attempts have been made to re-establish a carbonate extraction 
protocol in yeast based on Eckers et al. (2013), but without providing reliable data. An authentic 
nominee for the structure in question might be the KISS domain, which comprises almost 200 amino 
acids of unknown activity and is not present in any Erv homologue of other eukaryotic classes (Eckers 
et al., 2013). The absence of a dominant negative effect of this domain in yeast (see complementation 
assays 3.1.1) further supports this hypothesis and would explain its membrane-association in yeast 
mitochondria. A second structure that should be considered is residue C17. The cysteine residue may 
interrupt the interaction between LtErv and ScMia40 because it instead interacts with a membrane 
receptor that adheres the protein within the IMS. One way or another, C17 seems to be involved in 
the mitochondrial localisation of the protist protein, as discusses earlier. The final clue to explain the 
unusual membrane association of LtErv could be provided by an investigation of the interaction 
between the protein and the membrane. Apart from the presence of a membrane bound import 
receptor, also a protein-lipid interaction might be plausible. This can be tested by protein-lipid overlay 
assays using commercial lipid strips as well as liposome flotation assays (Connerth et al., 2012).  
In conclusion, the data obtained from this study do not yet explain in detail how LtErv is imported into 
leishmania and yeast mitochondria but give first indications. Data in yeast suggest that residue C17 
initiates a Mia40-independent import route. Thereby, the residue may cause LtErv import as a class III 
IMS protein that associates with a binding site, possibly at the outer mitochondrial membrane. This 
pathway may import the wildtype LtErv into both yeast and leishmania mitochondria. However, when 
the clamp residue is exchanged, the protein most likely interacts with Mia40 and might be imported 
into yeast mitochondria via the classical oxidative folding pathway. In this case, the structural cysteine 
pair in LtErv might be crucial to form a transient mixed disulphide intermediate with ScMia40 as 
explained for the import of the endogenous yeast homologue.  
 
4.3 The quest of the holy Grail - or a Mia40 adapter replacement 
Mia40 was reported to be widely conserved with homologues in at least three eukaryotic supergroups 
(Allen et al., 2008). However, the nuclear genome of certain protists, such as apicomplexan parasites 
and trypanosomatids, appear to lack a Mia40 homologue. The conservation of only one key 
component of the MIA pathway gave rise to many fundamental questions: How are cysteine-rich 
proteins imported in these protist groups? Is the oxidative folding pathway conserved or are the 
proteins imported differently? Is there a Mia40 replacement or is Erv working alone? What is the 
function of Erv if not oxidizing Mia40?  
Without Mia40, there are three apparent possibilities how cysteine-rich proteins can be transported 
into mitochondria. (I) The Erv homologue is directly interacting with the substrates and does not 
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require a partner protein. (II) An unknown component replaces Mia40 in its position or (III) the 
substrates are imported in a completely different pathway. If the parasite’s Erv is actually working 
alone, as claimed by Haindrich et al. (2017) and others, it should be able to directly interact and oxidize 
substrates of the oxidative folding pathway. In other words, it should be capable to perform Mia40 
activities in a yeast model (Figure 3.5), as shown before for human CHCHD4 (Chacinska et al., 2008). 
Since this is not the case and a variety of protist constructs failed to replace ScMia40, even though 
import signals were found to be evolutionary conserved (Eckers et al., 2012), it is highly doubtful 
whether the oxidative folding system in protists consists of a single protein. This recognition is further 
supported by the findings of Basu et al. (2013), who reported that TbErv1 cannot oxidize or fold small 
Tim9. However, when TbErv1 was downregulated, Tim9 protein levels in the IMS gradually decreased 
while non-substrate protein levels were unchanged (Peikert et al., 2017). This means that the 
kinetoplastid Erv is definitely involved in the import pathway of cysteine-containing proteins but 
probably depends on a partner protein.  
The identification and characterisation of such a Mia40 adapter replacement was the major aim of an 
extensive study by Linda Liedgens (2018). Unfortunately, all strategies for the pull-down and chemical 
trapping of a mixed disulphide intermediate between the unknown component and the model 
substrate small Tim1 or the partner LtErv were unsuccessful. While Erv did not reveal any interaction 
partner, attempts from the substrate side were more promising but the low molecular weight and the 
high hydrophobicity of the protein caused problems on SDS-PAGE and western blot analysis. To 
overcome these problems, new substrates were carefully selected from a list of proteins, which were 
reduced in abundance in consequence of a RNAi-induced TbErv1 knock-down (Peikert et al., 2017). 
Among others, a protein classified as “substrate 2” was amplified from L. tarentolae gDNA as an 
orthologue of the T. brucei protein Tb927.10.4280. It harbored two cysteines in a non-conserved single 
Cx11C motif and with a sequence similarity of 94 % to T. theileri and T. grayi, it presented a putative 
subunit of the ETC complex III. The substrate was overexpressed from a vector in L. tarentolae and the 
mixed disulphide interaction with a putative Mia40 replacement was captured by the permanent 
blockage of free thiols with NEM (Figure 3.12). The small alkylating reagent is thought to diffuse 
through the intact cell and preserve the physiological redox state by preventing artificial thiol oxidation 
after cellular disruption. In addition, a stable mixed disulphide was potentially generated by mutating 
one of the cysteine residues in the substrate, as commonly done in the analysis of disulphides (Hansen 
and Winther, 2009; Engelhard et al., 2011; Heckler et al., 2013; Mermelekas et al., 2013; Rudyk and 
Eaton, 2014; Nakao et al., 2015; Wojdyla and Rogowska-Wrzesinska, 2015). Adducts of about 34 kDa, 
50 kDa and 60 kDa were detected in the higher molecular range of substrate 2 C105S when analysed 
under non-reducing conditions. This indicated the binding of a potential interaction partner with a 
molecular mass of 6 kDa, 22 kDa or 32 kDa, respectively. Since the IMS typically house molecules of  
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low molecular mass, often between seven and 15 kDa, it is quite plausible that the Mia40 replacement 
ranks in this size (Herrmann and Hell, 2005). Alternatively, the 60-kDa-band might correspond to a 
dimeric substrate conformation as shown previously for ScErv1 and LtErv, respectively (Terziyska et al., 
2009; Eckers et al., 2013). Visible intermediates were absent in cell lysates containing wildtype 
substrate 2 or the C117S mutant. This suggests a function for residue C105 interacting with the Mia40 
replacement whereas residue C117 might be unable to form mixed disulphides and may act as the 
resolving cysteine yielding an intramolecular disulphide (Nakao et al., 2015). When the mutant 
constructs were analysed for their interaction with LtErv, a potential mixed disulphide was also found 
at 50 kDa. This might imply a direct interaction between LtErv and the substrate or represent non-
identical redox partners. What this means to the oxidative folding pathway in early eukaryotes and 
which potential mixed disulphide might actually contain the desired Mia40 replacement is hard to 
interpret at this stage. However, previously established protocols for the endogenous disulphide 
trapping in L. tarentolae delivered promising results that together with the thoughtful chosen 
substrates may be indeed powerful enough to capture a potential Mia40 replacement. In the following 
steps, the correct intermediate has to be enriched and de novo purified before analysis by mass 
spectrometry can specify the potential Mia40 replacement candidate. As no fully defined medium is 
available to proper cultivate L. tarentolae, a stable isotope labelling of amino acids in cell culture 
(SILAC) is not possible (Liedgens, 2018). Hence, His-tagged and untagged import substrates were 
generated to discriminate between unspecific bindings and actual interaction partners (Dabir et al., 
2007).  
However, it is conceivable that the replacement candidate does not bind covalently to the substrates 
via disulphide bridges but functions more as a trans side import receptor. This import option has 
already been discussed for LtErv above and is further supported by observations of the redox-inactive 
Mia40-SPS mutant in yeast (Peleh et al., 2016). The authors demonstrated a Mia40-depleted strain 
where protein levels of Mia40 substrates were partially restored by expression of a Mia40 mutant 
lacking the redox-active cysteines. Instead of forming a disulphide intermediate, substrates were 
tightly associated to the binding pocket, which delayed but allowed a CPC-independent oxidation 
process. If such an interaction is present also in Kinetoplastida and Apicomplexa, the receptor could 
easily have been missed by the applied redox trapping methods. Another interesting phenomenon that 
might match this hypothesis concerns the hyperactive phenotype of Leishmania cells expressing the 
redox-inactive Mia40 (Figure 3.13). In contrast to wildtype Mia40, Mia40-SPS may be functional in 
Leishmania importing proteins via the hydrophobic binding site. Since Mia40-SPS is co-expressed with 
the endogenous import receptor, protein import may be intensified leading to either higher protein 
levels, as shown for yeast cells overexpressing ScMia40 (Terziyska et al., 2005; Longen et al., 2014; 
Peleh et al., 2016), or to more efficient protein processing and localisation, as claimed by Wrobel et al. 
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(2015). In yeast and mammalian systems it has been demonstrated that more proteins are synthesised 
in the cytosol as actually imported into mitochondria (Fischer et al., 2013; Longen et al., 2014). What 
is more, a thyroid hormone-induced upregulation of the mitochondrial import rate in the cardiac 
muscle was suggested to correlate with alterations of the mitochondrial volume fraction and the area 
of cristae (Craig et al., 1998; Colavecchia et al., 2003). The observed hyperactive phenotype might 
therefore be connected to a boost in metabolism or other cell functions in Leishmania, allowing certain 
processes to take place more quickly. However, neither the import and correct localisation of both the 
ScMia40 constructs into leishmania mitochondria nor the actual increased protein levels have been 
tested so far. Furthermore, the growth of transgenic cell lines was analysed under G418 selection 
pressure while the control strain did not contain a resistance cassette and was analysed in marker free 
medium. For that reason, it cannot be completely excluded that the selection pressure influenced the 
phenotype of the transgenic parasites.   
Notably, ScMia40 was expressed in leishmania cells but remained in a partially reduced redox state 
(oxidized Cx9C but reduced CPC motif) (Figure 3.14). I conclude from this, that the protein is not active 
in these cells. It was previously found that endogenous ScMia40 was oxidized to 70-80 % to be 
functional, which is regulated in the IMS by Erv1 and glutathione (Kojer et al., 2012). A similar scenario 
was described for human CHCHD4 (Erdogan et al., 2018), which implies a non-redox-regulated import 
receptor or inadequate systems for the oxidation of this yeast protein in L. tarentolae mitochondria. If 
the Mia40 replacement does not simultaneously import and oxidize substrates in a disulphide 
exchange reaction but rather imports and folds substrates as a trans side receptor without a mixed 
disulphide intermediate, how are the substrates oxidized (see Figure 4.1)? I have discussed earlier that 
protist Erv has to be involved in the protein import, since mitochondrial substrate levels were 
negatively affected upon TbErv1 downregulation (Peikert et al., 2017). Nevertheless, LtErv could not 
functionally complement for ScMi40 in yeast (Figure 3.5). However, I did not test whether LtErv can 
oxidize Mia40 substrates when they have previously been imported by the hydrophobic binding cleft 
of the ScMia40-SPS mutant, as demonstrated for AtErv1 (Peleh et al., 2017). Additionally, the recently 
identified thioredoxins and glutaredoxins in the IMS may be scavenge the excess of electrons after 
substrate oxidation (Vogtle et al., 2012; Kojer et al., 2015). Once it was postulated that in the course 
of evolution, higher eukaryotes have supplanted the thioredoxin-based oxidation system of the 
bacterial periplasm by the superior MIA40 machinery (Peleh et al., 2016). Based on this consideration, 
“primitive” eukaryotes that do not have Mia40 could still be, at least in part, dependent on the 
ancestor’s system.  
In summary, the oxidative folding system of early eukaryotes is still puzzling because important 
components are absent or altered in such a way that they are no longer recognizable. Nevertheless, 
the import pathway seems to be conserved with Erv as central component that is conditional to some 
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kind of Mia40 replacement. If this replacement represents a redox-active protein or a receptor has to 
be examined in the future. New exciting perspectives might also be gathered with an oxidation assay 
that analyses the relevance of an oxidative process for protein import under physiological conditions 
(Fischer et al., 2013; Kojer et al., 2015; Peleh et al., 2016). Complementation assays with a ∆scmia40 
strain co-expressing protist Erv and the redox-inactive Mia40-SPS might be interesting to explain the 
task of Erv as a substrate oxidase in more detail. Finally, the L. tarentolae strains expressing wildtype 
and mutant ScMia40 can be observed more closely to characterise the observed putative hyperactive 
phenotype and to explain how Mia40-SPS functions in Leishmania mitochondria.  
 
Figure 4.1 | Schematic representation of the “folding trap” and the trans side receptor models.  (A) According to the folding 
trap mechanism reduced substrates are unfolded and translocated in and out of the intermembrane space (IMS) until they 
are oxidized and folded by Mia40. Mia40 subsequently interacts with Erv1 to transfer the electrons (e-). (B) In the trans side 
receptor model, import is driven by the substrate affinity of the receptor. In case of Mia40, the substrates are subsequently 
oxidized and released in a folded state as shown in A. Without a redox-active cysteine, another electron receptor has to be 
involved. Figure was modified from Peleh et al. (2016).    
 
4.4 The physiological relevance of protist Erv homologues 
Chromosomal PFERV was impossible to delete in a primal strategy whereas the MIA substrate small 
Tim13 was most likely removed from the chromosome (Figure 3.11). Analytical PCRs have to be 
performed to verify a ∆pftim13 strain before assessing whether PFERV could not be knocked out for 
technical or functional reasons. Either way, the protein is suspected to be essential since the Erv 
homologues of the parasites L. infantum and T. brucei were discovered as indispensable alongside 
those of fungi and mammals (Basu et al., 2013; Haindrich et al., 2017; Peikert et al., 2017; Specht et 
al., 2018).  
In order to obtain a viable ∆pferv strain, I have cloned a rescue plasmid expressing a PFERV variant 
having three mismatches close to the PAM sequence to interfere with the Cas9 activity (Cong et al., 
2013; Hsu et al., 2013; Sternberg et al., 2014; Stemmer et al., 2015). Chromosomal PFERV should be 
knocked-out, while the episomal copy ensures parasite’s survival. In the subsequent experiments, 
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parasites will be either co-transfected with both the pL7 knock-out and the pHBIRH rescue plasmid or 
exclusively with pL7. I expect viable cells for the co-transfectants but not for the control.  
Apart from its participation in the oxidative folding pathway, the protist Erv was suggested to be 
involved in many processes of the cell, including the maintenance of mitochondrial morphology and 
the export and assembly of iron sulphur clusters in the cytosol (Basu et al., 2013; Basu et al., 2014; 
Haindrich et al., 2017). This might point to the physiological importance of the protein even when not 
oxidizing Mia40. As parasites become increasingly resistant to currently used medication, effective 
treatment relies on the constant exploration of new potential drug targets (WHO, 2012b, 2014). The 
mitochondrial import machinery comprises many essential components whose interference can have 
fatal consequences for the parasite (Mather et al., 2007; Vaidya and Mather, 2009). In particular the 
essential MIA pathway exhibits particularities that differ significantly to the human system and might 
therefore be an excellent candidate target for drug development.  
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5 Conclusion  
In this thesis, I analysed structure-function relationships of the protist sulfhydryl electron transferase 
LtErv to frame a clearer picture of the oxidative protein folding pathway in the IMS without Mia40. By 
understanding this “primitive” import route, valuable drug target candidates may be described, and 
the evolutionary development of the mitochondrial protein import system can be tracked from the 
roots.    
LtErv consists of an amino terminal flavodomain as well as a carboxyl terminal KISS domain and 
encompass seven cysteine residues that form up to three intramolecular disulphide bonds (Figure 5.1). 
The N-terminal C17 has shown to be the main reason why the parasite Erv cannot replace the yeast 
homologue in its function. However, the disturbing effect can be overcome by extending the protein 
N-terminally by the yeast shuttle arm (Figure 5.1A) or by exchanging the cysteine residue for a serine 
(Figure 5.1B). Although the shuttle cysteine pair of the Leishmania protein differs in motif and 
localisation from the homologue in yeast, it can accomplish the yeast function (Figure 5.1C). Both the 
C-terminal shuttle cysteine pair (Figure 5.1E) and the disulphide bond in the active site (Figure 5.1H) 
are responsible for the oxidoreductase activity of the protein (Eckers et al., 2013). By disrupting any of 
these redox-active cysteine motifs, the LtErvC17S mutant can no longer complement for ScErv1. The 
structural cysteine pair is most likely responsible for intramolecular stability and might mediate a 
Mia40-depended import into yeast mitochondria when C17 is removed (Figure 5.1D). Even though the 
KISS domain is restricted to Kinetoplastida, it did not negatively influence the proteins’ function in 
yeast (Figure 5.1F). On the contrary, it rather supported the parasite’s flavodomain in 
complementation assays and did not distract the flavodomain of yeast (Figure 5.1G). 
Both the KISS domain and residue C17 have assignments in the parasite protein that have not yet been 
fully understood. They might induce the special membrane association that imports and traps the 
protein in the IMS. If this import is driven by a conserved receptor or by a special protein-lipid 
interaction has not yet been investigated. It is however tempting to speculate that C17 interrupts the 
interaction with ScMia40 in yeast because it instead initiates a different import pathway via membrane 
association. With certainty, neither of the two structures exert full ScMia40 activity and accordingly 
represent no Mia40 replacement. 
Since LtErv is unable to import MIA substrates on its own, there should be some kind of Mia40 
replacement in parasitic protists. The most obvious scenario would be a redox-enzyme that imports 
and oxidizes cysteine-containing substrates in analogy to ScMia40 and subsequently interacts with 
LtErv to pass the received electrons to the ETC. Alternatively, an ancient Mia40 may be a simple trans 
side receptor that has no redox activity, but controls substrate import through hydrophobic binding 
(Figure 4.1). To do so, it requires additional assistance from redox proteins, such as thioredoxins, 
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glutaredoxins and maybe even Erv to oxidize and fold the substrates after their translocation. The 
oxidative folding pathway in protists may therefore reflect a scenario that is in between the ancient 
bacterial system and the superior MIA40 machinery of opisthokonts. So instead of a stepwise model, 
where early eukaryotes have no Mia40 at all, as it is often postulated (Allen et al., 2008; Carrie and 
Soll, 2017; Peleh et al., 2017), there may be a primitive Mia40 replacement with a receptor function.  
 
Figure 5.1 | Schematic summary of structure-function relationships of LtErv.  The boxes show mutant or chimeric LtErv 
properties that have been tested in a yeast ∆erv1 strain. (A) N-terminal extension with the yeast shuttle arm. (B) Mutation of 
C17 to serine. (C) Replacement of the yeast shuttle cysteine motif by the parasite motif. (D) Double mutation of C17 and the 
structural disulphide bond. (E) Double mutation of C17 and the shuttle cysteine pair. (F) Truncation of the KISS domain while 
the protein is extended by the yeast shuttle arm. (G) Influence of the KISS domain in the yeast protein. (H) Double mutation 
of C17 and the disulphide of the active site. Alterations in the protein that produced viable yeast cells are symbolised with a 
green pulse sign while red skulls mark the opposite. Know functions of the respective properties and indicated. Big question 
marks symbolise unknown function. 
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7 Supplementary information 
 
 
Supplementary figure 1 | Yeast SCERV1 and SCMIA40 complementation assays with chimeric, truncated, and mutant 
LTERV.   Adapted from Specht et al. (2018). 
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Supplementary figure 2 | Western blot and PCR analysis of ∆erv1 yeast strains harbouring chimera 1-6.   Adapted from 
Specht et al. (2018). 
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Supplementary figure 3 | Western blot analysis of ∆erv1 yeast strains harbouring wildtype, truncated, and mutant LTERV. 
Adapted from Specht et al. (2018). 
  
 
 
 
Supplementary figure 4 | Growth assays of ∆erv1 yeast strains harbouring chimera 1-6 or LTERVC17S.  Adapted from Specht 
et al. (2018). 
 
